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Tuberculosis remains a major public health problem, claiming three million deaths 
annually in developing countries; the resurgence of the disease in industrialized 
countries and the emergence of multi-drug resistant mycobacteria have renewed 
interest in understanding the mechanisms of drug resistance in these pathogens. The 
acid-fast bacillus Mycobacterium tuberculosis is the causative agent of tuberculosis 
(TB). This infection is the leading cause of mortality in adults due to an infectious 
agent and accounts for 26% of all preventable adult deaths globally. Pyrazinamide 
(PZA), one of the antituberculous drugs has a special place in therapy in that it 
appears to kill a population of semi-dormant tubercle bacilli that are not affected by 
other antituberculous drugs, shortening the duration of treatment from the earlier norm 
of 12-18 months to the current standard of 6 months. However, the exact mode of 
action of PZA is unknown. A commonly accepted hypothesis is that PZA susceptible 
M tuberculosis strains produce pyrazinamidase (Pzase), which hydrolyses PZA to the 
antibacterial moiety, pyrazinoic acid (POA). It is not clear whether POA has specific 
antimicrobial activity or that the inhibition of growth caused by POA is due to its 
ability to lower the pH of the environment below the limits of tolerance of M 
tuberculosis growth. 
This study attempted to address the question of the mode of action of PZA in 
macrophages as well as in cultures free of macrophages i.e., non-cell associated free 
M tuberculosis exposed to I 00 �tg/ml PZA. The survival rate was assessed by 
counting colony forming units (CFUs). PZA had no bacteriocidal effect on 
susceptible and resistant strains that were macrophage bound. nor on non cell 
associated mycobacteria. Intracellular multiplication was observed after 72 h in 
macrophages infected with M tuberculosis, but not subjected to any PZA. 
Concurrently high performance liquid chromatography (HPLC) was used to assess 
intracellular, extracellular and intrabacterial PZA and POA c,oncentrations. This 
methodology was developed to measure POA because this was so far impossible. 
Fractions were separated by silicone oil density gradient. Methanol and phosphate 
buffer (20%:80%) was the mobile phase and the detection was done at UV of 265 nm. 
XVlll 
Pzase positive mycobacteria, kept in RPMI 1640 without macrophages did take up 
PZA and there was also POA detected in these bacteria. PZA also entered Pzase 
negative mycobacteria but no POA was detected. No PZA or POA could be detected 
in mycobacteria in macrophages over the 72h period studied. While PZA did enter 
the cells, no POA could be detected in cells infected with Pzase positive or negative 
mycobacteria. The amount of intracellular PZA was lower when the cells were 
inoculated with Pzase positive mycobacteria as compared to uninfected macrophages 
and macrophages infected with Pzase negative strains. 
To further quantify and resolve the location of action of PZA, immunocytochemistry 
was used. However, commercial PZA antibodies are not available, thus these were 
raised in rabbits using the carrier keyhole limpet haemocyanin (KLH). Purified 
antibodies were used in gold labelling experiments where macrophages were infected 
with j\.tf tuberculosis and the non cell associated mycobacteria were exposed to l 00 
µg/ml PZA for 48h. The cultures were prepared for TEM and sections were stained 
with PZA antibodies and counter stained with gold labelled IgG. Gold label was 
quantified using a Zeiss Kontron 300 Image Analyser. Most gold label was located in 
the non cell associated mycobacteria followed by the macrophage bound 
mycobacteria. Within the macrophage, the membrane bound mycobacteria had the 
highest label density, followed by the cytoplasm and nucleus. Although no clear 
distinction can be made between PZA and POA, the high accumulation of PZA label 
in the internalised mycobacteria could suggest that PZA acts on the mycobacteria 
itself. 
This study shows that PZA or POA concentrates in mycobacteria in;;ide macrophages. 
However, the methodologies used were unable to clarify whether the drug is present 
as PZA or POA or both in Pzase positive strains. The drug concentrates in both Pzase 
producing and non Pzase producing bacteria, even in macrophages that themselves 
take up only a limited amount of PZA. 
INTRODUCTION 
This thesis is presented in 7 chapters. Chapters 2-6 represents separate aspects of the 
study but collectively address the mode of action of PZA. Each chapter commences 
with an introduction which includes the objectives, followed by the methodologies 
used, the results obtained and the discussion. Each of the above chapters is presented 
according to the format outlined by the university. Chapter I, the literature review 
places the study in perspective while chapter 7, the general discussion reconciles the 
differences of each chapter and concludes the study. This gives a clear understanding 
and logical approach to dealing \\'ith all aspects of the highly complex nature of the 
basic science methodologies undertaken. Summarising all methodologies in one 
chapter, following by a summary of all results and then discussion would make 
understanding the thesis difficult since a \Vide array of aspects are dealt with in this 
thesis and they need to be presented separately to enable a clear understanding of the 
basic science research undertaken. 
Tuberculosis is back on the world stage with a vengeance perhaps at least partly as a 
consequence of complacency about the threat it posed in the recent past. A number of 
historical sources have documented that much of the currently developed world was, 
in the past, subject to a epidemic of tuberculosis that ran its course over a period of 
several centuries. It seems likely that one of the main causes of this epidemic was the 
process of urbanisation, industralisation, the accompanying stresses and strains 
imposed by overcrowding, unemployment and the associated social disruption. Long 
before the available chemotherapy it was apparent that the mortality associated with 
the tuberculosis epidemic was declining. In the opinion of some researchers this 
decline also antedated any improvement in the precipitating poor socio-economic 
factors, suggesting that the elimination of susceptible individuals had created a 
population with increased resistance to tuberculosis. On its introduction into a 
susceptible population. tuberculosis spreads rapidly and have obviously evolved 
mechanisms for ensuring their survival in the intracellular phagocytic host cell 
environment (Beyers et al, 1996). 
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Globally, the World Health Organisation (WHO) estimates that about 8 million new 
cases of tuberculosis occur, and that there are about 3 million deaths from 
tuberculosis, each year (Sudre er al, 1992-cited by De Cock and Wilkinson, 1996). 
The situation is so grave that the WHO has declared tuberculosis to be a global public 
health emergency (WHO-cited by De Cock and Wilkinson, 1996). With the current 
HIV pandemic, the tuberculosis situation (in Africa in particular) is very serious; case 
rates have doubled in some African countries. In central Africa more than 70% of 
adults with tuberculosis may be HIV positive (De Cock et al, 1992-cited by De Cock 
and Wilkinson, 1996). 
South Africa·s tuberculosis problem reflects that of the global community. More 
cases of tuberculosis than any other disease are reported annually in South Africa. 
There were about 82 500 cases in 1992. \Vith an overall incidence of about 250/100 
000. The basic epidemiology of tuberculosis in South Africa is well described; for
example, incidence rates are highest in the coloured population in the Western Cape 
(700/100 000). South Africa is suffering an explosive HIV epidemic, with KwaZulu­
Natal hardest hit. At Hlabisa Hospital, a typical rural district hospital in the northern 
part of the province, 35% of adults diagnosed with tuberculosis in mid-1993 were HIV 
positive (The HIV seroprevelence in \VOmen attending antenatal clinics in Hlabisa 
district was 7.9% at that time) (Department of National Health and Population 
Development, 1995-cited by De Cock and Wilkinson, 1996). 
The most common agent of pulmonary mycobacteriosis 1s the acid-fast bacillus 
1v/ycobacterium ruberculosis which is one of the slow growing, non-pigmented 
mycobacteria (Wayne and Hawkins. 1988). The development of pulmonary tuberculosis 
from its onset to its various clinical manifestations may be pictured as a series of battles 
between host and invader. The inhaled bacillus may multiply, or it may be eliminated 
by alveolar macrophages before any lesions are produced. Small caseous lesions may 
progress or may heal or stabilize before they are detectable by radiography. Larger 
caseous lesions may also heal or stabilize, or they may grow locally and shed bacillus 
into the blood and lymph. Alternatively, caseous lesions may liquefy and introduce 
bacilli and their products into the bronchial tree. which makes arrest of the disease more 
difficult. Thus, each successive battle is won by the host with increasing difficulty. 
Also, within a given lesion, the battles bet\veen the host and the bacillus are fought 
almost independently of the battles being fought within the other lesions (Dannenberg 
and Tomashefski, 1988). 
It is postulated that in a patient \\·ith pulmonary tuberculosis there are three different 
populations of mycobacteria; those located extracellularly in open cavities, those located 
intracellularly in macrophages and those in closed caseous lesions. Organisms in each 
site have different metabolic acti\·ities and rates of replication (Wayne and Hawkins, 
1988). The signs and symptoms associated with pulmonary tuberculosis can be caused 
by a number of infectious agents in addition to lvf tuberculosis. These include a variety 
of species of mycobacteria, members of the genus Nocardia and fungi such as 
Histoplasma capsulatwn and Coccidioides immitis. A definitive diagnosis cannot be 
made without data from the bacteriology laboratory (Wayne and Hawkins, 1988). 
Tuberculosis has been a therapeutic challenge throughout recorded history and has 
earned the epithet " Captain of All Men of Death" (Howard and Damato, 1987). The era 
of specific chemotherapy began in 19-4-4 with the isolation of streptomycin by Selman 
Waksman. Streptomycin together with isoniazid, rifampin, ethambutanol and 
pyrazinamide are the first line antituberculous drugs used in chemotherapy (MacGreyor, 
1988). Pyrazinamide (PZA) is a synthetic pyrnzine analogue of nicotinamide. It exerts 
bactericidal activity only in an acid environment, but this enables it to kill tubercle 
bacilli inside monocytes and has become an important component of short-course 
therapy, thus listed as a first line agent (MacGreyor, 1988). Konno et al. ( 1967) 
proposed the following mechanism of action of PZA to account for the need for an acid 
environment; susceptible M tuberculosis strains are known to produce the enzyme 
pyrazinamidase (Pzase), which conve11s PZA to pyrazinoic acid (POA). It was 
suggested that it is this enzyme generated product, POA. that has high antibacterial 
activity in an acid environment, \vhereas PZ.-\ itself has no activity at all. Strains that are 
resistant to PZA do not produce Pzase, thus do not convert PZA into POA and are, 
therefore, not vulnerable to the antibacterial activity of POA (Heifers et al, 1989). 
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The difficulty in performing PZA susceptibility tests is due to the fact that an acid pH of 
the medium is required to demonstrate activity of the drng and Atf tuberculosis strains do 
not grow well at pH 5.5 (Butler et al, 1983; Konno et al, 1967). The incorporation of 
enrichment. using oleic acid-albumin-dextrose-catalase (OADC) into 7H 10 agar is 
necessary for optimal growth of lvf tuberculosis at acid pH (Stottmeier et al, 1967), 
however, oleic acid in an acid medium is often inhibitory to many strains of Af 
tuberculosis (Tummon et al, 1975). During routine determinations of PZA 
susceptibility, it was noted that the growth response of 1\1! tuberculosis at pH 5.5 
appeared better with certain lots of albumin-dextrose-catalase (ADC), even though none 
of these preparations contained added oleic acid (Butler and Kilburn, 1982). 
Sal finger et al. ( 1990) investigated PZA and POA activity against tubercle bacilli in 
cultured human macrophages and in the Bactec system. The virulent Erdman strain was 
used with every batch of human macrophages as an internal standard. During the 7 day 
period, the tubercle bacilli multiplied by a factor of 3 7. PZA was inhibitory at the lowest 
concentrations tested (25 mg. ml"1). However, even at 800 mg. ml"1 the drug only
slowed intracellular bacillary grow1h and was not bactericidal. 
In another experiment by Sal finger et al. ( 1990), it was found that the Erdman strain 
grew more betvveen days 4 and 7 than between days O and 4. This suggested that PZA 
might be losing effectiveness by being metabolised. Additional drug equal to the initial 
concentration was added daily to the culture medium e.g. 800 mg. r' became 5 600 mg. 
r' by day 7. Despite the large amounts of PZA, no significant decrease in tubercle 
bacilli was observed during the first 4 days and only minimal decline by day 7. 
In the Bactec system there was inhibition of the Erdman strain proportional to the PZA 
concentration up to 400 mg. r'. Activity of PZA or POA in the Bactec system is not 
dependent on drug penetration, as it is in the macrophage model. POA was active in the 
Bactec system but not in cultured macrophages, whereas PZA which can readily enter 
cultured macrophages, was active in both (Salfinger et al, 1990). These researchers also 
found that the cultured macrophage must contribute actively or passively to 
effectiveness of PZA such as through the proposed mechanism of low pH generated by 
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Pzase in the phagolysosomes. A purely in vitro test such as the Bactec system can serve 
as a convenient tool for evaluating antimycobacterial drugs, but the cultured 
macrophages system may more closely approximate in vivo reality (Salfinger et al, 
1990). 
Although there are numerous studies on the effect of PZA on mycobacteria, the exact 
mode of action has not been elucidated, although the mechanism of action proposed by 
Konno et al. ( 1967) is widely accepted. This study was undertaken to provide further 
insight into the mode of action of PZA. The objectives of this study were to: 
(I) assess the effect of PZAIPOA on macrophage bound and non cell associated
mycobacteria by colony counts
(2) measure PZAIPOA concentrations in lysed macrophages ( infected with Pzase
positive and negative strains) and extrabacterially in non cell associated
mycobacteria
(3) to assess whether the disruption of the mycobacteria contributes towards a
significant increase in the concentrations of PZA and POA detected prior to their
disruption
(4) identify site of location of PZA in macrophages and in non cell associated
mycobacteria
Chapter I is the extensive literature review which sets the ·scene' for the other chapters. 
Chapter 2 is an introductory chapter to the experiments undertaken to understand the 
mode of action of PZA. It addresses objective I and comparison is made to other 
similar studies. Prior to addressing objective 2, the HPLC methodology had to be 
developed for POA. Although published reports show good resolution for PZA, POA 
was not well resolved into a clear chromatograph. These events are extensively 
discussed in chapter 3. Chapter 4 gives an account of all HPLC results obtained by 
measuring PZA and POA concentrations using different mycobacterial strains. 
Immunocytochemistry was then used in an attempt to further quantify PZA and POA in 
both systems. Since gold labelled PZA antibodies are not commercially available, 
chapter 5 discusses the production of these antibodies and chapter 6 gives an extensive 
account of all the gold labelling experiments with the various strains. Finally chapter 7, 
the general discussion sums up the thesis in its entirety. 
CHAPTER ONE 
LITERATURE REVIE\V 
1.1 MEDICAL IMPORTAI\CE OF TUBERCULOSIS 
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Adult tuberculosis is a disease of two worlds: no longer is it strictly divisible into 
developed and developing countries but rather by ethnic differences (Davies, 1996). 
The white population of western Europe, America and Australia have very low 
incidences of disease, between 5 and 15/105/annum (Nisar et al, 1992). 
Among ethnic minority groups in developed countries, rates are nearer 100/10
5
/annum 
and the disease is as common in young adults as it was in the white population of 
Europe 50 years ago. In developing countries where the incidence of infection is 
already high, in young adults the advent of human immunodeficiency virus (HIV) has 
resulted in rates of disease exceeding I 000/105 /annum (Nisar et al, 1992, Hass et al,
I 994 ). The greatest impact of the interaction between HIV infection and tuberculosis 
has been in Sub-Saharan Africa where HIV infection has penetrated widely and 
tuberculosis is highly prevalent. As the HIV epidemic spreads rapidly in Asia it is 
likely that an even greater problem will occur in the Indian Sub-continent in the next 
decade (De Cock et al., 1992). 
The prevalence of tuberculous infection in children is related to the number of smear 
positive adults in the community. Development of tuberculosis disease depends on 
age, nutrition, socio-economic circumstances, poverty, intercurrent infection, host's 
immune response doses of organisms (Coulter, 1996). The incidence of tuberculosis 
in children in developing countries is difficult to estimate because of problems m 
making diagnosis. Often the only guide is the number of children referred to 
tuberculosis units for treatment. A recent estimate of the incidence of tuberculosis in 
0-14 years age group from 1990-2000 showed that the rate per 105 would increase
from 14 to 142 in Africa. Although, in the other areas the total number of cases 
would increase due to increasing population, the rate per 105 would be static or fall. In 
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Sub-Saharan Africa, one major cause of this increase is the co-infection of HIV and 
tuberculosis in the adult population (Dolin er al, 1994). 
1.1.1 HISTORICAL PERSPECTIVE OF THE DfSEASE 
The history of mycobacterial disease is divisible into three eras: those of the 
ignorance, hope and enlightenment. The era of ignorance lasted from the dawn of 
recorded history until the discovery of the causative organisms in the latter part of the 
nineteenth century. The era of hope lasted from then until the introduction of 
effective therapy around 1950. In the present era, that of enlightenment, we are 
acquiring detailed kno"vledge of the mycobacteria and the disease they cause. Can we 
hope that this will enable us to enter the fourth and final era?-that of conquest 
(Grange, 1988). 
Tuberculosis is an ancient disease, the presence has been referred from early as 4000 
BC from Egyptian tomb paintings and by examination of mummies for spinal 
tuberculosis (Cave, 1939-cited by Hart el al. 1996). Tuberculosis may have emerged 
during neolithic times when human populations increased and aggregated 
(Manchester, 1984-cited by Hart el al., 1996.) Tuberculosis was present in America 
prior to the arrival of Columbus ( Ritchie, 1952 and Pfeiffer, 1984 - cited by Hart et
al, 1996 ). The earliest evidence of tuberculosis in Britian comes from Roman times. 
Tuberculosis was well described by the time of Hippocrates and Aristotle in fifth 
century before the birth of Christ (BC) when it was described as phthisis, which was 
translated into English as consumption (Stirland and Waldron, 1990 - cited by Hart et
al, 1996). 
The turning point in the history of tuberculosis occurred at a meeting of the Berlin 
Physiological Society on the evening of 24 March 1882, when R?bert Koch described 
the isolation of the causative organism of the disease. This was eight years after 
Armauer Hansen published his observation of the leprosy bacillus in lepromatous 
nodules, however, Hansen's work did not receive the adulation accorded to Koch as 
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he was unable to isolate the orgamsm m pure culture. The germ theory of 
communicable disease by Louis Pasteur was clearly established and in particular by 
the experimental demonstration of the transmissibility of tuberculosis in rabbits by 
Jean Antoine Villemin, a French military surgeon in 1868. Koch's discovery heralded 
the era of hope. Much work was required before practical benefits were to be reaped 
from the discoveries of Hansen and Koch. Such work started rapidly in three main 
directions: isolation and culture of the bacillus for diagnostic purposes, the search for 
an effective cure, and the development of a vaccine (Grange, 1988). 
Koch's discovery coincided with the birth of the discipline of immunology, however, 
he did not regard himself as an immunologist. When Metchnikoff demonstrated the 
phenomenon of phagocytosis, Koch remarked '· I am a hygienist and it is of no interest 
to me where the microbes are, \Vhether inside or outside of the cells. He attempted to
develop an agglutination test for tuberculosis using the whole bacillus as antigen and 
also tried to attenuate a human strain for use as a vaccine for tuberculosis in cattle. 
However, his main interest was the development of a cure for tuberculosis which led 
to the development of old Tuberculin which was a filtrate of a broth culture which 
was concentrated by evaporation in a heated waterbath. A series of experiments in 
guinea pigs led to the description of the necrotic hypersensitivity reaction termed the 
Koch Phenomenon. ,vhich was caused by impurities derived from the medium 
(Grange. 1988). 
Siebert ( 1934 - cited by Grange, 1988) tried to overcome this problem by isolating 
tuberculoproteins by precipitation with acetone and ammonium sulphate which 
resulted in purified protein derivative of tuberculin (PPD). However, PPD, despite the 
name is not a pure protein and suffers from several disadvantages. Its mode of 
preparation involves prolonged cultivation of the tubercule bacillus to enable antigens 
to be released by autolysis; heating to 100°C to kill the bacillus and then precipitation 
of the protein . which caused denaturation of protein. Stanfor� and his colleagues 
( 1975), produced the ·· New Tuberculins'·, the first been Burulin, prepared for studies 
on Buruli ulcer in Africa. These reagents were prepared by harvesting mycobacteria 
during the gro'v',:ing phase from non-antigenic media, washing thoroughly, disrupting 
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the cell mass in an ultrasonicator, sterilizing by repeated membrane filtration and 
diluting to a suitable protein concentration. 
A vaccine \vas eventually produced by Calmette and Guerin after passaging a 
supposedly bovine tubercle bacillus 230 times on potato slices soaked in bile and 
glycerol over a period of 13 years. This vaccine Bacille Calmette-Guerin (BCG) was 
first used in 1921 as oral vaccine for infants. The next milestone in the history of 
mycobacterial disease occurred in the mid-twentieth century \.vith the first effective 
drugs (Grange, 1988). 
1.1.2 M ruberculosis: THE CAUSATIVE AGENT OF TB 
The generic name Alycobacrerium was introduced by Lehman and Neuman in the first 
edition of their Atlas of Bacteriology published in German in 1896. At that time the 
genus contained only two species, 1\1/ycobacreriwn tuberculosis and Mycobacterium 
leprae. The name i'vfycobacteriwn meaning fungus-bacterium was derived from the 
mould-like pellicular grow1h of the tubercle bacillus on liquid media (Grange, 1988). 
The mycobacteria are acid fast, aerobic, non-spore forming, non-motile bacteria, 
slightly curved or straight bacilli, 0.2 to 0.6 by 1.0 to IO �Lm in size. They have cell 
walls rich in lipid content, which is responsible for the ability of the organism to 
withstand staining by usual aniline dyes (Roberts er al, 1991 ). 
The grow1h rate for the mycobacteria is slow and requires 2 to 8 weeks or longer for 
detection by use of traditional mycobacteriology media. They can be detected much 
earlier with the use of a radiometric system that detects the metabolism of a 14C 
labelled substrate and detection of the evolution of ,.iC labelled CO2 as a metabolic 
by-product of the organism (Middlebrook et al., 1977). 
1.1.2.1 Ultrastructure of the cell 
The mycobacteria consist of cytoplasm bounded by a plasma membrane and enclosed 
by a complex lipid rich wall. The single chromosome is tightly wrapped into a 
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nuclear body but is not bounded by a nuclear membrane. Some mycobacteria contain 
additional small circles of deoxyribonucleic acid (DNA) termed plasmids or episomes. 
The cell membrane consists of a bilayer of polar phospholipids with their hydrophobic 
ends facing inwards and their hydrophilic ends facing outwards (Grange, 1988). M 
tuberculosis was an early object of study by electron microscopy because of its 
importance as a human pathogen ( Rosenblatt et al, 19-1-2). This pathogen differs from 
the majority of other bacteria in that it can multiply within the phagocytic cells of the 
host. 
1.1.2.1.1 Envelope of M tuberculosis 
Bacterial envelopes provide protection and support for the bacterial cell and also 
contain the mechanisms that alto".,- passage of substances between bacterial cell and 
the environment (Brennan and Draper, 199-l-). lvf tuberculosis and other mycobacteria 
are biologically part of the gram-positive group, but they have some distinctive 
features in that these bacteria possess lipids rather than pruteins and polysaccharides 
found in other bacteria (Lederer et al. 1975 - cited by Brennan and Draper, 199-l-). 
However, mycobacteria possess a wall polysaccharide that resembles that of other 
gram-positive bacteria in having a disaccharide phosphoryl linker between the 
peptidoglycan and the polysaccharide (McNeil et al, 1990 - cited by Brennan and 
Draper, I 994). 
Since 1vf tuberculosis is one of a small group of species able to survive inside the 
phagocytic cells of a animal host, it is likely that its envelope has special properties 
defending the bacterium against host microbiocidal processes. There have been 
attempts to associate ultrastructural features with resistance to phagocytes, however, 
no special feature has yet been conclusively identified; the envelopes of M 
tuberculosis do not differ visibly from those of non pathogenic mycobacteria. The 
envelope consists of tvvo distinct parts: the plasma membrane and around it the wall. 
These parts provide osmotic protection, transport of ions and molecules, mechanical 
support and protection (Brennan and Draper, 1994). 
1 1 
1.1.2.1.2 Cell Wall of A;J wberculosis
The mycobacterial cell wall is the most complex in all of nature. Lipids consist of 60 
% of the cell wall mass and they consist of a wide range of compounds, some being 
similar to those found in other organisms and others being unique to mycobacteria. 
Freeze-fracturing techniques show that the cell wall has se\"eral distinct layers 
(Barksdale and Kim, 1977). The inner layer overlying the cell membrane is composed 
of peptidoglycan (murein) which consists of long polysaccharide chains cross-linked 
by short peptide chains, forming a net-like macromolecule that gives the cell its shape 
and rigidity. The polysaccharide chains contain N-glycolyl muramic acid and N­
acetyl glucosamine in alternating positions and the cross-linking peptide chains 
consist of the four amino acids L-alanine. O-isoglutamine. mesodiamino-pimelic acid 
and O-alanine. The mycobacterial murein is very similar to that in other genera 
except that it contains N-glycolyl muramic acid instead of the more usual N-acetyl 
analogue (Grange, 1988). 
The most characteristic feature of the mycobacterial cell wall is the chemotype IV 
peptidoglycan. ,.,vhich is composed of substantial quantities of meso-diaminopimelic 
acid. The tripartite structure of the mycobacterial cell wall was labeled L 1, L2 and L3 
by Barksdale and Kim ( 1977). It was later concluded that the L3 layer corresponded 
to a true cell wall. The two outermost layers, LI and L2, corresponded to capsule-like 
structures that \Vere not covalently linked to the cell wall. Electron microscopy 
studies showed that the envelope possesses an electron dense layer of peptidoglycan 
that is surrounded by an electron transparent layer of arabinogalactan and mycolic 
acids (Besra and Chatterjee, 1994). A schematic representation of the cell wall of 1\,f 
tuberculosis is illustrated in FIG. 1.1. 
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1.2 INTERACTIO:'.'i OF ;l,/. tuberculosis WITH MACROPHAGES 
13 
The mononuclear phagocyte system is a complex system of cells widely distributed 
throughout the bodv. The earliest members of the cell line are found in the bone 
- , 
marrow and include monoblasts and promonoc)tes. These mature within the bone 
marrow to monocytes which leave the marrov; and briefly enter the blood. After 
circulating for only a few hours, monocytes leave the bloodstream and enter the 
tissues, \Vhere they differentiate into macrophages. A schematic representation of the 
development of the mononuclear phagocyte system is shown in FIG.1.2. 
With maturation from the monocyte to the macrophage, the cell greatly enlarges and 
may become multinucleate. it acquires a large number of granules (lysosomes) which 
are membrane bound packets containing acid activated hydrolytic enzymes. as the 
cell matures from monocyte to macrophage, its ability to ingest (phagocytise) particles 
also increases. these cells are avidly phagoc:,,tic and can engulf a wide range of 
organic and inorganic particles (Cline, 1981 ). the ultimate end stage of development 
of this cell is the multinuclcate giant cell seen in granulomatous diseases such as 
tuberculosis, leprosy or sarcoidosis. these cells are very large and contain multiple 
nuclei, abundant cytoplasm and a large store of hydrolytic enzymes packaged in 
lysosomes (Cline 1981). 
1.2.1 MORPHOLOGY OF MOt OCYTES AND MACROPHAGES 
Monocytes are found both in the blood and in tissues and body cavities in which they 
have morphologic variation. Study of monocytes by light microscopy showed that its 
nucleus occupies about half the area of the cell and is usually eccentrically placed. 
Under the phase contrast microscope the monocyte nucleus shows a distinct chromatin 
pattern. Mitochrondria are extremely fine and on occasion form a small juxtanuclear 
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FIG. 1.2 Kinetics of the monocyte macrophage system in man. Promonocytes undergo two divisions before 
difTerentiating into monocytes. Monocytes leave the marrow, pass through the blood, and enter the tissue where 
they mature to macrophages ( Cline, 1981 ). 
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contrast microscope is the ruffled plasma membranes vvhich is visible as prominent 
phase dense folds at the cell surfaces and edges. Some cells have a dense thickening 
at the edge of the cytoplasm v.:ith microextensions on the thickened edge (Ackerman 
and Douglas. I 983; Beiss, 1973; Cline, 1981 ). 
Scanning electron microscopy showed that very prominent ruffles and small surface 
blebs are apparent in monocytes. Extensive ruffling of the monocyte plasma 
membrane is of functional significance. The monocyte is both motile and phagocytic 
and those functions require physical contact with fibers or cell surfaces (Ackerman 
and Douglas, 1983 ). 
Study of monocyte morphology by transmission electron microscope showed that 
nucleus of the monocy1e contains one or two small nucleoli surrounded by nucleolar 
associated chromatin. The mitochondria are usually numerous, small and elongated. 
Golgi complex is well developed. Microtubules are numerous and microfibrils are 
found in bundles surrounding the nucleus (Ackerman and Douglas, 1983; Beiss, 1973 
and Cline 1981 ). 
Macrophages display attributes of morphologic specialisation specific to their 
location and function. Light microscopy showed that they have an eccentrically 
placed fusiform nucleus with one or two distinct nucleoli and finely dispersed loosely 
stranded nuclear chromatin which tends to clump in the nuclear interior and along the 
internal aspect of the nuclear membrane. On phase contrast microscopy living 
macrophages are large cells with a propensity to adhere and spread on glass surfaces. 
Vesicles and contractile vacuoles are seen about the cell periphery and in the cell 
interior ( Ackerman and Douglas, 1983). 
Transmission microscopy showed that macrophages show a variable degree of 
differentiation, nuclear·· maturity"' ribosomes, mitochrondria and lysosome content. 
In thin sections, the nucleus varies from horse shoe shaped to fusiform. The 
heterochromatin is disposed in fine clumps in the interior of the nucleus and along 
the internal aspect of the nuclear membrane. Polyribosomes and scant smooth and 
16 
rough endoplasmic reticulum are seen about the cell periphery. A well developed 
Golgi complex is in a juxtanuclear location which is often multicentric and contains a 
concatenation of vesicles, some with dense inclusions which mark them as early 
lysosome ( Ackerman and Douglas. 1983). 
1.2.2 UPTAKE OF Al tuberculosis BY MACROPHAGES 
It is thought that the .'vi. tuberculosis bacilli enter the macrophage via specific binding 
to several distinct cell surface molecules. FIG. 1.3 shows a TEM study of the 
ingestion of M tuberculosis by macrophages. A'/. tuberculosis can bind directly via 
complement receptors and the macrophage mannose receptor (MMRc). The MMRc 
participates in nonopsonin mediated phagocytosis by recognition of terminal 
mannose residues on targeted particles (Fenton and Vermeulen, 1996). Macrophage 
phagocytosis of virulent strains of .\rl. tuberculosis (e.g., Erdman and H37Rv) in the 
absence of serum can be substantially inhibited by soluble mannan, mannose­
albumin and anti-Mrv!Rc antibodies (Schlesinger, 1993). Binding of the attenuated 
M tuberculosis strain H3 7Ra to macrophages is not blocked by these agents. 
Expression of MMRc on the cell surface is regulated by a variety of mediators that 
play a role in the pathogenesis of tuberculosis. Gamma interferon (IFN-y) down 
regulates MMRc expression while concomitantly increasing the capacity of the cells 
to kill microorganisms, suggesting enhanced coupling of the MMRc to microbicidal 
functions. In contrast. interleukin-4 (IL-4) is a potent enhancer of MMRc expression 
(Fenton and Vermeulen. 1996). 
The binding of virulent M tuberculosis to the MMRc may be mediated by Mannose 
Lipoarabinomannan (ManLAM). This \Vas suggested by the finding that anti­
ManLAM monoclonal antibodies reduced M tuberculosis binding to macrophages 
by as much as 49% (Schlesinger et al, 199-+). 
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FIG. 1.3 Monocytes ingest M tuberculosis by conventional phagocytosis. Micrographs A 
to G show sequential stages in monocyte phagocytosis of M tuberculosis. Micrographs A 
and 8 show early stages of ingestion. Bacteria are tightly adherent to the monocyte 
surface. Micrographs C to E show more advanced stages of ingestion. The bacteria are in 
the process of being internalised. Micrographs F and G show the final stages of ingestion. 
The bacteria are completely enclosed within the membrane bound vacuoles or 
phagosomes. Phagocytosis appears to involve two simultaneous processes - the extension 
of monocyte pseudopods circumferentially about the organism until they meet at the distal 
side ( 8 to D, F) and the displacement of the cytoplasm at the zone of contact between the 
monocyte and the bacterium such that the bacterium appears to sink into the phagocyte 
( A, E ). ( A and B ) x 32 000; ( C ) x 40 000; ( 0 ) x 32 000; ( E ) x 24 000; 
( F ) x 48 000; ( G ) x 24 000, ( Schlesinger et al., 1990 ). 
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It was reported that a mannose-dependent pathway for particle uptake by 
macrophages. distinct from the MMRc is mediated by lung surfactant protein A. It 
remains to be tested whether the surfactant protein A may serve as an opsonin for 
inhaled organisms and may provide an alternative means for mycobacteria to enter 
the macrophage. Mannose-dependent binding is likely to account for only a portion 
of total phagocytosed J/ tuberculosis (Fenton and Vermeulen, 1996). 
Peterson et al. (1995) implicated COl4, a signalling receptor for gram-negative 
bacterial lipopolysaccharide (LPS), in the uptake of nonopsonised J\;/ tuberculosis. 
Treatment of human microglial cells with anti-CO14 antibodies or soluble CO14 was 
found to significantly block the infection of these cells by M tuberculosis. 
An important role for heat-labile serum components and the complement receptors 
CR! (CD35), CR3 (COi lb/CO18) and CR4 (COi l c/CO18) in the binding of Af 
tuberculosis to macrophages has also been well established (Schlesinger et al, 1990; 
Schlesinger and Horo\vitz, 199 I and Schlesinger, 1993). The adherence and ingestion 
of M tuberculosis can be markedly inhibited (up to 84%) by antibodies against CR I, 
CR3 and CR➔ in the presence or absence of fresh serum. Uptake of 1\1! ruberculosis is 
also reduced in serum depleted of the complement component 3 (C3). Anti-C3 
monoclonal antibodies inhibited monocyte adherence of preopsonized M ruberculosis 
by 71 %. Schlesinger et al, ( 1990) showed that a monoclonal antibody against the type 
I CR (CR I) inhibits adherence of M tuberculosis by 40 ± 5% and three different 
monoclonal antibodies against CR3 each inhibit adherence by 39% ± 5% to 47% ± 
5%. A monoclonal antibody against CR I used in combination with one of the three 
monoclonal antibodies against CR3 inhibits adherence by up to 64 ± 7%. FIG. 1.4 





FIG. I .4. Antituberculosis macrophage activities and evasion mechanisms. Accumulating evidence 
suggests that M. tuberculosis enters macrophages is specific binding to cell surface molecules of 
phagocytes. It has been reported that the tubercle bacillus can bind directly to the mannoase receptor 
via the cell wall associated mannosylated glycolipid LAM (I) or indirectly via complement receptors of 
the integrin family (CR 1, CR3) or Fe receptors (2). Phagocytosis (3) triggered by engaging certain cell 
surface molecules such as the Fe receptor stimulates the production of ROI via activation of the 
oxidative burst ( 4 ). Experimental data indicate that M tuberculosis can interfere with the toxic effect of 
ROI by various mechanisms. First, various mycobacterial compounds including glycolipids (GL), 
sulfatides (ST) and LAM can downregulate the oxidative cytotoxic mechanism. Second uptake via 
CR I bypasses activation of the respiratory burst. Cytokine activated macrophages produce RNI that at 
least in the mouse system mediate potent antimycobacterial activity (6). The acidic condition of the 
phagolysosomal vacuole can be conducive to the toxic effect of RNI (7). However, NH,· production by 
M. tuberculosis may attenuate the potency of the L-arginine dependent antimycobacterial mechanism
and that of lysosomal enzymes (8) which operate best at an acidic pH. In addition mycobacterial
products such as sulfatides and NH; may interfere with phagolysosomal fusion (9). Finally the
tubercle bacillus may evade the highly toxic environment by escaping into the cytoplasm via the
production of hemolysin ( I 0) (Chan and Kaufmann, 1994 ).
1.2.3 THE FA TE OF fNTRACELLULAR lvf tuberculosis 
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After attachment and subsequent phagocytosis of ii;/ ruberculosis, sustained 
intracellular bacterial growth depends on the ability to avoid destruction by lysosomal 
enzymes, reactive oxygen intermediates (ROI) and the reactive nitrogen intermediates 
(RN!). A capacity to block the fusion of mycobacterium containing phagosomes with 
lysosomes could be critical for this survival; a key question is whether Iv! tuberculosis 
bacilli possess one. In 1975 Armstrong and Hart used ferritin-prelabelled secondary 
lysosomes to study the fusion of phagosomes \vith lysosomes. Their study showed 
that the virulent H3 7R v strain prevented lysosome-phagosome fusion in normal 
mouse peritoneal macrophages. 
McDonough et al. ( 1993) investigated the effect that Iv! tuberculosis has on 
phagolysosome fusion using thoria labelled lysosomes with virulent H37Rv, avirulent 
H3 7Ra M ruberculosis strains and lvlycobacterium bovis BCG at an electron 
microscopy level. At 2 h postinfection approximately 85% of the bacteria clearly 
resided in fused vacuoles, however, at 4 days postinfection, fusion levels for viable 
H37Rv and H37Ra were reduced by half, whereas, the fusion profiles of BCG and 
heat-killed H37Rv and H37Ra were unchanged. The results suggest a net transfer of 
bacteria out of the fused vacuoles and preferential bacterial multiplication in nonfused 
vacuoles. H37Rv and H37Ra appeared to bud from the phagolysosome into tight 
membrane vesicles that did not fuse with secondary lysosomes. 
lvf tuberculosis appears to have the ability too disrupt the normal functioning of 
phagosomes, preventing them from developing into acidic hydrolase-rich 
compartments. The restricted capacity of mycobacterial phagosomes to fuse with other 
vesicles suggested that their biochemical composition is altered, either preventing 
delivery of the mycobacteria into the lysosomal compartment or blocking association 
of phagosomes with host molecules that are harmful to the_ bacilli. This was
confirmed by studies that revealed that vacuolar membranes surrounding the bacilli 
lacked a proton-A TPase, which may be responsible for phagosomal acidification (Xu 
et al, 1994 ). 
1.2.4 MICROBICIDAL ACTION OF MACROPHAGES 
21 
Historically, researchers have assumed that activated macrophages can kill M. 
tuberculosis. However, this assumption has been difficult to prove unequivocally in 
vitro, especially with human monocytes and macrophages (Fenton and Vermeulen, 
1996). Douvas et al reported in 1986 that human monocytes cultured for 3 days were 
measurably better at suppressing the growth of virulent lvf tuberculosis than were 
either fresh monocytes or those cultured for 7 days. Also, in 199 la, Denis reported 
that human monocytes could be activated to high microbicidal activity following 
treatment with cytokines such as, interferon, IFN-y and tumor necrosis factor TNF. 
However, a more recent report by Warwick-Davies (1994) suggested that this 
apparent killing of M. tuberculosis could be an artifact of the experiment and that this 
cytokine treatment regimen actually renders macrophages more sensitive to the toxic 
effects of the mycobacteria. 
If the killing of ingested mycobacteria did occur then the most likely place will be 
within the macrophage phagolysosome. Toxic constituents found within this acidic 
vesicle include lysosomal hydrolases, ROI such as H202 and 02·, and RNI such as NO 
and N0 2•. The resistance of several strains of !'vf tuberculosis to RNI in vitro, 
generated at an acidic pH, was found to correlate significantly with the virulence of 
the strain tested. RN! production by murine macrophages is an important effector 
mechanism against a variety of pathogens. In macrophages, NO and other RNI are 
derived from L-arginine via an enzymatic pathway controlled by an inducible nitric 
oxide synthase (iNOS). Cytokines are powerful modulators of murine macrophage 
RNI synthesis, where TNF and IFN-y are potent activators of iNOS, while interleukin, 
IL-4 and IL- IO suppress it (Gazzinelli et al, 1992 and Ozwald et al, 1992). 
Transfonning grow1h factor � 1 (TGF-� I) has also been reported to attenuate NO 
production and RNI-mediated antimicrobial functions (Nelson et al, 1991 and Ozwald 
et al, 1992). Growth inhibition of mycobacteria by cytokine-stimulated murine 
macrophages strongly correlates \,\·ith the generation of RNI. IFN-y-deticient mice 
infected with lvf tuberculosis are unable to restrict the growth of the organisms. 
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These mice develop granulomas but fail to produce RNl (Flynn et al, 1993 - cited by 
Fenton and Vermeulen, 1996). 
There is much debate about the role of RNI in infected human macrophages (Denis, 
1991 a - cited by Fenton and Vermeulen, 1996). Although the production of iNOS 
mRNA and protein by primary human macrophages has been reported, efforts to 
demonstrate an L-arginine-dependent pathway for RNI production in human 
macrophages have generally produced inconsistent results. These observations may 
reflect intrinsic differences between human and murine cells. One possible difference 
may be the requirement for the cofactor tetrahydrobiopterin, which may not be present 
in sufficient quantities in resting human macrophages (Schoendon et al, 1987 and 
Werner et al, 1989). Alternatively, human macrophages may require additional 
induction signals for Rl'\Jl production. 
Nuss I er et al. ( I 992) showed that a combination of lipopolysaccharide (LPS) and the 
cytokines lL-1, TNF and IFN-y was required in order for human hepatocytes to 
produce RNI via an L-arginine dependent pathway. The iNOS activity was dependent 
on the coinduction of tetrahydrobiopterin synthesis. Another possibility is that human 
macrophages may produce higher amounts of cytokines that suppress RN! production 
(e.g., IL-4, IL- IO and TGF-� I) compared to murine cells. ROI alone may be 
insufficient to destroy Alf tuberculosis but combined with RNI can significantly 
enhance mycobacterial killing (Stamler et al, 1992). Several mycobacterial products, 
including sulfatides and lipoarabinomannan (LAM) can scavenge ROI or inhibit the 
respiratory burst that generate them (Chan et al, 1991 ). 
The capacities of resident alveolar macrophages and recruited monocy1es to destroy 
mycobacteria differ significantly and progressively throughout the course of an 
infection. Initial infection by M tuberculosis rapidly leads to the activation of 
alveolar macrophages, the induction of cy1okines which serve t� limit the growth of 
the ingested organisms, and the recruitment of additional leukocytes from the 
peripheral circulation. Enhancement of macrophage microbicidal function can be 




T cells that secrete IFN-y and IL-2. lFN-·r 
alone cannot activate macrophage sufficiently to inhibit M tuberculosis replication, 
although combined exposure to IFN-y and TNF was reported to be sufficient for 
effective killing (Denis, I 99 la). The immature monocytes recruited from the 
periphery are thought to be less effective in killing mycobacteria and are the preferred 
host. The local production of IFN-y and TNF by leukocytes is critical for the 
differentiation and activation of these recruited monocytes. Treatment of mice 
infected with BCG or lvf tuberculosis with a neutralizing antibody directed against 
TNF was originally shown to block granuloma formation and to enhance bacterial 
growth , Denis, 1991 b and Kindler et al, 1989). A recent study with transgenic mice 
(Flynn et al. 1995), lacking the 55 kDa THF receptor demonstrated that these animals 
cannot clear an M tuberculosis infection. These mice and others treated in vivo with 
anti-TNF neutralizing antibody formed granulomas but in delayed manner. The 
granulomas observed in mice lacking normal TNF function were qualitatively distinct, 
lacking epitheloid cells and containing larger numbers of Af tuberculosis. 
1.2.5 EFFECT OF LAM ON MACROPHAGES 
Studies by Sturgill-Koszycki et al. (I 994) and Xu et al. (I 994) suggests that lvf 
tuberculosis bacilli that have evaded the destruction by the macrophage not only 
multiply but release mycobacterial products that can affect local immune responses. 
Vesicles containing lipoarabinomannan (LAM) (and possibly other mycobacterial 
products) were released by phagosomes containing ingested mycobacteria, suggesting 
the active transport of mycobacterial products out of infected cells. LAM released by 
infected macrophages may act in a paracrine manner to modulate the function of 
surrounding leukocytes. The biological activities of LAMs from different 
mycobacteria have been studied and their chemical derivatives defined. 
AraLAM (the arabinose termini are capped with additional inositol phosphates) is 
I 00-fold more potent at inducing TNF production by macrophages than is ManLAM ( 
the arabinose termini are capped with a few additional mannose residues). Similar 
results have been observed for IL-!, IL-! 0, NO and chemokine induction (Roach et al, 
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1993 and Roach et al, I 994). It has also been sho"m that AraLAM rapidly activates 
the critical transcription factor NF-K� in murine macrophages to a much greater extent 
than does Man LAM. Both AraLAM and ManLAM induce sustained accumulation of 
KBF 1, which may inhibit NF-K�-dependent gene transcription (Brown and Taff et, 
1995). While studies differ with respect to the observed biological importance of 
polysaccharide domains at the nonreducing termini of LAM, there was general 
agreement that acyl groups associated with the phosphatidylinositol end of the 
molecule are essential for the biological activities of LAM on monocytic cells (Barnes 
et al, 1992 and Chatterjee et al, 1992). 
1.2.6 INTERACTIONS BETWEEN T-CELLS AND MACROPHAGES 
The collaboration betv.:een macrophages and T-cells is essential for eradication of Af 
tuberculosis via antigen specific delayed-type hypersensitivity (0TH) responses. 
Initially, activated macrophages present mycobacterial antigens to T-cells in 
association with major histocompatibility complex (MHC) class I or class 11 proteins 
or with nonpolymorphic MHC-like proteins. Macrophage derived cytokines play 
critical roles as costimulatory molecules for antigen specific T-cells. Thi type 
cytokines (e.g. IL-2 and IFN-y) may enhance antigen presentation and stimulate 
antimicrobial responses within the infected macrophage itself. The presence of both 
antigen-specific T-cells and activated macrophages within the granuloma provides 
long-term surveillance and containment of infected macrophages, although immune 
responses may shift over time to favour the suppression of 0TH reactions (Fenton and 
Vermeulen, 1996). 
In murine models of tuberculosis, the initial Th I type response needed for effective 
0TH development is followed by a Th 2 type response v.:hich probably serves to limit 
inflammation and minimize tissue injury at the site of infection.(Orme et al., 1993). 
The macrophage cytokine IL-2 may be important in favouring the developmemt of the 
0TH response by enhancing production of IFN-y which facilitates the development of 
Th I cells and augments the cytotoxicity of antigen specific T-cells and natural killer 
cells. Th 2 type responses may contribute to the immunosuppression often observed 
in advanced disease. Tuberculosis patients coinfected ,vith HIV have diminished Th 1 
type responses compared with HIV-seronegative tuberculosis patients (Zhang et al, 
1994). Macrophages are likely to contribute further to these responses through the 
production of the immunosuppressive cytokines II-IO and TGF-P 1. The cytokine 
network controls a complex set of responses that may be growth modulatory to lvf
tuberculosis, proinflammatory or immunosuppressive (Toossi et al, 1995). 
1.3 PZA: ANTIMYCOBACTERIAL AGENT UNDER STUDY 
PZA, a white, odourless, crystalline powder; is a synthetic pyrazme analogue of 
nicotinamide (MacGregor, 1988). PZA was first shov.rn to be an effective 
antitubercular drug in the year 1952 (Kushner et al, 1952 - cited by Lacroix et al, 
1989). However, it fell into disrepute subsequently due to the high incidence of 
hepatoto:xicity associated with its use in doses as high as 3g/day (Singh et al, 1993). 
PZA has regained its place in the front-line with reduced dosages and incidental 
minimal side effects (Singh et al, 1993). PZA has become an essential component of 
current six month regimens for therapy of tuberculosis (Salfinger et al, 1990). 
Inclusion of PZA for 2 months in regimens containing isoniazid and rifampicin 
throughout with ethambutol or streptomycin in the initial phase has produced highly 
effective short-term regimens which prevent failure associated with the emergence of 
resistance during chemotherapy and which are followed by negligible relapse rates 
(Girling, 1984). 
1.3.1 PROPOSED MODE OF ACTIO1. OF PZA 
The exact mode of action of PZA is not known (Singh et al, � 993). A commonly 
accepted hypothesis explaining the mechanisms of action of PZA 1s based on the 
assumption that PZA susceptible /vf tuberculosis strains produce pyrazinamidase, 
which hydrolyses PZA to the antibacterial moiety, POA. The proposed mode of 
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action is shown in FIG. 1.5. It is not clear whether POA has specific antimicrobial 
activity or the inhibition of growth caused by POA is due to its ability to lower the pH 
of the environment below the limits of tolerance of .'vi. tuberculosis growth (Heifers et 
al, 1989; Konno et al. 1967 and Singh et al. 1993). Strains resistant to PZA do not 
produce pyrazinamidase, thus do not convert PZA to POA and therefore are not 
vulnerable to PZA. 
1.3.2 PHARMACOLOGY AND PHARMACOKrNETICS OF PZA 
1.3.2.1 Absorption and fate 
PZA is readily absorbed from the gastro-intestinal tract (Reynolds, 1989). It is widely 
distributed throughout the body fluids and tissues, attaining concentrations above that 
needed to inhibit tubercle bacilli. Peak plasma concentrations are approximately 50 
µg. mi- 1, with a half life of 12-24 hours, making once daily or less frequent dosing 
practical (Alford, 1979 and Alford and Wallace, Jr. 1995). PZA crosses intlammed 
meninges and has been recommended in combination regimens for tuberculous 
meningitis (Donald and Seifart, 1988). Its absorption is not significantly hindered by 
food. The excellent penetration of PZA across the blood brain barrier is due to its 
moderately lipophilic nature, unchanged at body pH and not bound to serum proteins 
(Ellard et al, 1987 - cited by Singh et al, 1993). It is metabolised by the liver and 
metabolic products including principally pyrazinoic acid (POA), are excreted mainly 
by the kidneys. Thus, dosage modification is required in renal failure. PZA is 
dialyzable so that supplement dosage may be ad\·isable after dialysis sessions (Alford 
and Wallace, Jr, et al, 1995). It is excreted through the kidney mainly by glomerular 
filtration. About 70% of a dose appears in the unne within 24 hours mainly as 
metabolites and 4 to 14% as unchanged drug. PZA is excreted in breast milk 












FIG. 1.5 The proposed mode of action of PZA. Susceptible M. tuherculosis strains are known to produce 
the enzyme pyrazinamidase, which converts PZA to POA. It is suggested that it is this enzyme generated 




1.3.2.2 Administration and dosage 
The high incidence of hepatotoxicity associated with early regimens which used large 
doses of PZA given for prolonged periods led to PZA being considered unsuitable for 
use in the primary treatment of tuberculosis. Its uses was largely reserved for re­
treatment regimens for drug resistant tuberculosis and for initial therapy in developing 
countries where the incidence of primary resistance is high. Hov.-ever, the currently 
recommended doses are considerably safer and because of its unique activity against 
tubercle bacilli in an acid environment, PZA is now an important first line drug in 
intensive phase of short-term antituberculous regimens (Reynolds, 1989 and Singh et 
al, 1993). Transplacental passage of PZA has been shown but its use in pregnancy is 
not contra-indicated. No embryo fetotoxity or teratogenicity has been observed. PZA, 
though detected in human milk is far below the therapeutic range and is considered 
safe for use in nursing mothers (Singh et al, 1993). 
PZA is available in 500 mg tablets. Dosage is 20-35 mg/kg/day (often 1.5-2.0g) orally 
once a day or in two divided doses. PZA has been well tolerated in a twice weekly 
dosage of 50 mg/kg (not to exceed 3g/day) for short course regimens. It has been 
administered safely once weekly in a dose of 90 mg/kg ( Alford, 1979 and Alford and 
Wallace, 1995). 
1.3.2.3 Metabolism 
Lacroix el al. ( 1989) studied the plasma and urine pharmacokinetic parameters of 
PZA and its metabolites, pyrazinoic acid (POA), 5-hydroxy-pyrazinamide (5-OH­
PZA), 5-hydroxy-pyrazinoic acid (5-OH-POA) and pyrazinuric acid (PZU). These 
researchers found that limiting factor was the activity of a microsomal deamidase 
(POA formation from PZA and 5-OH-POA formation from 5-OH-PZA). In contrast, 
oxidation by xanthine oxidase occurred very rapidly (5-OH-PZA formation and POA 
catabolism to 5-OH-POA). 
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Weiner and Tinker ( 1972) described the main stages of PZA metabolism. The first 
stage invoh·es microsomal deamidase which leads to formation of POA and second 
xanthine oxidase which produces 5-OH-POA. These researchers also showed the 
existence of another metabolite \iVith polarographic characteristics similar to those of 
5-OH-POA but different electrophoretic mobility. A component with a similar
extinction coefficient to 5-OH-POA was isolated by Auscher et al. (1978 - cited by 
Lacroix et al, 1989). The nature of this component was examined by Pitre el al. ( 1981 
- cited by Lacroix, 1989) using rat liver cells and by Yamamoto et al. ( 1987a) and
Bereta el al. ( 1987) in man, all of whom considered it to be 5-OH-PZA, produced by 
the direct action of xanthine oxidase on PZA. Yamamoto et al. (1987b), then shown a 
second oxidizing enzyme which operates jointly \vith xanthine oxidase in the 
sequence PZA⇒ 5-OH-PZA. Through a minor route, POA combines with glycine to 
form pyrazinuric acid. Thus, a metabolic scheme was proposed as illustrated in FIG 
1.6. 
1.3.2.-t Adverse effects of PZA 
Hepatotoxicity is the most senous side effect of PZA therapy and its frequency 
appears to be related to dose and duration of treatment (Reynolds, 1989). 
Hepatotoxicity occurred in nearly 15% of PZA recipients in early trials that employed 
dosages of 40-50 mg/kg/day for prolonged periods. Current regimens are much safer. 
Patients with pre-existing liver disease who receive PZA should have symptoms and 
hepatic function tests monitored closely (Zierski and Bek, 1980). Hepatomegaly, 
splenomegaly and jaundice may develop and in rare cases fulminating acute yellow 
atrophy and death have occurred. Other side effects are anorexia, nausea. vomiting, 
arthralgia, malaise, fever, sideroblastic anaemia and dysuria. Photosensitivity and 
skin rashes have also been reported. Hyperuricaemia commonly occurs and may lead 
to attacks of gout (Dannenberg and Tomashefski, 1988; Alford, et al, 1979 and Alford 
and Wallace. Jr. 1995; Reynolds, 1989 and Singh et al, l �93). Treatment of 
overdosage with PZA consists of gastric lavage and supportive therapy. If 


























FIG. 1.6 The principal metabolic pathways of pyrazinamide (Lacroix et al., 1989) 
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although a uricosuric agent such as probenecid has been given. PZA is contra­
indicated in patients with liver damage. Liver function should be assessed before and 
regularly during treatment. Caution should be observed in patients with impaired 
renal function or a history of gout. It has also been reported that there is increased 
difficulty in controlling diabetes mellitus when diabetics are given PZA (Reynolds, 
1989). 
1.3.3 PZA ACTIVITY TN MACROPHAGES 
The persistence of certain pathogenic bacteria within phagocytes, most often 
macrophages, may lead to progressive or chronic clinical infections (Hand et al, 
1984). Viable intraphagocytic organisms are protected from the action of certain 
antimicrobial agents (Mackaness. 1952 and Suter, 1952). The efficacy of antibiotics 
in the treatment of these infections depends upon both the extracellular drug-bacterial 
interaction and the effect of intracellular drug on the phagocyte and the organism. 
Since chronic infections due to facultative intracellular organisms frequently occur in 
the lung, the interactions of antibiotics, bacteria and alveolar macrophages are of 
interest (Hand et al, 1983 and 198➔; Johnson et al, 1980). 
Carlone et al. ( 1985) investigated the killing capacity of rifampicin, PZA and POA 
on macrophage ingested live M tuberculosis. The three drugs were used at 
concentrations corresponding to the average peak levels observed in humans after 
administration of therapeutic doses viz., 30 pg/ml PZA, IO �tg/ml rifampicin and 8 
µg/ml POA as determined by Acocella et al. ( 1985). Comparing the degree of killing 
in the control drug free cultures with that observed in the drug containing systems 
over a period of 3 to 24h indicated that a greater, more rapidly, although not 
statistically significant killing of intracellular mycobacteria took place. At 48h the 
degree of killing was similar in the control and the drug con_taining cell cultures. 
There was a marked growth of intracellular mycobacteria observed between 48 and 
72h in the control cultures which was less evident in the drug containing cultures. 
There was no major increase in the killing effect with respect to that observed with the 
individual drugs after exposure of the macrophages to all possible combinations of the 
three drugs. This finding could be explained on the basis of the hypothesis that each 
drug achieved a maximal (or near maximal) killing effect when used alone, so that no 
excess killing could be expected to occur adding one or two drugs. Another possible 
interpretation is the one referring to a process of competition between drugs for either 
entry into the macrophage or for some binding relevant to antimicrobial activity 
within the macrophages (Carlone et al, 1985). 
Acocella and co-workers ( 1985) investigated the degree of penetration of rifampicin, 
PZA and POA in mouse macrophages. Unlike the study by Carlone et al. ( 1985) 
which investigated killing of ingested mycobacteria over 72h this study only evaluated 
penetration of the drugs for 24h. Also, drugs at concentrations corresponding to peak, 
trough and intermediate serum concentrations observed in humans after 
administration of therapeutic doses \.Vere used which differed from the studies by 
Carlone et al. ( 1985) \.Vhere peak serum concentrations were used. Another difference 
was the use of macrophages in different metabolic stages viz., resident, stimulated and 
dead. The drugs were radiolabelled with 
14
C \.Vhich enabled intracellular penetration 
to be assessed by a scintillation spectrophotometry. The results obtained in this study 
indicated that rifampicin, PZA and POA penetrate rapidly into macrophages, 
irrespective of their metabolic state. The penetration is almost complete at the lower 
concentrations. Increasing the concentration of exposure leads to increased 
penetration into the macrophage, but not proportionally with the concentration. While 
stimulation of macrophages had a marked effect on the degree of penetration of 
rifampicin at the higher concentrations, it affected PZA penetration only at the lower 
concentrations and seemed not to affect penetration of POA. This difference in 
behaviour may reflect different mechanisms of transfer through the macrophage 
membrane. Transfer across the macrophage membrane of the three drugs seems to be 
by simple diffusion. At the single concentration of each drug, the degree of 
penetration was similar in dead and live macrophages, strongly s�ggesting the absence 
of an energy requiring process. Rifampicin, PZA and POA appear to have different 
capacities to bind to intracellular proteins, where analysis of the free/bound ratios 
indicates that more "·binding sites·· are available for rifampicin than for the PZA and 
POA (Acocella et al, 1985). 
At neutral pH PZA is almost de\·oid of antibacterial activity against tubercle bacilli 
growing in commonly used bacteriologic culture mediums (Dickinson and Mitchison, 
1970 and Butler and Kilburn, 1982). Its effectiveness in laboratory animals is 
inconsistent, thus PZA is bactericidal in mice but it seems to be inactive in the guinea 
pig (McCune et al, 1966a and b ). Crowle et al. ( 1986) investigated the effect of PZA 
alone on tubercle bacilli within cultured human macrophages. In this study the effect 
of PZA on intracellular bacilli were assessed by counts of acid fast bacilli and colony 
forming units (CFU). PZA was active in the macrophage model as it was clinically 
inhibiting virulent tubercle bacilli at concentrations of 20 �tg/ml or higher, however, it 
was ineffective in 7H9 bacteriologic culture medium. It could either be bacteriostatic 
or bactericidal against intramacrophage tubercle bacilli, depending on its 
concentration, the donor of the macrophage and the length of exposure of the infected 
macrophages to the drug. The results obtained by Crowle er al. ( 1986) \.Vith human 
blood monocyte derived macrophages agree well with the findings of Mackaness 
( 1956) \Vith similarly cultured rabbit peritoneal exudate macrophages. 
Crowle et al. (1986) observed that the inhibitory effect of PZA in their macrophage 
cultures diminished between the fourth and seventh days after infection and that 
adding PZA a second time at 4 days did not change this. The following rationale 
could explain this paradox. Active tubercle bacilli produce amidase which converts 
PZA to bacillus inhibiting POA (Butler and Kilburn, 1982 and 1983; Ellard, I 969; 
Konno er al, 1967). They also produce ammonia (Gordon er al, 1980) which 
increases phagolysosome pH. Increased pH diminishes the effectiveness of POA 
which is almost ineffective at pH 6 or higher, as well as the effectiveness of acid 
dependent, potentially antimicrobial lysosomal enzymes. Thus, active bacilli will be 
converting PZA to POA and inhibiting themselves, bu! also be raising 
phagolysosomal pH and protecting themselves. Ammonia escapes rapidly from 
phagolysosomes. It would not be replenished by POA inhibited bacilli and the net 
early effect on active bacilli of PZA will be conversion to POA \.Vithout much pH 
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change and therefore bacillary inhibition. Later, as the bacilli become inhibited they 
should make less amidase and, therefore, less POA and effectiveness of PZA should 
decrease. Consequently, the effects of PZA on tubercle bacilli appear to be self 
modulating and both bacillus interdependent (e.g. production of protective ammonia) 
and host interdependent (acid pH in phagolysosomes, lysosomal enzymes with acid 
pH optima. xanthine oxidase converting active POA to inactive 5-hydropyrazinoic 
acid (Crowle et al, 1986). 
In this study it was also found that tubercle bacilli may replicate within human 
macrophage in non-acid form, thus indicating that colony forming units are inherently 
more accurate than acid fast bacilli counts. This also suggests that important changes 
in the bacillary cell wall composition may occur among tubercle bacilli within 
infected human macrophages after exposure to PZA (Crowle et al, 1986). It may also 
account for the undetectability of --persisting" tubercle bacilli in PZA treated mice as 
described by McCune et al. ( l 966a.b ). 
Sal finger et al. ( 1989) reported a simple radiometric method for susceptibility testing 
of M. tuberculosis against PZA at pH 6.0 viz., the BACTEC method. In 1990 
Sal finger et al. reported on a comparison of PZA and POA activity in cultured human 
macrophages and in the BACTEC system. PZA susceptibility results obtained in 
cultured human macrophages were compared with those in the broth BACTEC system 
with 7H 12 mediun at pH 6.0 for strains known to be pyrazinamidase positive or 
negative. Pyrazinamidase negative tubercle bacilli were resistant to PZA in both 
infected macrophages and the BACTEC system. However, POA was unable to inhibit 
tubercle bacilli in cultured macrophages, but it was able to inhibit them at high 
concentrations in the BACTEC system. POA's ability to inhibit tubercle bacilli in the 
BACTEC system was proportional to its concentration and to the decrease in pH that 
in itself may be inhibitory. It is possible, therefore, that PZA inhibits tubercle bacilli 
in cultured macrophages physically rather than biochemically (Salfinger et al, 1990). 
The comparative activity of PZA and POA against tubercle bacilli in the infected 
macrophage and broth BACTEC systems provides further insights into the possible 
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mechanism of PZA ·s clinical effectiveness versus iv! tuberculosis. Activity of PZA 
or POA in the BACTEC system is not dependent on drug penetration, as it is in the 
macrophage model. The results of Sal finger er al. ( 1990) suggest that the cultured 
macrophage must contribute actively or passively to effectiveness of PZA, such as 
through the proposed mechanism of low pH generated by pyrazinamidase in the 
phagolysosomes. A purely in vitro test such as the BACTEC system can serve as a 
convenient tool for evaluating antimycobacterial drugs, but the cultured macrophage 
system may more closely approximate in vivo reality (Salfinger et al, 1990). 
The outbreaks of multi drug resistant (MOR) tuberculosis have raised questions as to 
the most appropriate therapeutic response for those exposed to such organisms. 
Sbarbaro et al. ( 1996) investigated the combined effect of PZA and a quinolone 
( ofloxacin) as a potential preventive therapy regimen. Three different concentrations 
of ofloxacin (OFL) (0.625�tg, I .25�tg, 2.5pg/ml) were tested in combination with 40 
�tg/ml dosage of PZA, \vhich demonstrated an inhibitory effect upon intracellular 
tubercle bacillary grov,1h. PZA enhanced the effectiveness of both bacteriostatic 
concentrations of OFL. converting the bacteriostatic impact of 1.25 �tg/ml to a 
bactericidal effect. The addition of PZA did not diminish the killing effect of the 2.5 
µg/ml OFL. This differs from a previous study by Sbarbaro et al. ( 1992) where the 
bactericidal effectiveness of rifampin was reduced when administered simultaneously 
with PZA. The additive or interactive actions appear to be equally present even when 
the drugs are administered sequentially two days apart, however the killing impact of 
rifampin \Vas clearly diminished when PZA was administered two days in advance to 
rifampin (Sbarbaro et al, 1992). 
The observations of Sbarbaro et al. ( 1996) suggest that the combination of a 
fluoroquinolone and PZA will provide an effective alternative regimen for 
prophylactic or preventive intervention. However, both OFL and PZA are eliminated 
from the kidneys. When used together clinically, competitiv.e inhibition of drug 
elimination might be expected, and probably underlies the unexpectedly high rate 
(44%) of arthralgias observed by 7 of 16 health workers treated with a preventive 
regimen of 800 mg/day of OFL and 1500 �tg/day PZA (Horn et al, 1994). Arthralgias 
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are a well documented side effect of PZA and can be minimized with a reduction in 
daily dosage or by limiting treatment with PZA to three times per week (Sbarbaro et 
al, 1996). 
Mor and Esfandiari (1997) investigated the synergistic activities of clarithromycin 
(CLA) and pyrazinamide against Af tuberculosis. CLA is an acid stable macrolide 
antibiotic with good bioavailability after oral administration, however, its activity 
against M tuberculosis has been relatively poor (Gorzynski et al, 1989 and Traffert­
Pemot, 1995). Since PZA works most effectively on bacteria in an acid environment 
and within macrophages, any drug that could enhance its activity should therefore be 
invaluable in the treatment of tuberculosis. The combination of CLA and PZA 
exerted a synergistic effect in preventing intracellular bacterial growth, however the 
combination of rifampin and PZA produced only an additive effect. CLA, even at 
subinhibitory concentrations significantly enhanced the effect of PZA. This indicates 
that CLA tends to enhance the effectiveness of PZA against tubercle bacilli within 
cultured human macrophages, however this effect was not demonstrated to be 
bactericidal during the eight days of this study (Mor and Esfandiari, 1997). 
1.3.4 ANTIBACTERIAL ACTIVITY OF PZA 
The commonly accepted hypothesis regarding the mechanism of action of PZA is the 
production by PZA susceptible ,\,/ tuberculosis strains of pyrazinamidase, which 
hydrolyses PZA to the antibacterial moiety POA. It is not clear whether POA has 
specific antimicrobial activity or that the inhibition of grovvth caused by POA is due to 
its ability to lower the pH of the environment below the limits of tolerance of ,\ti 
tuberculosis grovv1h (Konno et al, I 967). Pavlov et al. ( 1974 - cited by Heifets et al, 
1989) showed that exposure to PZA increased the acidity in small areas surrounding 
phagocytosed M. tuberculosis organisms, lowering the usual i�tracellular pH range 
from 5.0 to 5.3 to 4.5 to 4.7 which could be due to the transformation of PZA to POA. 
Heifets et al. ( 1989) then addressed the question whether POA has any specific 
antimicrobial activity or whether it affects the grovvth of }.tf tuberculosis simply by 
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lowering the pH belo\v the limits of tolerance. There was a clear dose-effect 
correlation when the inhibitory activities of different concentrations of POA under 
identical pH conditions (5.6) in 7Hl2 liquid medium was evaluated. This showed that 
POA does have specific activity against .vi tuberculosis. The minimum inhibitory 
concentrations (MICs) of POA were determined using the radiometric BACTEC 
system (Heifets et al, 1985; Salfinger and Heifets, 1988) and it was found that under 
these conditions the MI Cs were 240 to 480 �tg/ml. This is 8 to 16 times higher than 
the MICs of PZA. There were previous suggestions that POA is less active in vitro 
than PZA (Dickinson and Mitchison, 1970; Ellard, 1969), with only a two fold 
difference between the MI Cs of POA and PZA (Ellard, 1969). However, the ultimate 
question concerns the validity of the theory that PZA acts by its conversion to POA in 
vivo, since the concentration of POA in human serum does not exceed l O �tg/ml 
(Ellard, 1969). This study supports that part of the hypothesis that states that POA is 
an antimicrobial agent, but seems to contradict (owing to the high MICs) the 
suggestion that it is the only antimicrobial moiety of PZA. A possible explanation is 
the assumption that high concentrations of POA, close to the MIC and much higher 
than the concentrations of both PZA and POA found in serum, might be achieved in 
the immediate surroundings of mycobacterial cells, which is supported by studies by 
Pavlov et al.( 1974 - cited by Heifets et al, 1989). An assumption made is that 
mycobacterial cells act like pumps consuming PZA from the surrounding environment 
and transforming it into POA, \,Vhich accumulates at the surface of each cell and is 
delayed in diffusing into the medium. Another possibility is that the MIC for POA 
decreases with a drop in pH. The action of POA in an acid environment could be a 
combined effect of its specific activity and its ability to lower the pH below the limits 
of tolerance of the target organism (Heifets et al, 1989). 
The activity of PZA can be demonstrated only in an acid medium in vitro (McDermott 
and Tompsett, 1954), which is not favourable to the growth of/\;/ tuberculosis. Thus, 
this poses a problem when testing the susceptibilities of 1\lf lt(berculosis strains to 
PZA as shown by Butler and Kilburn ( 1982). The incorporation of enrichment, 
usually oleic acid-albumin-dextrose-catalase (OAOC) into the 7H l O agar is necessary 
for optimal growth of .'vf tuberculosis at acid pH (Stottmeier et al, 1967), however, 
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oleic acid in an acid environment is inhibitory to many strains. (Tummon, 1975 - cited 
by Butler and Kilburn. 1982). Butler and Kilburn ( 1982) reported that grovvth of 25% 
of M tuberculosis strains were inhibited by the presence of oleic acid at pH 5.5. 
Growth appeared better with certain lots of albumin-dextrose-catalase (ADC) at pH 
5.5 but some lots did not support growth at low pH. The growth supporting ability of 
different lots of ADC were assayed for by observing the turbidimetric measurements 
of Bacillus subtilis in an ADC-heart infusion broth test which provided a rapid 24 
hour preselection method for ADC. It was found that lots of ADC that gives a 
change in OD of 0.145 or below with B. subtilis were able to support growth of 37% 
of 1\lf tuberculosis strains, whereas those that showed a change in OD of 0.165 or 
greater were able to support 90% of the strains of M tuberculosis ( Butler and 
Kilburn, 1982). 
In the same study Butler and Kilburn ( 1982) investigated the effect of carbon dioxide 
(CO2) and inoculum size on PZA inhibition. Strains of J\11. tuberculosis incubated in 
the presence of 7% CO2 in air at pH 5.5 for three weeks yielded larger colonies than 
the same strains incubated without CO2. Inoculum size was also important, when 
drug-containing medium was inoculated with greater than 300 CFU of PZA 
susceptible strains. Colonies developed in 3 weeks in the absence of added CO2 in the 
atmosphere, but grO\v1h was stimulated (greater number of colonies and larger colony 
size) by added CO2 during incubation (Butler and Kilburn, 1982). 
In vitro experiments only appro:--imate in vivo conditions. Important cofactors for 
certain biologic effects may be lacking in in vitro models because they are unknown. 
Crow le et al. ( 1989) showed the synergistic effect of 1,25 (OH)2-vitamin D3 ( 1,25D3) 
with PZA to kill intracellular bacilli. The two used together synergises to decrease 
concentrations of PZA which were inhibitory and to switch the action of PZA from 
weakly inhibitory to bacteriostatic or mildly bactericidal, however, 1,25D3 has no anti­
tuberculosis effect in the absence of macrophages as determined in acidified 
bacteriologic culture medium (Crowle et al, 1989). 
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The difficulty in performing the PZA susceptibility tests because an acid of the 
medium is required to demonstrate activity of the drug (McDermott and Tompert, 
1954) and Af wberculosis strains do not grow well at pH 5.5 (Stottmeier et al, 1967) 
lead to alternatives been investigated. Butler and Kilburn (1983) reported on the 
detection of pyrazinamidase activity as an alternative as PZA susceptible strains have 
the pyrazinamidase enzyme that hydrolyses PZA to POA. McClatchy et al. ( 1981) 
also recommended the detection of pyrazinamidase activity as a useful indicator for 
screening Af tuberculosis for PZA susceptibility, as this would overcome the problem 
of acid medium. The standard Wayne's test was used to investigate the enzyme 
activity (Wayne, I 974), where a postive is indicative of a pink to red colour 
development upon addition of freshly prepared ferrous ammonium sulfate solution. 
However, Butler and Kilburn ( 1983) found that the detection of pyrazinamidase 
activity by Wayne·s ( 1974) method was of limited value when compared to the 
standard PZA susceptibility tests, especially when high levels of PZA resistance was 
found. When resistance to PZA reached a level of 150 to 200 �Lg/ml, there was too 
much variability in Wayne·s tests results to accurately define PZA susceptibility 
(Butler and Kilburn, I 983 ). 
The M!Cs of PZA at pH 5.5 or 5.6 has been reported (Dickinson and Mitchison, 
1970; Salfinger and Heifets, 1988 and Heifets et al, 1989), however, the MBC i.e., the 
lov, est concentration killing more than 99% of the bacterial population in vitro was 
not reported. In 1990 (Heifets and Lindholm-Levy) reported on the MBC using PZA 
susceptible strains cultivated in 7H 12 broth at pH 5.6, the lowest pH favourable for 
active bacterial growth. 33 to 57% of the bacterial population was killed during the 
I 5 day period of cultivation in the presence of PZA concentrations t\vo fold greater 
than the MIC. Increasing the PZA concentration as high as 500 and I 000 µg/ml did 
not substantially increase the proportion of bacterial population killed, which was not 
greater than 7-+%. Thus, the MBC could not be determined and they concluded that the 
MBC was greater than I 000 �Lg/ml. It is a paradox that one of the most clinically 
efficient antituberculosis drugs has such poor bactericidal activity in vitro against 
actively multiplying bacteria (Heifets and Lindholm-Levy, 1990). 
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Heifets and Lindholm-Levy ( 1992) then tried to find some explanations to this 
paradox by determining the in virro activity of PZA against tubercle bacilli at a lov,:er 
pH, closer to that in \vhich the part of the bacterial population presumably affected by 
PZA in vivo. This approach required cultivation at pH 5 and lower, instead of pH 5.5 
to 5.6 used in their previous study (Heifets and Lindholm-Levy, 1990). The number 
of viable tubercle bacilli remained almost unchanged within a period of 3 to 4 weeks 
of cultivation in a liquid medium with a pH of 4.8 to 5.0. They referred to this state as 
semi dormant rather than dormant, assuming that the relatively stable number of viable 
cells was a reflection of the simultaneous existence of cells in various states of 
dormancy, multiplication and dying (Heifets and Lindholm-Levy, 1992). 
The CFU/ml declined I 000 fold in the presence of 50 �tg/ml PZA over the same 
period. The high ··bactericidal'' effect of PZA at pH 4.8 to 5.0 occurs because the 
tubercle bacilli are probably somehow damaged by this acidic environment but 
continue to be metabolically active. It is also possible that this increased vulnerability 
of tubercle bacilli to PZA is a result of some changes of the metabolic pathways at pH 
4.8 to 5.0 Therefore, the sterilising activity of PZA found under these conditions is 
most likely a result of the combined effect of the unfavourable pH environment and 
PZA (Heifets and Lindholm-Levy, 1992). 
The ability of tubercle bacilli to grow at low pH had not been questioned because one 
of the accepted sites of multiplication in vivo was the phagolysosomes of 
macrophages. However, in recent times this theory has being challenged by Crowle er 
al. ( 1991 ), who proposed that vesicles containing living, virulent 1\,/. ruberculosis or 
1'vl. avium in cultured macrophages are not acidic. It was confirmed by 
immunocytochemistry that both chloroquine and NH4Cl raise the pH of acidic vesicles 
in the infected macrophage. However, neither caused any pH related change in the 
antimycobacterial activities of PZA, streptomycin or isoniazid. Therefore, the 
suggestions by Heifets and Lindholm-Levy (1992) that PZA ma� accelerate the toxic 
effect of low pH in virro supports the same events taking place in vivo, especially 
considering that most of the bacterial population persisting there in an acid 
environment is extracellular rather than intracellular (Jindani et al, 1980). 
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The sterilising effect is quite different from the actual bactericidal activity of other 
drugs against actively growing cultures, which usually can be expressed in MBC 
values. The importance of the distinction between early bactericidal and sterilizing 
activity of the antituberculous drugs in patients was suggested by Mitchinson (1985). 
A special clinical observation on 14 days of monotherapy has shown that PZA, along 
with thiacetazone and streptomycin, had the poorest early bactericidal activity among 
all the antituberculous drugs, especially during the first two days of treatment when 
the bacteria are actively multiplying (Jindani et al, 1980). However, Mitchinson 
(I 985) found that PZA was one of the most potent drugs when judged by its activity in 
patients. According to Mitchinson's hypothesis (1985) the early bactericidal activity 
of a drug reflects its interaction with the actively multiplying part of the bacterial 
population, 'vvhereas the sterilising activity of PZA is a result of its ability to affect the 
semidormant subpopulation at low pH, mostly extracellular in sites of acute 
inflammation (Jindani et al, 1980). 
The in vitro observations on differences m the activity of PZA against actively 
growing (Heifers and Lindholm-Levy, 1990) and the semidormant bacterial 
populations (Heifers and Lindholm-Levy, 1992) can be considered a confirmation of 
Mitchinson's explanation of the activity of PZA in patients: low bactericidal activity 
of PZA against bacteria actively growing at pH 5.6 correlates with the poor early 
bactericidal activity in patients and the high sterilising effect in vitro at pH 4.8 to 5.0 
against non-multiplying bacterial population correlates with the high sterilising 
activity in vivo. 
Susceptibilities to PZA correlates with amidase activity of 1\tf tuberculosis. Spiers et 
al. ( 1995) studied the in vitro activity of n-propyl pyrazinoate (nPPA) against a series 
of PZA-susceptible and PZA-resistant isolates of Al tuberculosis. In a previous study 
by Cynamon et al. ( 1992) a series of synthesised esters of pyrazinoic acid 
demonstrated enhanced in vitro activity against both PZA s_usceptible and PZA 
resistant Al tuberculosis isolates. Spiers er al. ( 1995) hypothesised that POA esters 
would not require activation by amidase but would be converted to POA by 
mycobacterial esterase. The MICs of POA and nPPA for M tuberculosis were found 
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to be more favourable than those of PZA. PZA resistant isolates retain susceptibility 
in vilro to POA and nPP A. This supports the hypothesis that esters of POA can 
circumvent the requirement for activation by mycobacterial amidase. The MICs of 
nPPA for M tuberculosis were found to be the same or one to fivefold lower than 
those of POA which suggests that the biochemical basis for antituberculosis activity 
of POA is not simply the reduction in pH caused by the POA moiety. An alternative 
explanation could be that POA and nPPA are transported more efficiently than PZA 
into the mycobacterial cell (Spiers et al, 1995). These researchers are performing 
further studies which investigate the effects of modifications of the alcohol and 
pyrazine moieties of pyrazinoate esters on in vitro and in vivo antituberculosis 
activity, \.Yhich may lead to a candidate compound with enhanced activity against both 
PZA susceptible and PZA resistant lvf tuberculosis isolates (Spiers et al, 1995). 
Cynamon er al. ( 1998) evaluated the in vitro activity of 5-chloro-PZA (5-Cl PZA) and 
5-Cl PO . \ against various mycobacterial isolates. including resistant 1vf tuberculosis
cultures using the broth dilution method. 5-CI PZA \.vas more active than PZA against 
all organisms tested. The assumption based upon the effect of POA increasing the 
intracellular pH was confounded by the observation that 5-Cl POA is significantly less 
effective than POA against 1'vl. tuberculosis. The largest difference, an eightfold 
increase in the MIC of 5-CI POA relative to that of POA was found in a strain A TCC 
35828, which was resistant to PZA and deficient in amidase (Cynamon et al, 1998). 
1.3.5 A MOLECULAR PERSPECTIVE 
Pyrazinamidase is the same as nicotinamidase in M tuberculosis. Nicotinamidase is 
involved in the degradation of nicotinamide to nicotinic acid (Konno et al, 1967). 1\1I 
tuberculosis strains that are resistant to PZA (an analog of nicotinamide) lose both 
pyrazinamidase and nicotinamidase activity. It has been sugg�sted that the role of 
pyrazinamidase/nicotinamidase is to convert PZA to bactericidal POA inside the 
bacterial cell and that the absence of pyrazinamidase may be responsible for PZA 
resistance in both acquired PZA-resistant M tuberculosis and naturally resistant M
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bovis strains. To provide insights into \vhy .\I bovis are naturally resistant to PZA and 
to define the molecular mechanism of PZA resistance in M tuberculosis, Scorpio and 
Zhang (1996) cloned and characterised the pyrazinamidase gene (pncA) and 
demonstrated that mutations identified in the pncA gene are the cause for PZA 
resistance in both types of resistant bacilli. 
1.3.5.1 Cloning and characterisation of the 1l1. tuberculosis pncA 
gene 
Since the pyrazinamidase enzyme is the same as the nicotinamidase in M r11berculosis 
Scorpio and Zhang ( 1996) cloned the Al tuberculosis pncA gene by the polymerase 
chain reaction (PCR) using degenerate primers based on the amino acid sequence 
derived from Escherichia coli nicotinamidase gene (pncA) (Jerlstrom er al, 1989). 
The kl tuberculosis pncA gene \vas initially cloned on a 500 base pair PCR product 
from a PZA susceptible 1\lf 111berculosis strain and subjected to sequence analysis, 
which showed that the PCR product contained a partial open reading frame with 
homology to the £. coli pncA sequence (Jerlstrom et al, 1989). The M tuberculosis 
integrating cosmid DNA library was screened using the 500 bp pncA containing PCR 
product as a probe to obtain the complete Af tuberculosis pncA gene. A pncA 
hybridising cosmid clone was isolated and used to transform bacillus Calmette-Guerin 
(BCG), an attenuated vaccine strain derived from M. bovis, in order to confirm the 
identity of the putative i'vf tuberculosis pncA. The cosmid DNA containing the 
putative M. ruberc11losis pncA conferred pyrazinamidase activity to BCG, a natural 
mutant defective in pyrazinamidase. Southern analysis conferred the integration of 
the pncA cosmid DNA into M. bovis BCG genome (Scorpio and Zhang, 1996). 
The functional 1\lf tuberculosis pncA gene was localised on a 3 .2 kilobase EcoR 1-Pst 1 
fragment by restriction mapping of the cosmid DNA in combination with BCG 
transformation studies using DNA constructs derived from the cosmid DNA insert. 
To confirm that pyrazinamidase activity is due to the pncA gene, but not to other DNA 
in the pncA upstream region on the 3 .2 kb EcoR 1-Pstl fragment, BCG \Vas 
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transformed with the 2.3 kb EcoR 1-Sma I DNA construct that contains the upstream 
region and partial pnc,-l gene, however no pyrazinamidase activity was detectable in 
the BCG transformant. Sequence analysis of the 2.3 kb EcoR 1-Sma I fragment does 
not show significant open reading frames with homology to other known proteins in 
the database. Transformation of BCG with a construct that contains the pncA gene 
alone with its 120-bp upstream sequence as a PCR fragment gave functional 
expression of pyrazinamidase activity, indicating that the pyrazinamidase activity was 
indeed conferred by the pncA gene (Scorpio and Zhang, 1996). 
Sequence analysis showed that the kl tuberculosis pncA gene (558 bp) encoded a 
protein of 186 amino acids with 35.5% overall amino acid identity to the E. coli 
nicotinamidase (Jerlstrom, 1989). The predicted molecular mass of the M 
tuberculosis pyrazinamidse is about 20 kDa and is smaller than the £. coli homolog, 
which consists of213 amino acids with a size of23 kDa (Scorpio and Zhang, 1996). 
1.3.5.2 Identification of mutations in the pncA gene of resistant 
strains 
Scorpio and Zhang ( 1996) wanted to determine the genetic basis of the defective 
pyrazinamidase and PZA resistance in tubercle bacilli. Southern analysis was 
performed using the 3.2 kb EcoR 1-Pst 1 pncA containing DNA fragment as a probe on 
a panel of PZA resistant strains. There was no gross deletions of the pncA gene or 
restriction fragment length polymorphism. The AI .bovis species, which is well known 
to lack pyrazinamidase activity had the pncA gene as that in 1vl. tuberculosis which 
was showed by the same size hybridisation fragments from the two species. This 
indicated that these PZA resistant strains probably had point mutations in the pncA 
gene. Sequence analysis was carried out on the pncA gene to determine if point 
mutations did exist. Point mutations were found and it was concluded that a particular 
substitution caused the defective pyrazinamidase in these resistant strains of M 
tuberculosis and 1'vl. bovis (Scorpio and Zhang, 1996). 
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1.3.5.3 Transformation of PZA resistant strains with pncA gene 
To determine whether PZA resistance is due to point mutations identified in the pncA 
gene of resistant strains. the susceptibility of PZA of naturally PZA resistant BCG and 
the acquired PZA resistant 1'vf ruberculosis strain PZA-R derived from H37Rv \vas 
tested. These strains were transformed with the 3.2 kb EcoRI-Pstl plasmid construct 
that contains the functional pncA gene. The recombinant BCG and the PZA-R pncA 
transformants expressed functional pyrazinamidase activity and became susceptible to 
PZA (MIC= 50 �tg/ml) under acid conditions (pH 5.5) in virro, whereas the BCG and 
PZA-R vector control strains remained pyrazinamidase negative and PZA resistant 
(MIC> I 000 �tg/ml). The susceptibility of recombinant BCG to PZA inside 
macrophages \Vere also tested. [t was shown that the PZA susceptibility of the 
recombinant BCG is due to the expression of the pyrazinamidase activity conferred by 
the M tuberculosis pncA gene (Scorpio and Zhang, 1996). 
1.3.5.-t p11cA mutations in PZA resistant 1l-'I. tuberculosis 
A study of 38 PZA resistant clinical isolates of ,'vi tuberculosis was carried out by 
Scorpio er al. (1997). Various mutations were found viz., nucleotide substitution, 
insertions or deletions in the pncA gene. The identified mutations were dispersed 
along the pncA gene but some degree of clustering of mutations was found at the 
following regions: Glyl32-Thr l-l2. Pro69-Leu85, and Ile5-Aspl2. PCR-single strand 
conformation polymorphism (SSCP) analysis was useful for the rapid detection of 
pncA mutations in the PZA resistant strains (Scorpio et al, 1997). A similar study 
carried out by Hirano er al. ( I 998) on 168 Asian isolates of M tuberculosis, where 
135 isolates were Pzase positive and 33 were negative. Among the 33 Pzase negative 
isolates 32 (97%) had mutations within the pncr!. gene. Three strains that were PZA 
resistant mutants were Pzase positive and showed no change in the pncA gene, 
suggesting an additional mechanism may be involved in PZA res.istant. No mutations 
were observed in all of the I 35 Pzase positive isolates tested, indicating that mutations 
in the pncA gene could be involved in the loss of Pzase activity (Hirano et al, 1998, 
and Ramaswamy and Musser, 1998). 
1.4 TREATMENT OF TUBERCULOSIS 
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A century of treating tuberculosis is well described by Bignall ( 1982), where he starts 
with one of the earliest documented treatment regimens of Professor Jaccoud of Paris 
who published "The Curability and Treatment of Pulmonary Phthisis" The treatment 
consisted of ·hygienic measures'. The patient should reside in a dry dwelling in 
rooms facing south and the temperature of the bedroom should not exceed I 5°C. The 
windows should be closed even in summer. In addition several drugs were advised, 
including salts of iron, cod liver oil, preparations of arsenic and antimony, quinine 
salts, salicylates. Bignall ( 1982) comments: "It is tempting to look at condescension 
and faint amusement at the efforts of physicians to treat tuberculosis a century ago. 
The temptation should be firmly resisted. Is our present treatment of some diseases 
more rational or effective? And do we not, in our efforts to be scientific, sometimes 
forget Jaccoud's concept of 'our duty' that the treatment should benefit the patient 
and not cause distress". 
Sanatorium treatment was another alternative. which was first used in 1859 at 
Gorbersdorf in Germany. Although sanatorium treatment remained one of the main 
weapons for over 50 years, there is no scientifically acceptable evidence that it did 
reduce the toll of the disease. Nevertheless, sanatoriun treatment remained popular 
until effective chemotherapy arrived in the l950·s. In 1882. the year of Koch's 
discovery, Carlo Forlanani of Milan speculated on the feasibility and efficacy of 
collapsing the lung by introducing air into the pleural space, however, like the 
sanatorium treatment, it was difficult to estimate its value in reducing mortality and 
transmission of the disease. There was also the curious episode of the "gold decade", 
which began in 1925 by the publication of Mollgaard who published with enthusiasm 
the benefits of gold salt, sodium aurothiosulphate. How·ever, just as fast as it had 
spread it began to fade and by 1935 the fashion was over. 
Then came the modern chemotherapy which began with the discovery of the first 
effective drug, streptomycin in 1944. 
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1.4. l ANTIMYCOBACTERIAL AGENTS 
1.4.1.1 Streptomycin 
Streptomycin was the first of the aminoglycoside antibiotics to be developed and the 
first drug to be effective in treating pulmonary tuberculosis (MacGregor, 1988 and 
Alford and Wallace Jr, 1995). Streptomycin is bactericidal against M tuberculosis in 
vitro, but is inactive against intracellular tubercle bacilli because of its failure to 
penetrate into phagocytes and its lack of activity within the acid environment of 
caseous necrosis (Chambers and Jawetz, 1998). Sensitive organisms are inhibited by 
concentrations of less than IO µg/ml, sometimes as low as 0.4 �tg/ml (MacGregor, 
1988 and Alford and Wallace Jr, 1995). 
Streptomycin binds to bacterial ribosomes, causing misreading of the mRNA codons 
and subsequent production of nonfunctional proteins. It also inhibits bacterial cell 
respiration and damages cellular membranes. Approximately 1 in every 108 M. 
tuberculosis bacteria are resistant. When used as a single agent to treat cavitary 
pulmonary tuberculosis in the late l 940's, up to 75% of patients were found to have 
resistant organisms after four months of treatment, thus streptomycin must be used in 
combination with other drugs. Streptomycin is not absorbed from the gastrointestinal 
tract and therefore requires parenteral administration. This is a disadvantage when 
compared to other first line drugs that can be administered orally. It is widely 
distributed into extracellular fluid but does not cross the uninflamed meninges or enter 
intracellular space (MacGregor. 1988). Streptomycin toxicity is like that of other 
aminoglycoside antibiotics but with less renal and acoustic toxicity and greater 
vestibular toxicity than more commonly used aminoglycosides ( Alford and Wallace 
Jr, 1995). 
1.4.1.2 lsoniazid 
Isoniazid (!NH). the hydrazide of isonicotinic acid was shown to be effective against 
human tuberculosis in 1952 (Chambers and Jawetz, 1998). !NH is bactericidal against 
actively grov,"ing ,\If tuberculosis (Alford and Wallace Jr, 1995). It acts by inhibition 
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of oxygen-dependent synthetic path\vays of mycolic acid, an important constituent of 
mycobacterial cell \Valls (Herman and Weber, 1980). 
fNH concentrations of 0.025-0.05 pg/ml is inhibitory to i\lf tuberculosis, and higher 
concentrations are bactericidal against replicating organisms. When fNH is 
administered alone for three months, resistance tends to emerge in over 70 % of cases. 
Resistance results from selection under antimicrobic pressure of incompletely 
susceptible variants of At/ tuberculosis that number 1 in 106 among untreated bacillary 
populations. Surviving tubercle bacilli exhibit decreased fNH uptake. The large 
populations (109-10 10) bacilli in pulmonary cavities are especially likely to contain 
significant numbers of inherently resistant tubercle bacilli that regrow because of 
inadequate therapy to express secondary resistance (Alford and Wallace, 1995). 
fNH is well absorbed orally or intramuscularly and is distributed throughout the body, 
with therapeutic levels detectable in pleural, ascitic and cerebrospinal fluids as well as 
in tissue including caseous abscess material (Alford and Wallace, 1995; Chambers 
and Jawetz, 1998, and MacGregor, 1988). Metabolism of fNH occurs initially by liver 
N-acetyltransferase. Diminished acetylation capacity is inherited as an autosomal
recessive trait, which varies from a 5 % prevalence rate in Canadian Eskimos to 83 % 
in Egyptians. Ten to fifteen % of Orientals are ·'slow" acetylators as are 58 % of 
American Whites. The striking bimodal distribution of plasma half lives of fNH 
depending on acetylator status does not affect outcome with daily therapy, because 
plasma levels are maintained well above inhibitory concentrations (MacGregor, 1988, 
and Alford and Wallace, 1995). 
fNH has infrequent major toxicities, most notably hepatitis. Approximately 15% of 
fNH recipients have minor asymptomatic elevations in serum aspartate 
aminotransferase levels that usually resolve with continued the�apy. Patients should 
be advised to discontinue !NH therapy at the onset of symptoms consistent with 
incipient hepatitis, such as nausea, loss of appetite and dull midabdominal pain. 
Peripheral neuropathy developed in 17% of recipients taking 6mg/kg/day of fNH but 
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1s less frequent when adults receive the standard dose of 300 mg/day. INH 1s 
available as tablets, syrup and injectable solutions (Alford and Wallace, 1995). 
1.-U.3 Rifampin 
Rifampin (termed rifampicin in the United Kingdom) is a semisynthetic derivative of 
a complex macrocyclic antibiotic, rifamycin B, produced by Streptomyces 
mediterranei (Chambers and Jawetz, 1998). It was introduced into clinical trails in 
1967. Its mode of action involves the inhibition of mycobacterial DNA-dependent 
RNA polymerase; human RNA polymerase is insensitive. Rifampicin binds to the P­
subunit of the polymerase enzyme which acts as the catalytic centre of the enzyme, 
thus inhibits the initiation of Rl'\JA synthesis (Tillotson et al, 1996). It is bactericidal 
against susceptible J'vf tuberculosis strains at 0.005-0.2 �tg/ml (Alford and Wallace, 
Jr,. 1995). Organisms can develop one-step resistance by modifying the target 
polymerase and mutants occur with a frequency of I in I 07 to I 08 organisms. To 
avoid selection of resistant strains, rifampin should always be used in combination 
with other antituberculous drugs (MacGregor, 1988) 
Rifampin is well absorbed orally with peak plasma concentration yields of 7-8 �tg/ml 
after dose of 600 mg. It is widely distributed throughout the body, including CSF. Its 
high lipid solubility enhances phagosomal penetration. Rifampin is bactericidal 
against actively replicating Atf 1uberculosis to a degree comparable to INH. It is also 
active against intracellular, slowly replicating bacilli. Its efficacy in treatment is 
indicated by sputum conversion two \,Veeks earlier with rifampin containing regimens 
than those without it. Due to rapid resistance emerging so frequently, precludes it 
from being used alone. Resistance results from a mutation causing specific amino 
acid substitution in RNA polymerase. Its major adverse effect is hepatotoxicity, 
which caused 16 deaths in 500 000 recipients (Alford and Wallac� Jr, 1995). 
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1.4.1.-t Ethambutol 
Ethambutol \Vas discovered in 1961 among synthetic compounds screened for 
antituberculous activity. When administered orally 75-80% is absorbed, yielding peak 
plasma concentrations of 5 ,Ltg/ml after dose of 25 mg/kg. It is distributed throughout 
the body including the CSF. Ethambutol is bacteriostatic in vitro or within 
macrophages at concentrations of 1 �tg/ml against susceptible strains of /vi 
tuberculosis. (Alford and Wallace Jr, 1995 and MacGregor, 1988). Two target sites 
for ethambutol have been elucidated, polyamine function and cell wall synthesis, 
where ethambutol was a specific inhibitor of spermidine synthase (Paso et al., 1983) 
and inhibited arabinogalactan synthesis \\'hich is critical in the development of cell 
wall synthesis (Takayama and Kilburn, 1989). Stepwise resistance occurs whenever 
ethambutol is administered without companion drugs, thus the principal role of 
ethambutol has been as ··companion" drug to curtail resistance (Alford and Wallace, 
Jr, 1995, and Chambers and Jav,:etz. 1998). The major toxicity of ethambutol is 
neuropathy. Peripheral neuropathy is infrequent, however retrobulbar neuritis is more 
common (Alford and Wallace Jr, 1995). 
1.4.1.5 Rifopentine 
The Food and Drug Administration (FDA), US Department of Health and Human 
Services granted approval of rifapentine as a new drug for pulmonary tuberculosis, 
making it the first drug approval in 25 years (FDA talk paper-www.FDA.com, 1998). 
Clinical trials compared to standard therapy, evaluating the drug were carried out 
predominantly in patients in South Africa. Rifapentine was studied with three other 
drugs: isoniazid. PZA and ethambutol. In follov.- ups there was a l 0 % rate of relapse 
in rifapentine patients compared to 5 % in rifampin patients, however the FDA 's 
Antiviral Drugs Advisory Committee recommended the approval of the drug due to 
the following reasons: 
i) Patients are more likely to comply with the obligations of the therapy because the
drug regimen is easier to follow, 
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ii) In the second course of therapy. patients are dosed weekly (rifapentine plus
isoniazid) rather than t\vice weekly (rifampin plus isoniazid). For compliance reasons 
patients must undergo '"directly observed therapy'·, 
iii) Better compliance not only improves patient outcomes, but should deter drug
resistance, 
iv) While the relapse rate with rifapentine was higher than that of rifampin, neither
was alarmingly high ( 10% to 5% ). 
Its safety profile is similar to rifampin. Rifapentine could cause increased liver 
enzyme levels which can be a precursor to liver damage and increased uric acid levels, 
which can be a precursor to gout. One of the most common side effects is 
discoloured. orange-reddish urine (FDA talk paper-www.FDA.com, 1998). 
1.4.l.6 Second-line Antituberculous Drugs 
Para-Aminosalicylic Acid (PAS) is a synthetic compound that inhibits growth of 
tubercle bacilli by impairment of folate synthesis. It is incompletely absorbed orally 
and its chief side effect is gastrointestinal intolerance. It has limited use in modern 
chemotherapy because of its poor compliance and primary resistance (Alford and 
Wallace Jr, 1995 and :VlacGregor, 1988). 
Cycloserine is a broad spectrum antibiotic which acts as an antimetabolite of 0-
alanine, a major component of bacterial cell \Valls. It is readily absorbed orally, 
producing peak plasma concentrations of 20-50 �tg/ml. Cycloserines can cause 
peripheral neuropathy or central nervous system dysfunction, including confusion, 
irritability, somnolence, headache, nervousness, vertigo, dysarthria and seizures 
(Alford and Wallace Jr, 1995). 
Ethionamide is a derivative of isonicotinic acid and was first synt_hesised in 1956. It is 
tuberculostatic at 0.6-2.5 �Lg/ml against susceptible strains presumably by inhibition of 
oxygen-dependent mycolic acid synthesis. It is well absorbed orally, yielding peal 
plasma concentrations of 20 �tg/ml. Gastrointestinal distress with nausea and 
vomiting frequently leads to poor compliance and drug discontinuance, although 
ethionamide can be chosen for treatment of resistant tuberculosis (Alford and Wallace 
Jr, 1995, and MacGregor, 1988). 
Capreomycin, amikacin, kanamycin and viomycin are considered a group of 
antimycobacterial drugs as they are all administered by intramuscular injection, have 
similar pharmacokinetics and toxicities and are excreted by the renal route. 
Capreomycin is a polypeptide antibiotic obtained from Streptomyces capreolus which 
is active against M tuberculosis, including MOR tuberculosis strains. It is emerging 
as a first line injectable agent in multidrug regimens for treatment of drug resistant 
tuberculosis, especially when there is resistance to streptomycin as there is no cross 
resistance between them. Amikacin is among the most active aminoglycosides against 
1'vf tuberculosis, hov, ever there is limited experience with it in human tuberculosis. 
Kanamycin is an aminoglycoside that has activity against most strains of streptomycin 
resistant tubercle bacilli. Except for its lower cost, kanamycin has no advantage over 
amikacin in combination therapy. Viomycin is a complex basic polypeptide antibiotic 
for injection and many MOR tuberculosis strains are susceptible to it. Cross 
resistance to viomycin and capreomycin occurs frequently but less between viomycin 
and kanamycin (Alford and Wallace Jr, 1995). 
Amithiozone, a thiosemicarbazole is active against many strains of M tuberculosis, 
where susceptible strains are inhibited by 1 �Lg/ml. Due to the development of 
resistance when used in single drug therapy, amithiozone is used in combination 
regimens (Alford and Wallace Jr, 1995). 
The emergence of MOR tuberculosis has stimulated investigation of new fluorinated 
quinolone antibiotics \Vith activity against mycobacteria. These are bactericidal 
against M. tuberculosis by inhibiting its DNA gyrase at concentrations well within 
achievable plasma levels. Ciprofloxacin and ofloxacin inhibit. 90 % of strains of 
susceptible tubercle bacilli at concentrations of 0.5 and 1.0 �Lg/ml, respectively 
(Caekenberghe, 1990; Chen et al, 1989; and Gay et al, 1984). Usage as a single agent 
in animal models has led to resistance, similarly human trials with fluoroquinolone 
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alone or with inactive drugs has led to the rapid emergence of resistance. 
Fluoroquinolones, particularly sparfloxacin have produced additive effects with other 
antituberculous drugs in vitro and in animals. Initial clinical trials of ofloxacin in 
combination v,:ith INH and rifampin indicate activity comparable to ethambutol. 
Ofloxacin used alone in a dose of 300 mg/day in patients having MOR tuberculosis 
has produced decreases in sputum colony counts, with sputum conversion in 26 %, in 
non converters resistance emerged (Alford and Wallace Jr, 1995). 
Several P-lactamase resistant P-lactam antibiotics or combinations with P-lactamase 
inhibitors such as clavulanic acid are active in vitro against M tuberculosis and other 
nontuberculous mycobacteria (Alford and Wallace Jr, 1995). Yoladri et al. (1998) 
reported that the major P-lactamase of kf tuberculosis is a class A P-lactamase with 
predominant penicillinase activity and that a minor P-lactamase with greater 
cephalosporinase activity is also present. A better understanding of the mechanisms 
by which 1vl. tuberculosis expresses resistance to P-lactams might ultimately lead to 
strategies in which these agents could be used in the treatment of tuberculosis as they 
are extensively developed, highly effective, widely used and relatively non toxic 
antimicrobial agents (Yoladri et al, 1998). 
1.4.2 TUBERCULOSIS CHEMOTHERAPY 
There are numerous articles and books that discuss the recommended tuberculosis 
chemotherapy e.g., Merck Manual of Diagnosis and Therapy (Berkow, 1992). 
Weyer and Kleeberg ( 1992) discuss the recommended therapy in South Africa in their 
article on primary and acquired resistance in South Africa. I have chosen to use the 
South African Medicines Formulary produced by the Department of Pharmacology, 
University of Cape To\vn, South Africa to discuss the therapy of tuberculosis mainly 
taking into account the South African scenerio (Gibbon and Swanepoel, 1997). 
Standardised short-course chemotherapy in developing countries has been successful 
when combined with a control programme in which drug administration is supervised 
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and facilities for sputum examination are available. Treatment regimens are divided 
into intensi\·e and follovv-up phases. During the intensive phase the bactericidal effect 
treatment leads to rapid bacteriological sputum conversion and culture negativity and 
an improvement of the illness. During the follow-up phase, when fewer drngs are 
given the sterilising effect of the treatment eliminates the remaining viable bacilli and 
prevents subsequent relapse (Gibbon and Swanepoel, 1997). 
For standardised chemotherapy it is necessary to categorise tuberculosis cases and to 
determine treatment regimens for each category: 
1.4.2.1 Regimen 1: Newly diagnosed adults 
Cases of smear or culture positive pulmonary tuberculosis and other newly diagnosed 
seriously ill patients with tuberculosis ( including tuberculosis meningitis, pericarditis, 
peritonitis, disseminated tuberculosis, bilateral or extensive pleurisy, spinal disease 
with complications, extensive pulmonary parenchyma involvement and 
gastrointestinal or genitourinary tuberculosis) who have never been treated before, or 
who have been previously treated for less than four weeks (Gibbon and Swanepoel, 
1997). This regimen is very similar to that recommended by Weyer and Kleeberg 
( 1992). 
Table 1.1: Regimen I- Newly diagnosed adults 
Intensi \·e Phase: 2 months under 50 kg over 50 kg 
Rifampicin/fNH/PZA 
combination tablet: 4 tablets 5 tablets 
120/80/250 mg 
Ethambutanol -WO mg 2 tablets 3 tablets 
Continuation Phase-+ months 
Rifampicin/INH 
Combination tablet 150/100 mg 3 tablets .... 
Combination tablet 300/150 mg .... 2 tablets 
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1.-t.2.2 Regimen 2: Retreatment adults 
Relapse or treatment failure (smear or culture positive). Anyone who has been treated 
at any time before for more than four weeks. These patients should have drug 
sensitivity tested at the start of treatment (Gibbon and Swanepoel, 1997). 
Table 1.2: Re-treatment of Adults 
Intensive Phase: 2 months Under 50 kg Over 50 kg 
Rifampicin/INH/Ethambutanol 
Combination tablet 150/75/300 mg 3 tablets 4 tablets 
PZA 500 mg 2 tablets 3 tablets 
Streptomycin* 750 mg 1000 mg 
* Streptomycin dose must be reduced to 750 mg in patients older than 45 years and
must not be given to those over 65 years or during pregnancy. The dose in renal 
patients should be reduced or the dosing interval increased. 
Table 1.3: Treatment at 3 months 
Third month under 50 kg over 50 kg 
Rifampicin/INH/ethambutol 
combination tablet: 3 tablets 4 tablets 
150/75/300 mg 
PZA 500 mg 2 tablets 3 tablets 
Continuation Phase 5 months 
Rifampicin/INH/ethambutol 
Combination tablet 150/75/300 mg 3 tablets 4 tablets 
1.-t.2.3 Regimen 3: Newly diagnosed children 
Children with newly diagnosed primary tuberculosis and/or pleural effusions should 
be treated with regimen 3 drugs (Gibbon and Swanepoel, 1997). 
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Table 1.4: Regimen 3- Newly diagnosed children 
Intensive Phase 2 months 5-10 kg ll-20kg 2l-30kg 
Rifampicin/INH 
combination tablet: 1/2 tablet I tablet 2 tablets 
150/100 mg 
PZA 500 mg 1/2 tablet I tablet 2 tablets 
Continuation Phase 2 months 
Rifampicin/INH 
Combination tablet 150/100 mg 1/2 tablet 1 tablet 2 tablets 
Regimen 4 combination should be used for newly diagnosed tuberculosis in children 
with progressive primary or cavitating tuberculosis or non-pulmonary tuberculosis. 
This regimen is the same as regimen 3 with the exception that the continuation phase 
is longer i.e., 4 months (Gibbon and Swanepoel, 1997). 
1.4.2.4 Regimen 5: Chemoprophylaxis in Children < 2 years 
Children under 2 years of age who have been in close household contact with a smear 
positive case of tuberculosis are at considerably increased risk of infection and 
disseminated disease. Regimen 5 is the recommended combination of therapy. 






under 5 kg 5-10 kg 11-20 kg
I /4 tablet 1/2 tablet I tablet 
Regimen 6: Chemoprophylaxis for healt�1y 2-5 year old 
contacts 
Children 2- 5 years of age should recetve 6 months of !NH prophylaxis (5-10 
mg/kg/ day). Regimen 6 is shown in the table below. 
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Table 1.6: Chemoprophylaxis for healthy 2-5 year old contacts 
6 months 10-20 kg 21-30 kg
INH 100 mg 200 mg 
1.4.2.6 Treatment of multi-drug resistant tuberculosis 
MDR tuberculosis is diagnosed when sensitivity tests show resistance to both 
isoniazid and rifampicin at least. Choice of appropriate regimen should be made 
individually. based on evaluation of previous treatment episodes or, preferably on 
sensitivity testing. A single drug should not be added to a failing regimen. Treatment 
should not be adjusted while awaiting bacteriological results, except m rapidly 
deteriorating patients. Treatment of drug resistant tuberculosis should not be 
attempted at general tuberculosis clinics; these patients should be referred to a hospital 
(Gibbon and Swanepoel, 1997). 
Contacts of sputum smear-negative drug resistant tuberculosis patients are managed 
according to the standard recommendations for contacts of drug-sensitive 
tuberculosis. The treatment of household contacts of smear-positive drug resistant 
tuberculosis patients can be carried in two ways: children younger than 2 years and all 
HIV postive contacts should be given preventive therapy, irrespective of their state of 
health and tuberculin response, where preventive therapy should include at least two 
drug to which the source strain is susceptible. The decision to treat depends on 
clinical assessment in the case of children older than two years and adult contacts, 
however, routine preventive chemotherapy is not recommended (Gibbon and 
Swanepoel, 1997). 
Cohn ( 1995) in his retrospective study on the treatment of MOR tuberculosis showed 
that in immunocompetent patients with secondary MDR tuherculosis, only 56% 
responded to prolonged courses of multiple drug regimens and 22% died of 
tuberculosis. In patients with AIDS even fev.rer patients respond, with median 
survivals of 2-4 months. Cohn (1995) comments that MOR tuberculosis is best 
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prevented by directly observed therapy of patients with susceptible organisms and 
rigorous infection control practices in areas of high incidence of MOR tuberculosis. 
1.4.2. 7 Supervision of therapy 
The taking of every capsule and tablet should be ideally supervised ( directly observed 
therapy-DOT). Non-compliance with self-medication can result in drug resistance. 
Supervisors of treatment do not necessarily need to be health workers (Gibbon and 
Swanepoel, 1997). Wilkinson and De Cock (1996) showed that non-health workers 
e.g., store keepers were just as good as clinic sisters where 89% of cases reached
completion of treatment. They should keep the drugs and the treatment card, supply 
the medication, watch the patient taking the treatment and sign according (Gibbon and 
Swanepoel, 1997). 
Wilkinson and De Cock ( 1996) reported on the treatment of tuberculosis in a rural 
South African community, Hlabisa. World Health Organisation (WHO) and 
International Union against Tuberculosis and Lung Disease (IUA TLD) recommend 
passive case finding and provision of short course (6 months) chemotherapy which 
should cure the vast majority of cases and if coverage is high enough, which will lead 
to a sustained reduction in case rates. Wilkinson and De Cock ( 1996) reported 
success achieved in Hlabisa with an alternative approach that being: all patients to be 
treated with an intermittent rather than a daily drug regimen, there should be only one 
regimen, all patients to receive directly observed therapy for full duration of their 
treatment, patients need not have sputum taken after diagnosis i.e., no smears at 2 
months and 6 months, the tuberculosis control programme must be structured and 
resourced in a way that is fully cognisant of the needs of a comprehensive district 
health system that provides a wide range of essential services, of \.vhich tuberculosis 
treatment is only one. 
Bacille Calmette-Guerin (BCG) is a freezed dried live vaccme prepared from an 
attenuated strain of bovine tubercle bacillus. BCG should not be administered 
concurrently with antituberculous therapy or chemoprophylaxis. Vaccination with 
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BCG is required in South Africa. Immunisation is commenced at birth, and repeated 
at 3 months if no scar is visible. Efficacy is controversial (Gibbon and Swanepoel, 
1997). 
1.4.3 MOLECULAR MECHANISMS OF RESISTANCE 
Until recently the molecular mechanisms of resistance in M tuberculosis remained 
largely unknown. The recent resurgence of tuberculosis, along with the outbreaks of 
MOR tuberculosis, has stimulated a great deal of interest in understanding the 
molecular basis of drug resistance in J'vf tuberculosis (Bloom and Murray, 1992). 
There has been tremendous progress in this field due to the application of 
mycobacterial molecular genetics (Zhang, 1996). Molecular analysis of some MOR 
tuberculosis strains suggest that the MOR phenotype is caused by sequential 
accumulation of individual mutations in separate genes, not by novel mechanisms due 
to single mutagenic event (Heym et al. 1994). 
Zhang et al. ( 1992) reported on the catalase-peroxidase gene, katG gene, which was 
responsible for isoniazid resistance. The katG gene was cloned and used as a probe, a 
katG deletion was identified in some highly fNH-resistant clinical isolates of 1\;f 
tuberculosis. To determine whether the loss of catalase activity (either due to katG 
gene deletion or point mutations) is the cause of fNH resistance, fNH resistant lvf 
tuberculosis strains that were defective in catalase activity were transformed with a 
functional katG gene, which resulted in complete restoration of fNH sensitivity to 
these strains resistant to different concentrations of fNH (Zhang et al, 1993). Among 
fNH resistant i'vf tuberculosis strains, katG deletion seems to be a relatively rare event, 
accounting for 5-10% of fNH resistant M tuberculosis strains, most have point 
mutation in the katG gene (Heym et al, 1994) and a few have point mutations in a 
second gene, inhA. which has being implicated in fNH resist�nce (Banerjee et al, 
1994). Point mutations in the inhA gene (Ser to Ala change at amino acid residue 94) 
was found to confer a low level of fNH resistance as well as ethionamide (a structural 
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analogue of INH) resistance m lvf smegmatis by allelic exchange experiments. 
Mutations in the inhA gene appear to be associated with low level INH resistance, in 
contrast to the high level of resistance caused by inactivation of catalase-peroxidase 
due to katG deletion or point mutations (Zhang et al, 1992). 
Resistance to rifampin in JV! tuberculosis has been associated with alterations in the 
segment of the rpoB gene encoding amino acids 430-456 of the Rl'\J'A polymerase � 
subunit (Teien ti et al, 1993 and Miller et al, 1994 ). Morris et al. ( 1995) analysed the 
mutations in rifampin resistant strains by PCR and nucleotide sequencing. Six 
different rpo B mutations were identified, with the most frequent gene alteration 
associated with rifampin resistant phenotype occurred at position 456. Sixteen of the 
rifampin resistant strains had a C to T transition in codon 456, which converted serine 
(TCG) to leucine (TTG). Five rifampin resistant isolates had mutations at position 
451: three C to T transition that changed histidine (CAC) to tyrosine (TAC) and two C 
to G transversions that substituted aspartic acid (GAC) at this position. Five A to T 
transversions that convert aspartic acid at position 441 to val ine (GTC) and a single G 
to T transversion that substitutes a tyrosine at codon 451 were detected. A unique G 
to A transition converted the codon 440 methionine (A TG) to isoleucine (AT A) 
(Morris et al, 1995). 
Mutations in genes encoding the ribosomal S 12 protein (rpsL) and 16s rRNA (rrs) 
have been detected in streptomycin resistant strains of lvf tuberculosis (Finken et al, 
1993). Morris et al. (1995) studied the genetic mutations in 11 singly streptomycin 
resistant clinical isolates and 33 streptomycin resistant MOR tuberculosis strains. 
Seven of the 11 strains resistant to only streptomycin had rpsL mutations. Six of 
these seven rpsL genes exhibited an A to G transition at codon 43, which converts 
lysine to arginine; the other was an A to G transition in codon 88, which also converts 
lysine to arginine. No rrs mutations were identified in singly streptomycin resistant 
strains. 
Eighteen of the 33 streptomycin resistant MOR tuberculosis isolates also had rpsL 
mutations. Sixteen had the A to G transition at codon 43 and 2 had the same codon 88 
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mutation described for singly streptomycin resistant strains. Also, A to C 
transversions \Vere identified at position 513 of the rrs genes in 5 of 33 MOR 
tuberculosis strains. A, C to T transition was also detected at position 491 in 2 MOR 
tuberculosis strains. No alterations were detected at other positions of the rrs gene 
(512, 516 and 904) that have been associated with streptomycin resistance (Morris et 
al. 1995). 
1.4.4 INFLUENCE OF THE AIDS-HIV PANDEMIC ON TUBERCULOSIS 
CHEMOTHERAPY 
Human immunodeficiency virus (HIV) infection affects up to IO million persons 
worldwide. It exerts a pronounced influence on the natural history of tuberculosis in 
several ways: in addition, infection with M tuberrnlosis appears to affect the course 
of HIV disease as follows: 
i) Among persons latently infected with tuberculosis who become HIV infected, active
tuberculosis develops at a rate of 7 to I 0% per year rather than 8 % per lifetime. 
ii) Persons with HIV (regardless of CD4
+ 
cell counts) who are newly infected with Al
tuberculosis progress to active tuberculosis at a rate as high as 37 % in the first 6 
months rather than 2 to 5 % in the first 2 years. 
iii) HIV confers anergy upon a large number of persons with HIV infection, thus
confounding tuberculin skin test (TST) interpretation, the prevalence of anergy 
increases as the CO4 cell counts decreases. In many areas where tuberculosis is 
endemic, prophylactic INH therapy is recommended for anergic persons with HIV 
infection. 
iv) HIV-infected persons may malabsorb drugs perhaps because of HIV related
enteropathy, \.vhich may further complicate the treatment of tuberculosis. In addition, 
immunocompetent persons who have undergone gastrectomy may, in the course of 
treatment for drug susceptible tuberculosis, progress to drug resistant tuberculosis 
because of malabsorption of drugs (Sepkowitz er al, 1995). 
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Tuberculosis may influence the natural history of HIV infection by activating 
macrophages that harbor HIV. The result of activation is expression of HIV, rather 
than prolonged latency without expression of HIV. In a study carried out by Pape er 
al. (1993) progression to AIDS occurred sooner among TST-positive persons not 
treated with INH than those treated with INH, even when tuberculosis was excluded 
as AIDS indicator disease, which suggests that treatment of latent tuberculosis can 
help preserve the immune function of HIV-infected individuals. These influences 
have conspired to create an epidemic of tuberculosis within the HIV epidemic that is 
particularly threatening to the public health in areas such as Africa, where large 
numbers of individuals are dually infected with 1vf tuberculosis and HIV (Sepkowitz 
et al, 199 5). 
Wilkinson and Moore ( 1996) assessed the difference between HIV infected and non­
infected tuberculosis patients in the Hlabisa hospital, Kwazulu-Natal, South Africa. 
They found that HIV-positive patients with tuberculosis were three times more likely 
to fai I to complete treatment than HIV-negative patients. HIV infection is clearly 
altering the epidemiological profile of tuberculosis in rural South Africa and poses an 
additional challenge to tuberculosis control programmes to maintain high case-holding 
rates among HIV-infected tuberculosis patients. 
JV! tuberculosis can cause disease at nearly all stages of HIV infection. There is a 
wide spectrum of clinical disease in adults which ranges from typical pulmonary 
presentation, in those \,Vith relatively well preserved immunity and CD4 counts in 
excess of 200 cells/mm3 , to atypical disseminated disease 1n markedly 
immunosuppressed individuals (Gilks, 1996). 
In adults with pulmonary disease, cavity formation occurs less frequently and there is 
much less predilection for the apical regions. Unusual lower lobe infiltrates which 
may be bilateral and are smear negative but culture positive . are the commonest 
diagnostic challenge. Without bronchoscopy or induced sputum, many diagnoses are 
established by a I-month therapeutic trial. Pleural effusions occur more frequently 
with HIV infection and can be sometimes be bilateral (Gilks, 1996). 
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The response to standard treatment appears adequate, at least in the earlier stages of 
HIV infection. The high mortality seen in endemic areas during therapy is usually the 
result of other severe bacterial infections such as pneumococcal pneumonia or 
disseminated non-typhi salmonellosis rather than a failure to respond to appropriate 
therapy. A difficulty in treating HIV-tuberculosis in poor resource countries is the 
widespread routine use of thiacetazone as a first line anti-tuberculous drug. This drug 
is toxic in individuals with underlying HIV infection and can cause hypersensitivity 
reactions and severe Stevens-Johnson syndrome in up to 20% of cases (Orobniewski 
et al, 1995 and Gilks, 1996). The cost implications of replacing thiacetazone with 
expensive short-course regimens containing rifampin are significant and many African 
countries cannot afford to switch even though this is a much safer policy (Gilks, 
1996). In Kenya the recurrence rate of tuberculosis in HIV-infected patients was 34-
fold greater than in HIV negative patients treated with thiacetazone containing 
regimens (Hawken et al .• 1993 ). In a study in Zambia, 22 of 23 7 children developed 
cutaneous hypersensitivity reactions whilst on a regimen that included thiacetazone; 
I 2 of the 22 children who developed Stevens-Johnson syndrome were HIV-positive 
(Chintu el al, 1993). 
There is little to be complacent or optimistic about when considering the impact that 
HIV has had and increasingly will have on tuberculosis. The impact is already 
devastating and in some areas totally disrupting existing tuberculosis programmes. 
The burden of the disease is increasing everywhere. The HIV epidemic has cruelly 
exposed weaknesses in tuberculosis control worldwide and is undoubtly making them 
worse. Tuberculosis remains a global priority even without the interaction with HIV 
(Gilks, 1996). 
1.5 1W. tuberculosis: THE MOLECULAR STORY 
The diagnosis of Jf Euberculosis infections are often delayed d�1e to slow generation 
time, about 15-20 hours which means that visible cultures are only apparent after 
several weeks of incubation. Direct microscopy on specimens by auramine­
rhodamine or Ziehl-Neelsen staining is rapid but has a detection limit of IO 000 
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bacilli/ml and sensitivity could range from 22 to 78% of culture proven cases. Culture 
is recognised as the "gold standard'. for the diagnosis of tuberculosis and has a 
detection limit of l 00 bacilli/ml. Although the BACTEC, a culture based method has 
been introduced, the procedures are still considerably slower than most conventional 
bacteriology (Butcher et al, 1996). 
The explosive development of the technology of molecular biology has provided a 
host of potential applications for diagnostic microbiology. Initially nucleic acid 
probes were applied to both cultured bacteria and clinical specimens, subsequently 
various radioactive and non-radioactive probes have been found to be most useful for 
the rapid identification of cultured mycobacteria. Nucleic acid amplification 
techniques, polymerase chain reaction (PCR), can be applied to the detection of 
specific and non-specific mycobacterial gene sequences in clinical specimens, cultures 
and environmental samples to provide an extremely sensitive and rapid diagnostic 
test. PCR may also be used to produce probes for the confirmation of amplimer 
identity, restriction fragment length polymorphism (RFLP) to amplify species specific 
rRNA sequences for species identification and direct PCR typing (Hawkey et al, 
1996). 
1.5.1 MOLECULAR TECHN[QUES FOR DIAGNOSIS 
Nucleic acid amplification-based methods for the detection and identification of 
mycobacteria can be divided into three types: 
a) amplification of genus specific sequences;
b) amplification of genus specific sequences followed by oligonucleotide probing to
give a species specific test; 
c) amplification of species specific sequences
A wide range of target sequences has been used. although in the <:ase of genus specific 
primer pairs, the genes encoding the 65 kDa antigen are popular and for the species 
specific primers those based on IS6 l 1 0/IS986 (Hawkey et al. 1996). The choice of 
target gene is an important determinant of sensitivity and specificity (Butcher et al, 
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1996). The method of extracting DNA from specimens has a great influence on the 
sensitivity and specificity of PCR protocols (Ha\\,'key er al, 1996). The main 
objectives are the efficient release of mycobacterial DNA and the removal of any 
material in the sample that may be inhibitory to the PCR; at the same time, it is 
desirable to avoid introducing chemicals that may themselves inhibit the PCR. A 
method that is suitable in a research laboratory \.Vith a handful of samples may not be 
workable in a diagnostic laboratory. Lysis of mycobacteria can be difficult because of 
the thick lipid-rich cell wall and the cell wall components can also contaminate the 
DNA preparation (Butcher et al, 1996). Good results can be obtained with simple 
methods, such as boiling, mechanical disruption and sonication (Hawkey er al, 1996). 
It is important to detect inhibition in order to identify false negative reactions. A 
simple method is the division of the extracted specimen into two and spiking one 
portion with a low level Al. tuberculosis DNA, however, this involves doubling the 
number of PCR tests. This could be a\·oided by using an internal control, which 
yields a product that can be distinguished from the test product. Use of a different 
DNA template is not ideal, as different primers may vary in their sensitivity to 
inhibition or amplification efficiencies. It is preferable to use an internal control that 
has the same primer binding sites as the natural target, but the product has to be 
distinguishable. Therefore, the control can be cloned, modified template yielding a 
different size of fragment, or with part of the target replaced by another sequence so 
that they can be distinguishable by specific probes (Butcher et al, 1996). 
Contamination occurs in all laboratories, but can be minimised. The first step is to 
design the laboratory and develop protocols to minimise contamination. Common 
procedures include physical separation of different stages of the process, and the use 
of dedicated equipment for clean processes. A \videly used method involves the use 
of uracil-N-glycosylase (UNG) which breaks dovm am pl icons containing deoxyuracil, 
resulting in the use of dUTP instead of dTTP in the PCR mix. T�e UNG destroys any 
amplicons present initially and is then inactivated at 94
°
C at the start of the PCR 
reaction. The efficiency of the PCR is not affected, however, this does not protect the 
PCR against contamination from other sources, including other uses of the target 
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DNA in the same laboratory or pre-existing contamination. Procedure such as the use 
of UNG must be used to supplement and not replace basic procedures against 
contamination. Also, a negative control should be included in all batches of a samples 
(Butcher et al, 1996). 
PCR in theory can detect the presence of a single bacillus within a few hours. In 
reality, the adaptation of PCR for the detection of mycobacterial disease 1s 
problematic. The problems include the difficulty and unreliability of extracting DNA 
from specimens; presence of inhibitors in the specimens; problem of contamination 
with amplicons giving false positives results; non-robust methods for the detection of 
the amplified product; poor sensitivity when there are few organisms present; the 
difficulty in interpreting the results in respect to active disease and PCR positive, 
culture negative samples. In a blind folded comparative study carried out by 
Noordhoek et al. ( 1994) in seven laboratories experienced in PCR for 1\1/. tuberculosis, 
they reported false positive rates ranging from 3-20% up to 77%. Reliable detection of 
M £Ubercu!osis is dependent on conventional methods, however this situation can 
change as automated techniques become available, thus reducing labour costs and 
increasing reliability. Until then the main value of PCR will be for specific situations 
where conventional methods are especially inadequate; limiting examination to 
selected cases makes it possible to carry out the PCR more thoroughly, using different 
sets of primers, hybridization to confirm specificity, checking for inhibition and 
repeating positive tests to exclude contamination (Butcher et al, 1996). 
Non-PCR based amplification techniques have been applied to the diagnosis of 
mycobacterial infections, these include: strand displacement assay (SDA) developed 
by Becton Dickinson, transcription mediated amplification (TMA) developed by Gen­
Probe and the reporter phage systems. The principle of the commercially avatlable 
TMA is that specific rRi"l'A is amplified isothermally by an autocatalytic process, the 
products being detected with an acridium-labelled DNA prob� in a homogeneous 
solution hybridisation following a reverse transcriptase step (Hawkey et al, 1996). 
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The detection limit of specific labelled gene probes that can detect mycobacteria by 
hybridisation is of the order of I 0 5 bacteria, whereas the number of bacilli in many 
clinical samples is much lower than this. Gene probes are not sufficiently sensitive 
for the direct detection of mycobacteria in clinical specimens, but have become the 
method of choice for speciation of mycobacteria after isolation and growth in culture. 
Probes available (Gen-Probe) have >95% specificity for several mycobacterial 
species. The target sequences are often short. The occurrence of a mutation or natural 
variation may lead to failure to identify that organism (Butcher et al, 1996). 
A further system is the Ligase Chain Reaction (LCR). This involves a thermostable 
ligase joining two oligonucleotides that are immediately adjacent to each other when 
they hybridise to target DNA. The products of a cycle of denaturation, annealing and 
ligation steps serve as templates for the next cycle, resulting in exponential 
amplification. The LCR is the basis of the Abbott Corporation mycobacterial 
detection test; it can detect dov,n to five mycobacteria and show a sensitivity and 
specificity similar to PCR and other amplification systems (Butcher et al, 1996). 
Cole ( 1996) reported on the need to study the nerve centre of the tubercle bacillus, its 
genome, by means of systematic deoxyribonucleic acid sequences analysis. He wrote 
this "will provide a wealth of information about 1\.,f tuberculosis that will undoubtly 
fuel the next generation of research·•. Cole et al. ( I 998) reported the complete 
genome sequence of the best characterised strain of Al tuberculosis, H37Rv. This 
will improve our understanding of the biology of this slow growing pathogen and help 
the conception of new prophylactic and therapeutic interventions. The genome 
comprises 4 411 529 base pairs and contains around 4 000 genes and has high guanine 
+ cytosine content (Cole et al, 1998).
1.5.2 MOLECULAR EPIDEMIOLOGY 
Identification of subtypes of Af tuberculosis has been a long-standing problem that 
has dogged epidemiologists and microbiologists. The development of molecular 
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fingerprinting techniques that identify subtypes that are related to the apparent 
epidemiology of cases promises to be one of the most exciting developments in the 
study of tuberculosis. The standard technique (restriction fragment length 
polymorphism) is based on the insertion sequence IS6 l l 0. Insertion elements are 
sequences of DNA bounded by short inverted repeated DNA sequences together with 
a direct repeat of the target sequence which are capable of movement within a replicon 
by a process analogous to transposition (Hawkey et al, 1996). 
In the standardised technique genomic DNA is cut with the restriction endonuclease 
Pvu II and the fragments are separated on an agarose gel and transferred to a nylon 
membrane. The restriction endonuclease Pvu II has one asymmetric site within 
IS6 l l O and the genomic DNA is probed with IS61 l O DNA generated from DNA to 
the right hand side of this site. The resulting fingerprint will contain a number of 
bands which correspond to the number of copies of 1S6110 in an individual strain. 
This technique has been found to produce a level of typability and strain 
discrimination that is appropriate for the investigation of cross-infection by 1\,f 
tuberculosis (Hawkey et al, 1996). 
Some strains of iv! tuberculosis have only a few copies of IS6 l 10 which greatly 
limits strain differentiation. Such strains have been distinguished by hybridisation of 
genomic DNA with probes to a polymorphic GC-rich repetitive sequence (PGRS), 
(GTG)5 or a 36 base pair DR (Direct repeat) sequence. PGRS offers a somewhat 
better discriminatory power over IS6 l IO (Butcher el al., 1996 and Hawkey et al, 
1996). 
Restriction endonuclease analysis types are stable and provide a valuable tool for 
studying mycobacterial transmission, however a very large number of fragments are 
produced which makes the electrophoretic conditions critical for good results and 
subsequent analysis is difficult. Some of the disadvantages of co!'lventional restriction 
endonuclease analysis can be overcome by using restriction enzymes that cut less 
frequently and these can be separated by pulsed field gel electrophoresis (PFGE). 
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RFLP typing with specific probes is much easier to perform and is therefore preferred 
for the analysis of large numbers of isolates (Butcher et al, 1996). 
With the current increases 10 the incidence of tuberculosis and emerging drug 
resistance molecular techniques \-viii be implemented as routine diagnostic and 
epidemiological tests. They will make substantial contributions to disease 
management and in community based infection control measures (Butcher et al, 1996 




The literature was reviewed with a view to emphasise the major health care problem 
that tuberculosis presents to the ,vor!d, to draw attention to the place that PZA has in 
modern chemotherapy of tuberculosis. Also to emphasise the importance of 
understanding the mode of action of a drug used in tuberculosis chemotherapy. The 
disease is first placed in its historical perspective followed by commenting on the 
interaction of tuberculosis with macrophages, since researchers have shown that the 
macrophage plays an important role in the mode of action of PZA. The proposed 
mode of action of PZA as out! ined by Konno et al. ( 1967) and the present molecular 
characterisation of the pncA gene coding for the enzyme Pzase is discussed. 
Chemotherapy of the entire millieu of drugs available for tuberculosis chemotherapy 
with their advantages and disadvantages are discussed. Finally, the influence of the 
HIV-AIDS pandemic on tuberculosis and the molecular studies undertaken for 
diagnosis and epidemiology are reviewed. The later two aspects emphasise the need 
for continued research in the tuberculosis arena as the eradication of the disease is far 
from over. With the following points in mind the experimental component of the 
study was commenced and are discussed in individual chapters. 
CHAPTER 2 
SURVIVAL OF N/. tuberculosis FOLLOWING EXPOSURE TO PZA 
2.1 INTRODUCTION 
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This chapter serves as a introduction to the other experimental procedures undertaken 
to study the mode of action of PZA on Iv! tuberculosis, viz., HPLC to measure the 
concentrations of PZA and POA in non cell associated mycobacteria as well as in the 
extracellular, intracellular and intra-bacterial compartments of infected macrophages, 
production of polyclonal antibodies to PZA and immunogold labelling experiments to 
locate the site of action of PZA. Thus, the objective of this chapter is to assess the 
survival or death of non cell associated mycobacteria and mycobacteria bound within 
macrophages following PZA treatment. 
The activity of PZA can be demonstrated only in an acid medium in vitro (McDermott 
and Tompset, 1954), which is not favourable to the growth of lvf tuberculosis. There 
have been studies which investigated the effect of PZA on M tuberculosis at acid pH 
5.5. Butler and Kilburn ( 1982) investigated the effect of carbon dioxide and inoculum 
size on PZA inhibition where At/ tuberculosis was incubated in the presence of 7% 
CO2 in air at pH 5.5. Heifets and Lindholm-Levy ( 1990) reported on the minimal 
bactericidal concentration using PZA susceptible strains cultivated in 7H 12 broth at 
pH 5.6. In 1992, Heifets and Lindholm-Levy investigated the in vitro activity of PZA 
at a lower pH of 5. Also, in our department, the in vitro activity of PZA and POA at 
various pH values has been extensively studied. Thus, the aim of this study was to 
evaluate the effect of the tissue culture medium, RPMI 1640 on non cell associated 
mycobacteria and their potential to convert PZA to POA in this medium. No 
manipulations of the pH of the medium were performed. 
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There are also numerous reports on the activity of PZA in macrophages with many 
studies investigating the effect of combinations of drugs with PZA. Mor and 
Estandiari ( 1997) investigated the synergistic activities of clarithromycin (CLA) and 
PZA against J\II tuberculosis. Sbarbaro et al. (1992) investigated the effect of rifampin 
and PZA on mycobacteria and in 1996 investigated the combined effect of PZA and a 
quinolone ( ofloxacin) as a potential preventive therapy regimen. Sal finger et al. 
(1990) reported on a comparison of PZA and POA activity in cultured human 
macrophages and in the BACTEC system. Crowle et al. (1986) investigated the effect 
of PZA alone on tubercle bacilli with cultured human macrophages, whereas Carlone 
et al. (1985) investigated the killing capacity of PZA, POA and rifampin on 
macrophages ingested live M tuberculosis. 
In this study the goal was to investigate the mode of action of PZA, thus combinations 
of drugs \vere not assessed for antibacterial activity. In experiments with non cell 
associated and macrophage bound mycobacteria exposed to PZA; the HPLC 
experiments were carried out concurrently with the growth assessment experiments. 
Although presented separately in the thesis for purposes of clarity we were able to co­
operatively assess PZA activity on mycobacteria in relationship to the PZA and POA 
concentrations detected in the non cell associated mycobacteria as well as in the 
different compartments viz., intracellular, extracellular and intra-bacterial, of the 
infected macrophages. We were also able to assess at which time interval PZA was 
converted to POA and the effect of this conversion on the growth of non cell 
associated mycobacteria in RPMI 1640. 
2.2 MATERIALS AND METHODS 
2.2.1 BACTERIAL ISOLATES 
Mycobacterium tuberculosis strains resistant and susceptible to PZA as obtained from 
the Department of Medical Microbiology, University of Natal-Medical School are 
listed in appendix 1. Cultures were maintained on antibiotic free Middlebrook 7H 10 
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agar slants (Appendix II), Lowenstein Jensen (LJ) slants and Middlebrook 7H9 broth 
(Appendix II). Ziehl-Neelsen (ZN) staining \Vas performed regularly on all cultures to 
confirm purity. The Wayne's test (Appendix II) was performed on all strains to 
determine the presence of the pyrazinamidase (Pzase) enzyme, thus indicating whether 
the strain was susceptible or resistant to PZA. Stock cultures were frozen in freezing 
medium containing proteose peptone broth supplemented with glycerol. 
One week old broth cultures were used in invasion assays with macrophages as well 
as in experiments with non cell associated mycobacteria in RPM! 1640. For the 
invasion assays with the macrophages, the mycobacterial cultures were centrifuged 
and the pellet resuspended in phosphate buffered saline (PBS). This suspension was 
vortexed for 1 min with 5 mm glass beads and allowed to settle for 15 mins at room 
temperature. The supernatant containing single mycobacteria and small clumps was 
adjusted to a McFarland No I standard (equivalent to 10
7 
cells/ml- Hindler, 1992) 
before use in the macrophage assays. 
2.2.2 SURVIVAL OF NON CELL ASSOCIATED MYCOBACTERIA 
FOLLOWING EXPOSURE TO PZA 
A McFarland No 1 standard of all clinical isolates and the reference strain, H37Rv 
was exposed to 100 µg/ml PZA in RPM! 1640 tissue culture medium. At time 
intervals of 4, 8, 16, 24, 48, 72, 1-+-+, 240 and 336 h the mycobacteria were plated out 
onto Middlebrook 7H IO agar plates. The colony forming units enabled us to assess 
survival or death of mycobacteria following exposure to PZA. 
ISOLATION OF MONOCYTES 
Peripheral blood monocytes were obtained by overlaying blood from healthy 
volunteers onto Ficoll-Histopaque I 077 (Sigma) in the ratio 5:4, followed by 
centrifugation at room temperature at 400 x g for 30 mins (Hirsch et al, 1994 and 
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Johnson et al, 1977). The cells vvere washed tvvice with RPMI 1640 tissue culture 
medium and resuspended in RPM! I 640 supplemented with 10 % fetal calf serum that 
was inactivated at 56°C for 30 min. The monocyte suspension was aliquoted in 5 ml 
volumes into 65 mm diameter petri dishes at a concentration of approximately 10
5 
cells/ml to obtain maximum yield for HPLC analysis. Monocytes were grown for 6 
days with changes of RPMI 1640 supplemented with IO % fetal calf serum every 2 
days. On the 6th day the monocyte derived macrophages were used in invasion 
assays. The trypan blue exclusion assay confirmed viability of the macrophages, 
while the esterase test confirmed maturation to the macrophage stage. 
2.2.4 SURVIVAL OF MACROPHAGE-BOUND MYCOBACTERIA 
FOLLOWING EXPOSURE TO PZA 
Macrophages were exposed to the bacteria for 1 hour in the ratio 1: l 0, after which all 
non cell associated bacteria were washed off. Five ml of fresh RPMI 1640 
supplemented with I 00 �tg/ml PZA was added to the petri dishes. At time intervals of 
4, 8, 16, 24, 48 and 72 h, the cells from 3 petri dishes were harvested and pooled to 
separate extracellular, intracellular and intra-bacterial fractions. 
2.2.5 SEPARATION OF EXTRACELLULAR. INTRACELLULAR AND INTRA­
BACTERIAL FRACTIONS 
The infected macrophages were gently scraped off the petri dishes using a Sterilin 
quadloop. The suspension obtained was centrifuged at 250 x g for 10 mins. The 
supernatant was discarded except for 500 �ti which was used to resuspend the pellet. 
To separate the extracellular from the intracellular fraction, silicone oil velocity 
gradient centrifugation was used (Johnson et al. 1980, Koga, .I 987, Pascual et al,
1994, Klem per and Stryt, 1981 ). A 6:5 mixture of silicone oils (500 �ti) of densities 
1.07 and 0.98, respectively, was placed in an eppendorf tube and 500 �ti of 
macrophage suspension was overlaid on the oil. This was then centrifuged for 3 mins 
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at 12 000 x g which resulted in a pellet of macrophages at the bottom of the tube. The 
extracellular fluid above the oil layer was removed. The pellet was resuspended in 
500 �tl of distilled water, vortexed and incubated at 3 7°C for l O mins to completely 
disrupt the macrophages. This fraction contained the intracellular mycobacteria. 
Serial dilutions of this fraction was made in distilled water and plated out onto 
Middlebrook 7H 10 agar plates to assess survival or death of macrophage bound 
mycobacteria following exposure to PZA. 
2.3 RESULTS 
Prior to assessing the effect of PZA on non cell associated and macrophage bound 
mycobacteria, purity of the strains and maturation of the macrophages had to be 
assessed. ZN staining of 1\1!. tuberrnlosis was performed regularly to confirm purity of 
the culture as shown in FIG. 2.1. The esterase test, FIG. 2.2., was performed on 
macrophages at 6 days of incubation in RPMf I 640 supplemented with l 0% fetal calf 
serum. A positive esterase test is indicated by black granulation over the 
macrophages, this indicates mature macrophages. Subsequent to infecting the 
macrophages with M tuberculosis, ZN staining was performed to assess the degree of 
infection as shown in FIG. 2.3. 
The reference strain, H3 7R v, as well as IO other clinical M tuberculosis strains that 
are Pzase positive were assessed for their ability to survive or die in non cell 
associated cultures as well as in macrophage co-cultures following PZA exposure. 
These susceptible strains were able to survive in both systems i. e., over a 336 h 
period in non cell associated cultures and over 72 h in macrophage co-cultures (FIG. 
2.4-2.14). The same pattern of survival was observed in Af bovis (naturally Pzase 
negative) as well as in clinical isolates that were Pzase negative (FIG. 2.15-2.20). 
These results are presented graphically. Composite graphs sho:v the mean CFU/ml 










FIG. 2.1. ZN staining of 1'vf tuberculosis cultures. (A) single mycobacteria and (B) 
characteristic clumps of mycobacteria 
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FIG. 2.6 Colony counts of a susceptible strain, 1 00R exposed ro 100 �tg/ml PZA in 
(A) RPMI 1640 and (B) infected macrophages.
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FIG. 2. 7 Colony counts of a susceptible strain, 11344 exposed ro 100 µg/ml PZA in 
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FIG. 2.8 Colony counts of a susceptible strain, 90s exposed to I 00 µg/ml PZA in (A) 
RPMI 1640 and (B) infected macrophages. 
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FIG. 2.9 Colony counts of a susceptible strain, 11102 exposed to 100 µg/ml PZA in 
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FIG. 2.10 Colony counts of a susceptible strain, 11191 exposed to I 00 µg/ml PZA in 
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FIG. 2.11 Colony counts of a susceptible strain, 11341 exposed to l 00 i.1g/ml PZA in 
(A) RPMI 1640 and (8) infected macrophages.
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FIG. 2. I 2 Colony counts of a susceptible strain, I I 851 exposed -to I 00 µg/ml PZA in 
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FIG. 2.13 Colony counts of a susceptible strain, 10486 exposed to 100 µg/ml PZA in 
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FIG. 2.14 Colony counts of a susceptible strain, 1195 exposed to 100 µg/ml PZA in 
(A) RPM! 1640 and (B) infected macrophages.
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FIG. 2.15 Colony counts of M bovis, a mycobacterial strain· in which the Pzase 
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FIG. 2.16 Colony counts of a resistant strain, 3886 exposed to 100 �Lg/ml PZA in (A) 
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FIG. 2.17 Colony counts of a resistant strain, 3732 exposed to roo µg/ml PZA in (A) 
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FIG. 2.18 Colony counts of a resistant strain, 60650 exposed to 100 µg/ml PZA in (A) 
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FIG. 2.19 Colony counts of a resistant strain, 79386 exposed to 100 �Lg/ml PZA in 










I■ colony counts I
I 6h 24h 48h 72h 240h 336h 
time (hours) 
B 
I■ colony counts I
16h 24h 48h 72h 
time (hours) 
FIG. 2.20 Colony counts of a resistant strain, 6114 exposed to 100 µg/ml PZA in 
(A) RPMI 1640 and (B) infected macrophages.
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FIG. 2.21 Mean CFU/ml for susceptible and resistant M. tuberculosis strains grown in RPM! 1640 supplemented with PZA as well as antibiotic free medium. Irrespective of 
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FIG. 2.22 Colony counts of M. tuberculosis strains located intracellularly in macrophages. No growth or death of resistant and susceptible 
strains were observed when macrophages were exposed to PZA, however, intracellular growth was observed in PZA free macrophages. 
2.4 DISCUSSION 
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The goal of this chapter was to assess the growth capacity of PZA susceptible and 
resistant clinical isolates of A,f tuberculosis on exposure to PZA, as non cell 
associated cultures as well as in macrophages. Prior to these experiments purity of the 
1vf. tuberculosis cultures were confirmed by ZN staining indicated in FIG 2.1 which 
shows single mycobacteria stained with ZN staining (FIG 2.1 A) as well as the 
characteristic clumping of mycobacteria (FIG 2.1 B). All cultures were subject to ZN 
staining to confirm purity prior to be used in experiments. Any cultures that were 
contaminated were subject to the decontamination procedure used for sputum and 
cultured on LJ slants and in Middlebrook 7H9 broth. After incubation at 3 7°C, 
cultures were stained again to confirm purity. 
The macrophages were subject to the esterase test at 6 days of incubation in RPMI 
1640 supplemented with l O % fetal calf serum. This confirmed maturation to the 
macrophage stage. A positive esterase test was indicated by black granulation on the 
macrophages. Thereafter, the macrophages were infected with the different strains of 
M tuberculosis. To confirm that the macrophages were indeed infected with M. 
tuberculosis, ZN staining was repeated (FIG 2.3). Thereafter, PZA assays were 
carried out. 
The non cell associated PZA assays were carried out by incubating strains at a final 
concentration of 107 CFU/ml. Also, the CO2 concentration was maintained at 5% 
throughout the experiments. The main goal was to investigate the mode of action of 
PZA on intracellular 1vf tuberculosis. The experiments with non cell associated 
bacteria were performed as controls for the experiments in macrophages. Thus, 
standard growth conditions were maintained throughout the experiments with 
emphasis being placed on the effect of the conversion or non-conversion of PZA to 
POA on M tuberculosis strains. This differed from the studies by Butler and Kilburn 
( 1982) who investigated the effect of CO2 and inoculum size on PZA inhibition. 
Strains of M tuberculosis incubated in the presence of 7% CO2 in air at pH 5.5 for 3 
weeks yielded larger colonies than the same strains incubated without CO2. They also 
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found that when medium was inoculated with greater than 300 CFU/ml of PZA 
susceptible strains, colonies developed in 3 weeks in the absence of added CO2 in the 
atmosphere, but growth was stimulated by addition of CO2 during incubation. In this 
study 7Hl0 agar plates were incubated with 5% CO2 and the initial inoculum used at 
the start of the experiments was l 07 CFU/ml. Both conditions served adequately to 
evaluate growth on plates after 3 weeks of incubation. There was no difficulty in 
counting of colonies formed and no further manipulations were carried out. 
The colony forming units observed in the experiments with non cell associated 
mycobacteria as well as with mycobacteria in macrophages have being plotted as 
individual graphs. PZA has no bactericidal effect on susceptible and resistant strains 
that were macrophage associated (FIG 2.4B-2.20B). This is further emphasised by 
analysing the composite graph, FIG. 2.22, where the mean CFU/ml are plotted for 
PZA susceptible and resistant strains. Intracellular growth was observed in 
macrophages infected with J\lf. wberculosis, but not subject to any PZA treatment. 
Thus, intracellular M tuberculosis has the ability to survive and multiply within 
untreated macrophages. 
This study differed from the other studies on PZA where the effect of combination of 
drugs on macrophages infected with M tuberculosis strains were investigated 
(Acocella et al, 1985, Carlone et al, 1985, Mor and Esfandiari, 1997 and Sbarbaro et 
al, 1996). Carlone et al. (1985) investigated the killing capacity of rifampicin, PZA 
and POA on macrophages ingested live M tuberculosis. They found over a 3 to 24 h 
period greater, more rapid, although not statistically significant killing of intracellular 
bacteria. There was a marked growth of intracellular mycobacteria observed between 
48 and 72 h in the control cultures which was less evident in the drug containing 
cultures. A similar trend was observed with the control experiments set up in this 
PhD study. No combinations of drugs were studied in antibiotic assays, thus there 
was no competition among the drugs for either entry into the macrophage or for 
binding to targets relevant to antimicrobial activity within the macrophage. It was, 
therefore, possible to assess the nett effect of PZA as an antimycobacterial agent. 
Carlone et al. ( 1985) found that there was no major increase in the killing effect with 
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respect to that observed with the individual drugs after exposure of the macrophage to 
all possible combinations of the 3 drugs. Another study that differed from this study 
was the study by Acocella et al. ( 1985) who investigated the degree of penetration of 
rifampicin, PZA and POA in mouse macrophages, where PZA was only evaluated for 
24 h. Macrophages in different metabolic phases were used viz., resident, stimulated 
and dead, which differed from this study where only actively growing peripheral 
blood derived macrophages were used. Also, Acocella et al. (1985) radiolabelled the 
antibiotics used and measured their penetration into macrophages by scintillation 
spectrophotometry. This study did not involve the addition of POA into the system. 
Thus, conversion from PZA to POA was of importance to us and HPLC was used as it 
could quantify PZA as well as the PZA converted to POA. 
Crowle et al. ( 1986) investigated the effect of PZA alone on tubercle bacilli within 
cultured human macrophages, similar to the culture aspect of this study. This studied 
the effect of PZA on intracellular bacilli by counts of acid fast bacilli and colony 
forming units. They found that PZA was active in the macrophage model as it was 
inhibiting virulent tubercle bacilli at concentrations of 20  µg/ml or higher, however, it 
was ineffective in 7H9 bacteriologic culture medium. Crowle et al. (1986) comments 
that PZA could either be bacteriostatic or bactericidal against intramacrophage 
tubercle bacilli depending on its concentration, the donor of the macrophages and 
length of exposure of the infected macrophage to the drug. In this study, irrespective 
of the donor of the macrophages, PZA had no bactericidal effect over the 72 h period 
studied. A fixed concentration of I 00 )-tg/ml was used throughout the experiments as 
high antibiotic concentrations were required to enable efficient quantification of PZA 
by HPLC in in vitro experiments as shown in later chapters. This has no bactericidal 
effect over the 72 h period studied. 
Combinations of drugs have also been studied. Sbarbaro et al. ( 1996) investigated the 
effect of PZA and a quinolone (of1oxacin) as a potential preventive therapy regimen. 
Three different concentrations of of1oxacin (OFL) (0.625, 1 . 25 and 2.5 µg/ml) were 
tested in combination with 40 µg/ml dosage of PZA. This demonstrated an inhibitory 
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effect upon intracellular tubercle bacillary grow1h. PZA enhanced the effectiveness of 
both bacteriostatic concentrations of OFL, converting the bacteriostatic impact of 
1.25 µg/ml to a bactericidal effect. The addition of PZA did not diminish the killing 
effect of the 2.5 µg/ml OFL. 
Mor and Esfandiari (1997) investigated the synergistic effect of clarithromycin (CLA) 
and PZA against M tuberculosis. This combination exerted a synergistic effect in 
preventing intracellular bacterial growth. CLA tends to enhance the effectiveness of 
PZA against tubercle bacilli within cultured human macrophages, however, this effect 
was not demonstrated to be bactericidal during the 8 days of this study. In this PhD 
study no combinations of drugs were studied as this had no purpose in the main aims 
of the project. 
The effect of pH on M tuberculosis has been studied extensively in our department 
(Matai, 1997) as well as internationally. Heifets et al. ( 1989) investigated whether 
POA has any specific antimicrobial activity or whether it affects the growth of M 
tuberculosis simply by lowering the pH below the limits of tolerance. They found that 
there was a clear dose effect correlation when inhibitory activities of different 
concentrations of POA under identical pH conditions (5.6) in 7H 12 liquid medium 
was evaluated. 
Matai (M. Sc thesis) investigated the MICs for PZA and POA against 17 M 
tuberculosis strains at each of the following pH values: 5.3, 5.8, 6.3, 6.8. She found 
that as the pH increased, the MICs of both drugs increased. At pH 6.3 the highest 
concentration of PZA of 512 mg/I had no activity on any of the organisms whereas 
POA at that concentration still retained some activity. She also found that all 17 M.
tuberculosis strains used in these experiments were able to grow at all of the 4 pH 
values tested, however, a reduction in colony size was observed at the lower pH 
values of pH 5.3 and pH 5.8. Since the effect of pH was extensively studied in our 
department the purpose of my experiments with non cell associated M tuberculosis
was to evaluate the effect of the tissue culture medium on the mycobacteria Also, to 
assess if the amount of PZA converted to POA by Pzase positive cultures has the 
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ability to inhibit the growth of i'vl tuberculosis. FIG. 2.2 I shows the mean values of 
IO susceptible and 5 resistant strains that were exposed to I 00 µg/ml PZA in RPMI 
1640. The control involved incubating 3 cultures in RPMI 1640 with no antibiotics. 
The graphs show that the cultures remain in a dormant state when incubated in 
antibiotic free RPMI 1640. Addition of PZA to the system does not change the 
overall effect i.e., the cells remain in a dormant state. Thus, PZA or the PZA 
converted to POA (see chapter 4 for HPLC results) in RPMI 1640 has no effect on the 
non-cell associated mycobacteria. This results differs from the macrophage bound 
mycobacteria where there is an increase in CFU/ml of intracellular mycobacteria 
exposed to antibiotic free RPMI 1640. Addition of PZA to the co-culture system 
shows that the mycobacteria are maintained in a bacteriostatic state throughout the 
experiment. Thus, there seems to be a clear distinction between the effect of PZA on 
intracellular mycobacteria as compared to non cell associated mycobacteria. 
There have been many manipulations of the media used to study the activity of PZA. 
Incorporation of enrichment usually oleic acid-albumin-dextrose-catalase (OADC) 
into 7H 10 agar is necessary for optimal growth of /vl tuberculosis at acid pH, 
however, oleic acid in an acid environment is inhibitory to many strains (Tummons, 
1975-cited by Butler and Kilburn , 1982). They also reported that growth of 25 % of 
M. tuberculosis strains were inhibited by presence of oleic acid at pH 5.5. Growth
appeared bener with certain lots of albumin-dextrose catalase (ADC) at pH 5.5 but 
some lots did not support growth at low pH. My study did not involve the evaluation 
of the OADC used in the /vl tuberculosis growth medium. All bottles of OADC used 
promoted optimum grov.th of J\;f tuberculosis strains, thus it did not warrant further 
evaluation. 
Butler and Kilburn ( 1983) reported on the detection of Pzase activity which 
hydrolyses PZA to POA as an alternative to PZA susceptibility tests. The standard 
Wayne's test (Wayne, 1974) was recommended, where a positiv� is indicative of pink 
to red colour development upon addition of freshly prepared ferrous ammonium 
sulfate solution. The Wayne's test was used initially on all the /vl tuberculosis strains 
used in my study to establish their Pzase status. There was good correlation with all 
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the strains, where all PZA resistant strains were Pzase negative and PZA susceptible 
strains were Pzase positive. 
Heifets and Lindholm-Levy (1990) reported on the MBC i.e., the lowest concentration 
killing more than 99 % of the bacterial population in vitro, using PZA susceptible 
strains cultivated in 7Hl2 broth at pH 5.6, the lowest pH favourable for active 
bacterial population growth. 33 to 57 % of the bacterial population was killed during 
the 15 day period of cultivation in the presence of PZA concentration two fold greater 
than the MIC. Increasing the PZA concentration as high as 500 and l 000 µg/ml did 
not substantially increase the proportion of bacterial population killed. They 
concluded that PZA has no bactericidal activity in vitro against actively multiplying 
bacteria. This is similar to this study where actively multiplying bacteria were 
incubated in RPMI I 640. PZA displayed poor bactericidal activiy under these 
conditions. The POA formed by PZA susceptible strains was not sufficient to lower 
the pH to levels intolerable to M tuberculosis strains. 
Heifets and Lindholm-Levy (1992) tried to determine in vitro activity of PZA against 
tubercle bacilli at a lower pH i.e., pH 5 or lower. The number of viable tubercle 
bacilli remained almost unchanged within a period of 3 to 4 weeks of cultivation in 
liquid medium with a pH of 4.8 to 5.0. This was referred to as the semi-dormant 
rather than dormant state, assuming that the relatively stable number of viable cells 
was a reflection of the simultaneous existence of cells in various states of the 
dormancy, multiplication and dying. The POA formed by Pzase positive strains, 
incubated in RPMI 1640 supplemented with PZA, was not able to decrease the pH to 
less than 5.0 to have a bactericidal effect on the cultures, thus the cultures remained in 
a (semi) dormant state. 
CHAPTER3 
DEVELOPMENT OF THE HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY METHODOLOGY FOR SIMULTANEOUS 
DETECTION OF PZA AND POA 
3.1 MANUSCRIPT 
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This chapter is presented as a manuscript being submitted for consideration for 
publication. It discusses the high performance liquid chromatography (HPLC) 
methodology that was developed for the simultaneous detection of PZA and POA. It 
also shows the initial results obtained with the reference strain H37Rv. 




Pyrazinamide (PZA) is known to be converted to pyrazinoic acid (POA) by the 
enzyme pyrazinamidase (Pzase). It is generally accepted that this conversion plays a 
role in the mechanism through which PZA exerts its antimycobacterial activity. This 
activity is thought to take place intracellularly in infected macrophages. High 
performance liquid chromatography (HPLC) methodology was developed to measure 
the concentration of PZA and POA in biological systems. A mobile phase of 
methanol and 10 mM phosphate buffer (20%:80%, v/v), pH 3.5 most effectively 
separated both compounds. The wavelength of 265 run was most efficient to resolve 
PZA and POA peaks. This methodology was used to quantify PZA and POA in the 
different compartments of a macrophage-mycobacterium co-culture system as well as 
in extracellularly growing mycobacteria, using strain H37Rv. Macrophages were 
separated from extracellular fluid by means of silicone oil velocity gradient 
centrifugation. The macrophages were lysed by means of distilled water and the 
bacterial cell walls disrupted by means of silica/zircona beads in a mini-bead beater. 
There was minimal entry of PZA into the macrophage, with most of the PZA 
remaining in the extracellular fraction. Also, no intracellular or extracellular POA 
could be detected. 
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INTRODUCTION 
The kfycobacterium tuberculosis population present in a patient with active 
tuberculosis is divided into four subpopulations: actively multiplying extracellular 
organisms, actively multiplying intracellular organisms, dormant extracellular 
organisms and dormant intracellular organisms (Mitchison, 1985). Each of the 
different drugs used in treatment of tuberculosis is thought to play a specific role in 
eradication of these subpopulations. 
It has been postulated that the role of pyrazinamide (PZA) is to eradicate dormant and 
actively multiplying organisms from the intracellular compartment. This thought is 
supported by the observation that the optimal pH at which this drug is active is 
between 5.0 and 5.5. This is the pH in the phagolysosomes of activated macrophages. 
j\;f tuberculosis is a facultative intracellular pathogen of these cells. 
To be able to test this hypothesis it must be possible to measure drug penetration in 
macrophages as well as the effect of the drug on intracellular mycobacteria. 
Circumstantial evidence suggests that the metabolic product, pyrazinoic acid (POA), 
produced on hydrolysis of PZA by the bacterial enzyme pyrazinamidase (Pzase), is the 
active compound (Heifets et al, 1989, Konno et al, 1967, Singh et al, 1993). Thus, 
there is a need for a test which is able to measure PZA as well as POA concentrations 
intracellularly. High performance liquid chromatography (HPLC) with acetonitrile 
and phosphate buffer pH 3.5 as mobile phase has been used to m�asure PZA in human 
plasma (Walubo et al, 1994) and cerebrospinal fluid (CSF) as well as in plasma of 
rabbits (Chan et al, 1986). This method does not resolve POA. So far, tests that 
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measure POA are based on spectrophotometry (Wayne, 1974). This technique is not 
sensitive enough to detect POA at concentrations expected to be present intracellularly 
in macrophages. 
We report on the development of a HPLC based method to measure both PZA and 
POA simultaneously in macrophages as well as in bacteria. 
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MATERIALS AND METHODS 
Bacteria. Pyrazinamide susceptible !vi tuberculosis, reference strain H37Rv (ATCC 
3 7294) was grown in antibiotic free Middlebrook 7H9 broth. One week old cultures 
were used in invasion assays with macrophages. The cultures were centrifuged at 
12 000 x g at room temperature and the pellet resuspended in phosphate buffered 
saline. This suspension was vortexed for I min with 5 mm glass beads and allowed to 
settle for 15 mins at room temperature. The supernatant containing single bacteria 
and small clumps adjusted to a McFarland No 1 standard (10
7
cells/ml) was used in the 
macrophage assays. 
PZA uptake by mycobacteria. A McFarland No 1 standard of H37Rv was exposed 
to I 00 µg/ml PZA in RPMI 1640 tissue culture medium. At time intervals of 4, 8, 16, 
24, 48 and 72h the mycobacteria were disrupted with 0.1-0.15 mm diameter 
zirconia/silica beads using a mini bead beater set at homogenise for 3 mins. 
Mycobacteria were centrifuged at 12 000 x g for l O mins (Biospec Products). The 
supernatant ,vas used to assess PZA and POA by HPLC. 
Isolation of monocytes. Peripheral blood monocytes were obtained by overlaying 
blood from healthy volunteers onto Ficoll-Histopaque l 077 (Sigma) in a ratio of 5:4, 
followed by centrifugation at room temperature at 400 x g for 30 mins. The cells were 
washed twice ,vi th RPMI 1640 tissue culture medium and resuspended in RPMI I 640 
supplemented with IO% fetal calf serum that was inactivated at 6_5°C for 30 min. The 
monocyte suspension was aliquoted in 5 ml volumes into 65 mm diameter petri dishes 
at a concentration of approximately 105 cells/ml to obtain maximum yield for HPLC 
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analysis. Monocytes were grown for 6 days with changes of RPMI 1640 
supplemented with IO % fetal calf serum every 2 days. On the 6th day the monocyte 
derived macrophages were used in invasion assays. The trypan blue exclusion assay 
confirmed viability of the macrophages. The monocyte suspension was stained with 
0.4 % trypan blue made in phosphate buffered saline. Viable cells have intact cell 
walls and does not allow for the uptake of the stain. Thus clear uncoloured cells are 
viable while blue cells are dead. Percentage viability of the cells were assessed. The 
esterase test confirmed maturation to the macrophage stage. The a-naphthyl-acetate 
esterase kit (Sigma) was used where black granulation over the macrophage cultures 
indicate mature macrophages. 
PZA uptake by infected macrophages. Macrophages were exposed to the bacteria 
for I hour, after which all extracellular bacteria were washed off by gently pipetting 
the RPM! and allowing the medium to flow over the petri dish. This washing 
procedure was carried out thrice before the medium was discarded. The infected 
macrophages were stained with ZN stain to determine if washing was effective and all 
free bacteria removed. Also, transmission electron microscopy was used to assess 
mycobacteria bound within macrophages ( data not shown). Fresh RPM! I 640 
supplemented with I 00 �tg/ml PZA was added to the petri dishes. To quantify 
extracellular, intracellular and intra-bacterial PZA/POA by HPLC, cells from 3 petri 
dishes were harvested and pooled at intervals of 4, 8, 16, 24, 48, and 72 hours. 
Separation of extracellular, intracellular and intra-bacterial fractions. The 
infected macrophages were gently scraped off the petri dishes using a l O �ti disposable 
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loop (Sterilin). The suspension obtained was centrifuged at 250 x g for 10 mins. The 
supernatant was discarded except for 500 µl which was used to resuspend the pellet. 
To separate the extracellular from the intracellular fraction, silicone oil velocity 
gradient centrifugation was used (Johnson et al, 1980, Klempner and Styrt, 1981, 
Koga, 1987, Pascual et al, 1994). A 6:5 mixture of silicone oils (500 µl) of densities 
1.07 and 0.98, respectively, was placed in an eppendorf tube and 500 pl of 
macrophage suspension was overlayed on the oil. This was then centrifuged for 3 
mins at 12 000 x g which resulted in a pellet of macrophages at the bottom of the tube. 
The extracellular fluid above the oil layer was removed. The pellet was resuspended 
in 500 µl of distilled water, vortexed and incubated at 3 7°C for IO mins to completely 
disrupt the macrophages. This constituted the intracellular extra-bacterial fraction. 
The mycobacteria in this fraction were disrupted with 0.1-0.15 mm diameter zirconia/ 
silica beads using a mini bead beater (Biospec Products). 
HPLC. HPLC was performed using a Hewlett Packard I 090 HPLC with a Merck 
reverse phase C8 column (250 mm) fitted with a C8 guard column and a column oven 
temperature of 40 °C. Mobile phases used to separate PZA and POA were a mixture 
of acetonitrile and I 0mM phosphate buffer pH 3.5 (20%:80%, v/v) (Chan et al, 1986, 
Woo, 1987); phosphate buffer pH 2.56 alone (Yamamoto et al, 1987); and a mixture 
of methanol and IO mM phosphate buffer pH 3.5 (20%:80%, v/v) (Ono et al, 1996). 
The flow rate of the mobile phase was I ml/min with a sample injection volume of 25 
ul in all experiments. Product analysis was done using a UV detector, at wavelengths 
of 215 run (Chan et al, 1986), 254 run and 265 nm (Ono et al, 1996). PZA, POA as 
well as paracetamol (PARA) were dissolved in warm distilled water (HPLC pure) to 
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obtain the following: standard solutions: 5, 10, 25, 50, 100 µg/ml of PZA; 5, 10, 25, 
50 µg/ml of POA, with the internal standard PARA at a final concentration of 100 
µg/ml. RPM! 1640 tissue culture medium without any of the drugs was used as a 
blank and the HPLC results obtained were subtracted from all measured extracellular 
concentrations. 
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RESULTS 
The combination of methanol and 10 mM phosphate buffer, pH 3.5 as the mobile 
phase was able to separate POA, PZA as well as PARA (FIG. 1 ). The retention times 
were 2.7, 4.1 and 5.5 mins respectively. The mobile phases of acetonitrile with 10 
mM phosphate buffer, pH 3.5 (Chan et al, 1986 and Woo, 1987) and 0.02 M 
phosphate buffer, pH 2.56 (Yamamoto et al, 1987) were able to resolve PZA only. 
With these mobile phases tailing of the POA peak occurred. Hence, acceptable 
correlation factors could not be obtained. Optimal resolution was achieved at 
wavelength 265 nm. At wavelength 215 nm (Chan et al, 1986) interference peaks 
were obtained. Wavelength of 254 run was optimal for PARA but not for PZA and 
POA. RPMI 1640 gave rise to HPLC peaks at wavelength 265 nm that interfered with 
the POA peak. Subtraction of results obtained with RPMI 16-t0 only was used to 
resolve this. With this method the minimal concentration of PZA and POA that gave 
a detectable peak was 0.1 and 0.5 µg/ml respectively. 
Results of the application of this HPLC methodology on H37Rv only and on 
macrophages infected \Vith H37Rv and exposed to PZA are shown in FIG. 2 and FIG. 
3, respectively. The concentration of PZA extracellularly decreased gradually over the 
first 24 h without the appearance of detectable amounts of POA with free 
mycobacteria in RPMI 1640. POA was first detected at 48 h. At that point there were 
also measurable concentrations of PZA and POA in the bacteria. The POA 
concentration increased in the next 24 h in the extra-bacterial fraction but not in the 
intra-bacterial fraction (FIG. 2). Intra-bacterial concentration of PZA and POA at 72 h 
were 4.58 and 0.650 µg/ml, respectively. In macrophages infected with H37Rv, no 
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POA was detected in the extracellular, intracellular or the intra-bacterial fractions. The 
PZA concentration was higher extracellularly than intracellularly. No PZA could be 
detected in the intra-bacterial fraction (FIG. 3). 
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DISCUSSION 
The combination of PZA with isoniazid and rifampicin is one of the most effective 
antituberculous regimens (Walubo et al, 1994). However, the exact mode and site of 
action of PZA are unknown. One of the hypothesis is that in macrophages infected 
with PZA susceptible strains, PZA is converted to POA by Pzase. This causes a 
lowering of pH in the macrophage environment. Either the decrease in pH alone or 
this enzyme generated product, POA, is responsible for the high antibacterial activity 
of PZA. We developed HPLC based methodology that can quantify PZA and POA 
simultaneously at concentrations as low as 0.1 and 0.5 µg/ml, respectively. This 
allows detection of PZA and POA extracellularly, intracellularly as well as in the 
intra-bacterial compartment of infected macrophages. 
We choose HPLC as a tool since it has the potential to quantify PZA and POA 
simultaneously in a single assay. Although, there have been numerous reports on the 
use of HPLC to quantify PZA in plasma, serum and CSF, the methodolgy used only 
yields a well resolved chromatograph for PZA (Chan et al, 1986, Walubo et al, 1994 
and Yamamoto et al, I 987). When the same mobile phase is used for POA, a peak 
with distinct tailing is observed, which resulted in poor correlation factors when 
standard curves were plotted. Thus, published mobile phases were unable to resolve 
POA. We successfully attempted to develop a mobile phase that would separate POA, 
PZA and the internal standard PARA into well resolved and distinctly separate peaks. 
Methanol and phosphate buffer proved to be the mobile phase that separates PZA, 
POA and PARA efficiently. Reproducibility was optimal at pH 3.5. Prolonged usage 
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of the column ( over a 2 year period) as well as pH of the buffer affects the POA peak 
drastically as compared to the PZA peak where no change in retention time was 
observed. The tissue culture medium RPMI 1640 gave rise to intereference peaks 
that affected the POA peak, thus RPMI 1640 had to be run as a blank with the results 
subtracted from measured concentrations. A UV wavelength of 265 nm was the 
optimum wavelength for the analysis of extracellular and intracellular PZA and POA 
as compared to 215 run as previously reported (Chan et al, 1986). The UV wavelength 
of 265 nm is also used for the separation of isoniazid and isonicotinic acid (Ono et al, 
l 996) which is similar in structure to PZA.
We also report on the results obtained with bacteria (H37Rv) exposed to PZA in 
tissue culture medium as well as in macrophages infected with H37Rv. With 
mycobacteria only, POA was detected at 48 h in tissue culture medium, where the 
quantity of detectable POA formed increased over time with the PZA concentration 
decreasing. This suggests that PZA is converted to POA. 
There are numerous studies that have investigated the effect of PZA in macrophage 
models infected with i\tf tuberculosis and challenged with PZA (Acocella et al, 1985, 
Carlone et al, 1985, Salfinger er al, 1989 and Sbarbaro et al, 1996). However, the 
main methodology applied was assessement of intracellular kill by bacterial counts. 
Carlone et al ( 1985) investigated the killing capacity of rifampicin, PZA and POA on 
macrophages infected with live M tuberculosis with �rug concentrations 
corresponding to the average peak levels observed in human after administration of 
therapeutic doses viz., 30 �tg/ml PZA, 10 µg/ml rifampicin and 8 µg/ml POA. There 
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was a marked grov,1h of intracellular mycobacteria observed between 48 and 72 h in 
the control cultures \.vhich was less evident in the drug containing cultures. The 
studies of Acocella et al ( 1985) differed from the studies by Carlone et al (1985) in 
that the concentration of rifampicin, PZA and POA corresponded to the peak, trough 
and intermediate serum concentrations observed in human. Also, macrophages were 
in different metabolic stages. The results obtained in that study indicated that 
rifampicin, PZA and POA penetrate rapidly into macrophages, irrespective of their 
metabolic state. The penetration is almost complete at lower concentrations. 
Sbarbaro et al ( 1996) investigated combined effect of PZA and otloxacin as a 
potential preventive therapy regimen. Three different concentrations of otloxacin 
(0.625, 1.25, 2.5 pg/ml) were tested in combination with 40 pg/ml of PZA. This 
demonstrated an inhibitory effect upon intracellular bacillary growth. However, there 
are no reports on the quantification of intracellular and extracellular PZA and POA. 
This is the key to understanding the location of action of PZA. 
To do so, cells had to be concentrated to enable intracellular PZA or POA to be 
quantified. Silicone oil velocity gradient separation using a mixture of silicone oil of 
two densities as described by Klempner and Stryt ( 1981) was used to separate the 
extracellular from the intracellular fractions. This resulted in efficient recovery of the 
antibiotic. Even with the high concentration of l 00 ug/ml, there was minimal 
detectable PZA in the infected macrophages. Most of it remained in the extracellular 
tissue culture medium. No POA was detected in the extracel.lular or intracellular 
compartment of the infected macrophage model nor was any PZA or POA detected 
after the bacteria were lysed. However, addition of the extracellular and intracellular 
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drug concentrations at each time interval equals approximately 80 ug/ml (FIG. 3). 
Thus, 20 % of the initial amount of I 00 µg/ml could have been converted to POA, 
that was used up by the intracellular mycobacteria resulting in antimycobacterial 
activity. This is supported by our findings with bacteria only (FIG.2). In this system, 
using the same medium and organism, we found over the first 24 h a  gradual decrease 
of PZA before POA became detectable extra- or intracellularly. In contrast to our 
observations with free bacteria, we did not find any PZA or POA in the intracellular 
bacteria. This might reflect a concentration dependent effect. Although exposed to a 
concentration 3 to 4 times higher than that achievable in blood, the intra-macrophage 
concentrations of PZA did not exceed 8 �Lg/ml. There was no detectable free drug 
intra-bacterially when exposed to this low concentration. In patients, with serum peak 
levels of PZA of appro:,;imately 30 �Lg/ml, one expects this to be even lower. MIC for 
PZA amongst M tuberculosis are in the order of 20 µg/ml at pH 5.5. If PZA has any 
anti-mycobacterial effect intracellularly it is most likely because of trapping of the 
drug (or its metabolite) in a intra-bacterial structure. Such an event could result in a 
constant influx even at low extra-bacterial concentrations and it explains why PZA 
disappears in the absence of detectable POA. 
With the establishment of an effective mobile phase as well as a method to separate 
test system fractions we are now able to carry out further experiments with clinical 
isolates of lvf. tuberculosis susceptible and resistant to PZA. 
In conclusion, we developed HPLC methodology that allows simultaneous 
quantification of PZA and POA with minimal detection levels of 0.1 and 0.5 �tg/ml. 
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Application of this methodology in macrophages infected with H3 7Rv suggest that, if 
the site of activity of PZA is in the macrophages, minimal amounts of the drug are 
needed. This is in contrast to the minimal inhibitory concentrations (MICs) obtained 




































































Fig 1: Separation of PZA, POA and PA.RA simultaneously using methanol and l 0mm 
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3.2 ADDITIONAL INFORMATION 
3.2.l HPLC fNSTRUMENTATION 
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The following figure indicates the functions of the different components of the HPLC. 
COMPONENT FUNCTION 
Automatic injector injects samples automatically into the 
column 
Diode array UV-vis detector measures absorbance at specific 
wavelengths and/or UV-vis spectrum of 
mobile phase and analytes 
C8 guard column to filter solid impurities that may be in 
sample 
C8 analytical column separates the components of samples 
injected 
Autosampler allows for the series of samples to be 
queued for automatic injection 
Column oven keeps column at optimum temperature for 
separation of samples 
Mobile phase solvents Carries samples across analytical column 
and allows optimum separation of sample 
Control panels instrument operation panel 
Chemstation and computerised control software that runs the HPLC as well as 
analysis of results can be done 
Low and high pressure pumps pumps mobile phase across the column 
Electronic panels electronics of instruments 
FIG. 3.1 Functions of the different components of the HPLC. 
3.3 ADDITIONAL RESULTS 
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PZA, POA and the internal standard was separated by the reported mobile phase of 
acetonitrile and phosphate buffer, pH 3.5. FIG. 3.2A, B, C and FIG 3.3A, B, C shows 
the chromatographs for PZA and POA, respectively. This mobile was not able to 
resolve POA satisfactory to obtain good correlation factors for the standard curves, 
thus other mobile phases were tried. Methanol and phosphate buffer, pH 3.5 was able 
to resolve all three antibiotics and was therefore the mobile phase of choice (FIG. 3.4). 
Also, three different wavelengths were used to obtain the best separation, viz., 215, 
254 and 265 run. FIG. 3.5A, B, C shows the separation of the standard solutions of 
PZA while FIG. 3.6A, B, C shows the separation of POA at wavelengths 215, 254 and 
265run, respectively. The tissue culture medium, RPMI caused interference peaks, 
therefore the chromatographs obtained for RPMI was substracted from all the 
chromatographs as showed in FIG. 3.7. With prolonged use of the column, 
deterioration of the packing material occurred which interfered with the retention time 
of POA only, causing the peak to coincide with PZA (FIG. 3.8). Different pH values 
was used in an attempt to correct this as shown in FIG. 3.9. pH values above and 
below pH 3.5 was used in an attempt to resolve the peaks. This was corrected by 
changing the pH of the buffer to 4.0 as shown in FIG. 3.10. The standard curves are 
shown in appendix II. 
FIG. 3.2A. Chromatographs of PZA (50 pg/ml) at wavelengths of (A) 215, (B) 254 
and (C) 265 nm using mobile phase of acetonitrile and phosphate buffer, pH 3.5 
(20%:80%). 
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FIG. 3.28. Chromatographs of PZA (25 �tg/ml) at wavelengths of (A) 215, (B) 254, 
and (C) 265 nm using mobile phase of acetonitrile and phosphate buffer, pH 3.5 
(20%:80%). 
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FIG. 3.2C. Chromatographs of PZA (IO µg/ml) at wavelengths of (A) 215, (B) 254 
and (C) 265 nm using mobile phase of acetonitrile and phosphate buffer, pH 3.5 
(20%:80%). 
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FIG. 3.3A. Chromatographs of POA ( I 00 pg/ml) at wavelengths of (A) 215, (B) 254 
and (C) 265 nm using mobile phase of acetonitrile and phosphate buffer, pH 3.5 
(20%:80%). 
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FIG. 3.3B. Chromatographs of POA (50 µg/ml) at wavelengths of (A) 215, (B) 254 
and (C) 265 nm using mobile phase of acetonitrile and phosphate buffer, pH 3.5 
(20%:80%). 
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FIG. 3 .3C. Chromatographs of POA (25 �1g/ml) at wavelengths of (A) 2 I 5, (B) 254, 
and (C) 265 nm using mobile phase of acetonitrile and phosphate buffer, pH 3.5 
(20%:80%). 
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FIG. 3.4. Chromatographs of POA, PZA and internal PARA with retention times of 
2. 795, 4.172 and 5.573 mins respectively as separated by methanol and phosphate
buffer, pH 3.5 (20%:80%). 
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FIG. 3.5A. Chromatographs of PZA standard solutions (A) I 00, (B) 50, (C) 25, (D) 
I 0, (E) 5 pg/ml separated with methanol and phosphate buffer, pH 3.5 (20%:80%) at 
215 nm. 
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FIG. 3.58. Chromatographs of PZA standard solutions (A) 100, (8) 50, (C) 25, (D) 
I 0, (E) 5 µg/ml separated with methanol and phosphate buffer, pH 3.5 (20%:80%) at 
254 run. 
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FIG. 3.5C. Chromatographs of PZA standard solutions (A) 100, (8) 50, (C) 25, (D) 
10, (E) 5 �tg/ml separated with methanol and phosphate buffer, pH 3.5 (20%:80%) at 
265 nm. 
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FIG. 3.6A. Chromatographs of POA standard solutions (A) 50, (B) 25, (C) I 0, 
(D) 5 pg/ml separated with methanol and phosphate buffer, pH 3.5 (20%:80%) at 215
nm. 
FIG. 3.6B. Chromatographs of POA standard solutions (A) 50, (B) 25, (C) I 0, 
(D) 5 �tg/ml separated with methanol and phosphate buffer, pH 3.5 (20%:80%) at
254 run. 
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FIG. 3.6C. Chromatographs of POA standard solutions (A) 50, (B) 25, (C) 10, 




FIG. 3.7. Subtraction of RPM! 1640 from all HPLC calculations to eliminate the 
interference peaks caused by RPM! 1640 (A) subtraction result-all interference peaks 
eliminated except for internal standard, (B) chromatograph of RPM! 1640, (C) RPM! 
1640 with internal standard. 
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FIG. 3.8. Chromatograph of POA (3.638 mins) that coincides with PZA (4.100 mins) 
as the column deteriorates with prolonged use. 
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FIG. 3.9. pH values above and below pH 3.5 was used in an attempt to separate the 
PZA and POA chromatographs after deterioration of the column (A) pH 5.2, (B) pH 
3.5, (C) pH 3.1. 
139 
FIG. 3.10. Separation of POA (3.119 min), PZA (4.091 min) and PARA (5.442 min) 
at pH 4 after deterioration of the column. 
3.4 ADDITIONAL DISCUSSION 
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The chromatographs obtained for the PZA and POA standards with a mobile phase of 
acetonitrile and phosphate buffer pH 3.5 is shovvn in FIG 3.2A, B, C and FIG 3.3A, B, 
C. Although many trials were carried out with this mobile phase the POA peak was
not satisfactory resolved. New stock powder was used to eliminate contamination. 
Also, different solvents were used to dissolve POA, but all solutions of POA resulted 
in poor chromatographs. Thus, an attempt was made to change the mobile phase to 
methanol and phosphate buffer which resolved POA peaks. The best chromatographs 
for PZA, POA and the internal standard PARA were obtained at 265 nm. 
141 
CHAPTER4 
DISTRIBUTION OF PZA AND POA IN NON CELL ASSOCIATED AND 
MACROPHAGE BOUND MYCOBACTERIA: A HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY ASSESSMENT 
4.1 INTRODUCTION 
The objectives of the high performance liquid chromatography (HPLC) experiments 
presented in this chapter were: 
a) to measure PZA concentrations as well as the amount of PZA converted to
POA upon exposure of mycobacteria in RPMI 1640 supplemented with
100 µg/ml PZA over time,
b) to measure PZA concentration and the amount of PZA converted to POA in
macrophages infected with mycobacteria and exposed to 100 µg/ml PZA, i.e.,
in the various fractions of the mycobacterial-macrophage co-cultures, viz., the
extracellular, intracellular and intra-bacterial fractions.
There are several methods available to quantify pharmaceutical compounds. 
Spectrophotometric methods (UV/visible, fluorescence) are fairly non-specific and 
usually do not discriminate between closely related metabolites or degradation 
products. Thin-layer chromatographic methods are widely used and inexpensive. 
However, quantitative analysis is difficult. Gas chromatography shows good 
specificity and sensitivity. Ho"vever, the elevated operating temperatures used may 
occasionally cause thennal degradation of compounds, and it is necessary to derivatise 
samples to increase their volatility and improve their chromatographic behaviour. 
HPLC offers many advantages for quantitative analysis. Extraction procedures and 
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sample clean-up prior to injection are much simpler than for most other methods. In 
the analysis of pharmaceutical products it is frequently sufficient to crush or mix the 
product with a suitable solvent, followed by filtration and injection into the analyser 
(Knox, 1978). 
HPLC has been used to measure PZA in human plasma (Walubo et al, 1994) and 
cerebrospinal fluid (CSF) as well as in plasma in rabbits (Chan et al, 1986). These 
HPLC studies were only able to quantify PZA. With acetonitrile and phosphate buffer, 
pH 3.5 as mobile phase, it was not possible to resolve POA. We developed a mobile 
phase to resolve PZA and POA simultaneously. Also, there have been no HPLC 
studies that have investigated the effect of PZA on macrophages infected with 
mycobacteria as well as non cell associated mycobacteria. 
By means of this method, we were able to measure PZA/POA in the various fractions 
of the macrophage. This enabled us to establish how these compounds were 
distributed in a mycobacterial macrophage co-culture system. We were also able to 
compare the degree of conversion of PZA to POA in non cell associated mycobacteria 
in RPMI 1640 as compared to macrophage bound mycobacteria. 
4.2 MATERIALS AND METHODS 
4.2. l HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
CONDITIONS 
HPLC was performed using a Hewlett Packard I 090 HPLC with a Merck reverse 
phase CS column fitted with a CS guard column. The column oven temperature was 
40 °C. Mobile phases used to separate PZA and POA were combinations of 
acetonitrile and I 0mM phosphate buffer pH 3.5 (20%:80%, v/v) (Appendix II) (Woo, 
1987 and Chan, 1986); phosphate buffer pH 2.56 (Yamamoto et al, 1987a); and a 
combination of methanol and 10 mM phosphate buffer pH 3.5 (Ono et al, 1996) and 
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with prolonged use of the column had to be changed to pH 4. The flow rate of the 
mobile phase was l ml/min "vith a sample injection volume of 25 µl in all 
experiments. Product analysis was done using a UV detector, a1:·wavelengths of 215 
run (Chan er al, 1986). 254 run and 265 nm (Ono et al, 1996). PZA and POA as well 
as paracetamol (PARA) were dissolved in warm distilled water to obtain the following 
standard solutions: 5, 10, 25, 50, l 00 �tg/ml of PZA and 5, l 0, 25, 50 �tg/ml of POA, 
with the internal standard PARA at a final concentration of 100 µg/ml. RPM! 1640 
tissue culture medium without any of the drugs was used as a blank and the HPLC 
results were subtracted from all extracellular calculations as the extracellular fraction 
only was in RPM! 1640. 
4.2.2 PZA UPTAKE BY MY CO BACTERIA ONLY 
A McFarland No I standard of the reference strain, H37Rv, as well as all Pzase 
positive and negative clinical mycobacterial isolates were exposed to I 00 µg/ml PZA 
in RPMI 16-40 tissue culture medium. At time intervals of 4, 8, 16, 24, 48, 72, 144, 
240, 336 h the mycobacteria were disrupted with 0.1-0.15 mm diameter zirconia/silica 
beads using a mini bead beater (Biospec Products) and PZA and POA concentrations 
were measured by HPLC. 
4.2.3 PZA UPTAKE BY INFECTED MACROPHAGES 
Macrophages were exposed to the mycobacteria in the ratio I: IO for I hour, after 
which all unbound mycobacteria were washed off. Fresh RPMI 1640 supplemented 
with I 00 µg/ml PZA was added to the petri dishes. To quantify extracellular, 
intracellular and intrabacterial PZA/POA by HPLC, cells from 3 petri dishes were 
harvested and pooled at intervals of 4, 8, 16, 24, 48, and 72 h. 
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4.2.4 SEPARATION OF EXTRACELLULAR. INTRACELLULAR AND INTRA­
BACTERIAL FRACTIONS 
The infected macrophages were gently scraped off the petri dishes using a Sterilin 
quadloop. The suspension obtained was centrifuged at 250 x g for 10 mins. The 
supernatant was discarded except for 500 µl which was used to resuspend the pellet. 
To separate the extracellular from the intracellular fraction, silicone oil velocity 
gradient centrifugation was used (Johnson er al, 1980, Koga, 1987, Pascual et al, 
1994, Klem per and Stryt, 1981 ). A 6:5 mixture of silicone oils (500 µl) of densities 
1.07 and 0.98, respectively, was placed in an eppendorf tube and 500 µl of 
macrophage suspension was overlayed on the oil. This was then centrifuged for 3 
ruins at 12 000 x g which resulted in a pellet of macrophages at the bottom of the tube. 
The extracellular fluid above the oil layer was removed. The pellet was resuspended 
in 500 �ti of distilled water, vortexed and incubated at 3 7°C for 10 ruins to completely 
disrupt the macrophages. This constituted the intracellular extra-bacterial fraction. 
The intra-bacterial antibiotic concentration was calculated after PZA and POA 
concentrations were measured in the intracellular fraction, in which the mycobacteria 
were disrupted by means of 0.1-0. I 5 mm diameter zirconia/ silica beads using a mini 
bead beater (Biospec Products). 
4.3 RESULTS 
Pzase positive mycobacteria, grown in RPM! 1640 without macrophages did take up 
PZA and there was also POA detected in these bacteria. FIG. 4.2A-FIG. 4.18A shows 
the variation in concentration of PZA and POA over a 336h period. PZA also entered 
Pzase negative bacteria but no POA was detected (FIG. 4. l 3A-FIG. 4.18A). No PZA 
or POA could be detected in bacteria in macrophages over the 72h period studied 
(FIG. 4.2B-FIG. 4.12B). While PZA did enter the cells, no POA .could be detected in 
infected cells or in cells infected with Pzase positive and negative mycobacteria. The 
differences in intracellular and extracellular concentrations of the drug for the 3 
different test systems, viz., uninfected macrophages, infected macrophages and free 
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mycobacteria are shovm in figures FIG. 4.1, 4.2B-4.18B and FIG. 4.2A-4.18A, 
respectively. The amount of intracellular PZA was lower when the cells were 
inoculated with Pzase positive mycobacteria as compared to uninfected macrophages 
and macrophages infected with Pzase negative strains. This difference was statistically 
significant (p=0.001 ). There was no difference in extracellular concentration over 
time in the test system with Pzase positive and negative bacteria (p=0.07). However, 
the extracellular concentration in the test system without bacteria were significantly 
lower over the 72 h studied \vhen compared to infection with susceptible strains 
(p=0.0008) and resistant strains (p<0.0001). 
All results are presented graphically for non cell associated cultures as well as 
macrophage bound mycobacteria. Composite graphs show the mean values for PZA 
and POA of all susceptible and resistant strains as macrophage bound mycobacteria 
(FIG. 4.19-FIG. 4.20) and non cell associated cultures ( FIG. 4.21-FIG. 4.22). Graphs 
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FIG. 4.2. PZA and POA concentrations in reference strain, H37Rv exposed to 
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FIG. 4.3. PZA and POA concentrations in a susceptible strain, 200R exposed to 
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FIG. 4.4. PZA and POA concentrations in a susceptible strain, I 0OR exposed to 
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FIG. 4.5. PZA and POA concentrations in a susceptible strain, 11344 exposed to 
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FIG. 4.6. PZA and POA concentrations in a susceptible strain, 90s exposed to 
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FIG. 4. 7. PZA and POA concentrations in a susceptible strain, 11.102 exposed to 
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FIG. 4.8. PZA and POA concentrations in a susceptible strain, 11191 exposed to 
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FIG. 4.9. PZA and POA concentrations in a susceptible strain, 11341 exposed to 
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FIG. 4.10. PZA and POA concentrations in a susceptible strain. 11851 exposed to 
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FIG. 4.11. PZA and POA concentrations in a susceptible strain, l 0486 exposed to 
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FIG. 4.12. PZA and POA concentrations in a susceptible strain, 1195 exposed to 
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FIG. 4.13. PZA and POA concentrations in M bovis, a mycobacterial strain in which 
the Pzase enzyme is naturally absent, exposed to I 00 µg/ml PZA in (A) RPMI 1640 
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FIG. 4.14. PZA and POA concentrations in a resistant strain, 3886 exposed to 
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FIG. 4.15. PZA and POA concentrations in a resistant strain, 3732 exposed to 
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FIG. 4.16. PZA and POA concentrations in a resistant strain, 60650 exposed to 
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FIG. 4.17. PZA and POA concentrations in a resistant strain, 79386 exposed to 
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FIG. 4.18. PZA and POA concentrations in a resistant strain, 6114 exposed to 
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FIG. 4.19 Mean values of intracellular and extracellular concentrations of PZA in macrophages infected individually with IO susceptible M. 111berc11/osis strains. Intracellular 
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FIG. 4.20 Mean values of intracellular and extracellular concentrations of PZA in macrophages infected individually with 5 resistant M. tuberc:11/osis strains. There is also 
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FIG. 4.21 Mean values of PZA and POA concentrations in Pzase positive M. t11berc11/osis cultures incubated in RPM! 1640 supplemented with PZA. PZA converted to POA 
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FIG. 4.22 Mean values of PZA concentrations for 5 Pzase negative M. 111berc11/osis strains incubated in RPMI I 640 supplemented with PZA. No POA was detected as these 
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FIG. 4.23 Mean intracellular PZA concentrations in uninfected macrophages as well as in macrophages infected with susceptible and resistant strains. The macrophages 
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FIG. 4.24 Mean extracellular PZA concentrations in uninfected macrophages as well as in macrophages infected with susceptible and resistant strains. The macrophages 
infected with the resistant strains and susceptible strains showed similar results, while the uninfected macrophages showed lower extracellular PZA concentrations. 
4.4 DISCUSSION 
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Once the HPLC methodology was established for the simultaneous detection of PZA 
and POA ( chapter 3), 10 Pzase positive and 5 Pzase negative clinical isolates were 
investigated. This involved exposing the mycobacteria as non cell associated cultures 
in RPMI 1640 to 100 µg/ml PZA. Also, peripheral blood derived macrophages were 
infected with the mycobacterial strains and exposed to PZA. After incubating over a 
designated period, the various fractions were separated i.e., extracellular, intracellular 
and intrabacterial fractions. Each fraction was quantified for PZA and POA in an 
effort to determine which fraction had the highest concentration of antibiotic. 
Only a small fraction of the I 00 �tg/ml PZA to which the organisms were exposed 
entered into Pzase positive and negative mycobacteria grown in the absence of 
macrophages i.e., non cell associated cultures (FIG. 4.2A-FIG. 4.18A). This would 
reflect the need for a high diffusion gradient or limited capacity of a transmembrane 
transport mechanism. POA was detected in minute quantities (0.67 µg/ml) in the intra 
bacterial fraction of Pzase positive strains. Most of the PZA and POA was found in 
the extrabacterial fraction of the non cell associated cultures. There are two 
explanations as to where the conversion of PZA to POA takes place, firstly PZA could 
be converted to POA by the mycobacterial Pzase in the extrabacterial fraction and 
secondly the conversion could take place in the intrabacterial fraction of the cultures 
after which POA diffuses back into the extracellular fraction. Raynaud et al. (1999) 
studied the localisation and distribution of Pzase in /vf tuberculosis and other 
mycobacteria. These authors used whole cells as well as material extracted by gentle 
mechanical treatment to investigate Pzase localisation. Pzase activity, as tested by the 
Wayne's test, was not detectable in any of the surface exposed materials examined, 
whilst easily found in whole cells of Af tuberculosis. Thus, Raynaud et al. ( I 999) 
found that Pzase is not located on the surface of the mycobacteria examined but may 
be present in inner compartments of both PZA susceptible and resistant strains. Thus, 
for the experiments in this study, the conclusion is that PZA must diffuse into the 
mycobacterial cells to be converted to POA and thus the second explanation must be 
accepted. 
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Uninfected macrophages have the ability to take up PZA. A consistent amount of 
PZA is taken up by the macrophages over the 72h period studied (FIG. 4.1 ). Also, the 
extracellular PZA remains constant over this 72h period. No POA was detected in the 
extracellular or intracellular fraction of the uninfected macrophage. However, 20 
µg/ml cannot be accounted for in the uninfected macrophages and could be 
complexed in internal compartments of the macrophages and thus undetectable. This 
could be as PZA or POA. Therefore, production of amidases that have the ability to 
convert intracellular PZA to POA, cannot be excluded. 
There is also limited entry of PZA into macrophages infected with Pzase positive and 
negative strains (FIG. 4.28-FIG. 4.188). However, there is no POA detected in any of 
the fractions i.e., extracellular, intracellular or intrabacterial in macrophages infected 
with Pzase positive or negative strains (FIG. 4.28-FIG.4. l 28). Thus, if PZA is 
converted to POA by Pzase positive strains, this POA is bound in some compartment 
of the macrophage or internalised mycobacteria, or the amount is too small to be 
detected by HPLC. With the reference strain, H37Rv, a total of approximately 80 
µg/ml PZA is detected in the extracellular and intracellular fractions over the time 
period 4-72h studied. Thus, 20 µg/ml cannot be detected compared to clinical 
susceptible isolates where only a total of 5 µg/ml was undetected at 72h. Because the 
macrophages used were from the same source, this phenomenon seems to be strain 
dependent. H37Rv might have a more effective transport mechanism but it seems 
more likely that it has a increased capacity to bind PZA or POA. The amidase seems 
to play a role because no loss is seen with Pzase negative strains. Raynaud et al.
(1999), showed that the uptake of PZA was by a ATP-dependent transport system. It 
was shown that one of the mechanisms of resistance to PZA resides in the failure of 
strains to take up the drug, which indicated that susceptibility to PZA in mycobacteria 
requires both the presence of functional Pzase and a PZA transport system. Thus, in 
this PhD study one could imply that although the clinical isolates. have Pzase activity, 
the ATP-dependent transport system present in the naturally Pzase positive reference 
strain, H3 7Rv, is much superior than those found in the clinical isolates depending on 
the MI Cs of the isolates. Thus, macrophages infected with H3 7R v are able to take up 
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much more PZA and this PZA stays bound in the intracellular compartments of the 
macrophages and mycobacteria. The clinical isolates may not have a PZA transport 
system that is as efficient as H37Rv. 
Chan et al. ( 1986) used HPLC to determine PZA concentration in cerebrospinal fluid 
(CSF) and plasma in rabbits. The HPLC methodology differences have being 
discussed in chapter 3. PZA was extracted from CSF and plasma using a mixture of 
dichloromethane-diethyl ether (2: 3 ). This extraction protocol was first used on 
samples used, however, the extraction procedure was not suitable for macrophages 
grown in RPM! 1640. No PZA or POA could be detected in RPMI 1640 spiked with 
PZA or POA. Thus, the extraction procedure was not used for any of the samples. At 
0.25 h 20.9 �tg/ml was recovered from plasma of rabbits after oral administration of 
30 mg/kg. Over a 24 h period studied the concentration of PZA progressively 
decreased with 0.4 µg/ml been detected at 24 h. The absorption of PZA was very 
rapid, also the drug was widely distributed in body tissues as it was still detectable at 
24 h (Chan et al, 1986). There was minimal entry of PZA into the macrophages even 
with a higher starting concentration of PZA. Therefore, this rapid distribution seems 
not to include the intra-macrophage compartment. The question if the limited 
intracellular amount is sufficient to provide antimicrobial effect remains to be 
answered. 
In another study, Woo (1987) used HPLC to simultaneously determine PZA and 
rifampicin concentration in serum samples from patients with tuberculous meningitis. 
With a dose of PZA of 25-35 mg/kg body weight, 42.96 µg/ml PZA was detected in 
the serum of patients at 2 h and decreased over time to 27.4 �tg/ml at 8 h. In this PhD 
study with infected macrophages, only a fraction of intracellular PZA could be 
detected even with an initial concentration of 100 µg/ml of· PZA added to the 
macrophage-mycobacterium co-culture system. This does not exclude that this 
fraction is enough to exert antibacterial activity. There was no activity in the 72h 
period studied. 
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Yamamoto er al. (1987b) also used HPLC to determine PZA and its metabolites 
concentrations in human plasma. Initially plasma was spiked with various 
concentrations of PZA, POA, 5 hydroxypyrazinamide and 5 hydroxypyrazinoic acid, 
extracted and run on HPLC to determine percentage recovery. Good recovery was 
obtained after which a healthy volunteer was given 3 g of PZA and the volunteer's 
plasma tested for PZA and its metabolites. The highest concentration obtained was 
for PZA (67.60 µg/ml) followed by pyrazinoic acid (4.37 µg/ml) and 5-
hydroxypyrazinamide (2.30 µg/ml). The PZA concentration of 67.60 µg/ml obtained 
is comparable to the extrabacterial PZA concentration of 61.48 µg/ml obtained at 
336h for non cell associated mycobacteria. The pyrazinoic acid concentration of 4.3 7 
µg/ml is comparable to the extrabacterial POA concentration obtained at 48h. 
Although 0.02 M KH2PO.i (pH 2.56) has been reported to resolve POA by HPLC 
(Yamamoto et al., 1987a), the chromatograph obtained using this mobile phase was 
unsatisfactory. Thus, this mobile phase was not used. Although the reported 
extraction procedures (Chan et al, 1986, Woo, 1987, Yamamoto et al, 1987) gave 
good recovery of antibiotics in plasma, they were not suitable to efficiently recover 
PZA or POA from the in vitro system set up in my experiments. However, the 
silicone oil density gradient centrifugation technique used was very efficient to 
separate extracellular and intracellular antibiotic. 
Walubo er al. (1994) also used HPLC to detect PZA, rifampicin and isoniazid in 
human plasma by HPLC. They also found good recovery of the antibiotics from the 
plasma. They did not evaluate the method for in vitro assays. 
There is no reports on the in vitro assessment of PZA concentrations in non cell 
associated mycobacteria or on macrophages infected with mycobacteria. Thus, this 
study is unique in that intracellular, extracellular and intrabacterial PZA has been 
quantified in in vitro assays in an attempt to understand the mode of action of PZA. 
Most of the in vitro studies involving PZA have only assessed the effect on 
intracellular growth using colony forming units as discussed in chapter 2. All the in 
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vivo studies using HPLC to quantify PZA showed that the concentration of PZA in
vivo is below l 00 µg/ml. If the in vivo situation mimic ks the in virro situation where 
minute quantities of PZA was detected in infected macrophages exposed to 100 µg/ml 
PZA, this could suggest that the activity is mainly extracellular. 
Composite graphs of the l O PZA susceptible clinical isolates (FIG. 4.19) shows that 
there is an influx of PZA into the macrophages (mean values) from 4-16 h after which 
an efflux into the extracellular environment is observed. This observation is further 
enhanced by statistical analysis using the general linear models procedures where over 
the time period studied (72 h) the macrophages infected with susceptible strains show 
significant differences to uninfected macrophages at every time point (p=0.000 I). 
The macrophages infected with susceptible strains are significantly different from 
those with resistant strains at each time point until 16h (p=0.0005), then the PZA 
concentration for the resistant strains decreases and the differences between 
macrophages infected with susceptible and resistant strains become insignificant at 
48h (p=0.12). The mean intracellular PZA concentration remains almost constant 
throughout the time period studied. The PZA detected in macrophages infected with 
resistant strains compared to the uninfected macrophages was statistically not 
significant (p=0.79), while a significant difference was found when comparing the 
PZA concentration detected in macrophages infected with resistant strains compared 
to macrophages infected with susceptible strains (p=0.001) (FIG. 4.23). Also, a 
significant difference was found when macrophages infected with susceptible strains 
were compared to uninfected macrophages (p=0.001). This suggests that the 
macrophage has the ability to absorb only a certain percentage of antibiotic, thus once 
the macrophage is saturated the excess antibiotic is found in the extracellular 
environment. 
The significant difference between intracellular PZA in macrophages infected with 
resistant and susceptible strains (p=0.00 I) implies that susceptible strains do enhance 
the uptake of PZA intracellularly, however, extracellular PZA concentrations in this 
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systems with both resistant and susceptible strains do not differ significantly (p=0.07). 
This suggests that the macrophage infected with susceptible bacteria has a better PZA 
transport system as shown by Raynaud et al. (1999) and has the ability to enhance 
uptake of PZA. Over the 72 h period studied the constant ratio of intracellular PZA 
concentration/extracellular PZA concentration is 0.03 suggests that uptake is by 
diffusion gradient across the macrophage membrane. The lower intracellular PZA 
concentration found in macrophages infected with susceptible strains compared to 
resistant strains and their statistically significant difference (p=0.001) suggest that a 
fraction of intracellular PZA is converted to POA. However, this POA is bound in 
cellular compartments of the bacteria or macrophage and cannot be detected. The 
significant difference between intracellular PZA in susceptible and uninfected 
macrophages (p=0.001) further suggest that intracellular PZA is being converted to 
POA which is bound in some cellular component. The intracellular PZA in 
uninfected macrophages does not differ significantly from that in macrophages 
infected with resistant strains (p=0. 79), thus it can be suggested that infection of 
macrophages in itself does not enhance uptake of PZA but that a PZA transport 
system must be present. 
Composite graphs of 5 PZA resistant strains (FIG. 4.20) show an influx of PZA 
(mean values) into the macrophages. However, a distinct pattern is not observed. 
Statistical analysis showed that the intracellular PZA concentration detected in 
macrophages infected with resistant strains does not differ significantly at each time 
period compared to uninfected macrophages (p=0.79). There is no time effect on the 
amount of PZA detected in the intracellular compartment of the uninfected 
macrophage or the macrophages infected with susceptible or resistant strains. The 
concentration of intracellular PZA remains fairly constant over the 72 h period 
studied. Since these are Pzase negative strains, the absence of POA could be 
expected. The total recovery of intracellular and extrac�llular PZA equals 
approximately 100 µg/ml at 72 h. Although there is an influx of PZA into the 
macrophage, there seems to be unrestrained binding of the antibiotic to cellular 
components ( 16 h), where the extracellular PZA concentration is lower. Thereafter, 
176 
(24-72 h) there is an efflux into the extracellular environment, with the extracellular 
PZA concentration increasing. This implies that two pump mechanisms operate. The 
first pump mechanism operates between the internalised mycobacteria and the 
cytoplasm of the macrophages. Once the PZA reaches saturation concentration within 
the internalised mycobacteria, the excess PZA is pumped across the mycobacterial 
membrane into the macrophage cytoplasm. The second pump mechanism exists 
between the macrophage cytoplasm and the extracellular environment. The PZA 
pumped out of the internalised mycobacteria into the cytoplasm is finally pumped out 
into the extracellular environment. The composite graph (FIG.4.19) showing the 
increase in the extracellular PZA concentration at 72 h supports the theory that pump 
mechanisms operates pumping excess PZA into the extracellular environment. The 
amount of PZA that can be retained within the macrophage cytoplasm is limiting. 
The concentration of PZA in macrophages was lower for those infected with Pzase 
positive strains as compared to Pzase negative strains. Although POA was not 
detected, this finding suggest that this difference was the result of partial conversion 
by the enzyme producing organisms. The fact that POA was not detected could be 
because the concentration was below the detection limit of the HPLC methodology, 
(0.5 µg/ml), or because this forms complexes with other molecules in the bacteria or 
the macrophage. With the reference strain, H37Rv, the amount of undetectable drug 
(PZA or POA) was higher as compared to the susceptible clinical isolates. This might 
reflect the very high Pzase activity of this strain as well as the efficient PZA transport 
system. The fact the the conversion into POA did not result in a compensating influx 
of PZA into the macrophage, indicates that the POA still influences the concentration 
gradient. This goes against the hypothesis of complex formation. Another possibility 
is the accumulation in a biological structure. 
Comparing the extracellular PZA concentrations statistically (FIG. 4.24) it was found 
that the uninfected macrophages behave significantly different from the macrophages 
infected with susceptible strains (p=0.008) and resistant strains (p<0.000 I), however, 
there was no statistically significant difference between the extracellular PZA found in 
the experiments with macrophages infected with susceptible and resistant strains 
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(p=0.07). Over each time interval studied the difference between macrophages 
infected with susceptible strains and uninfected macrophages increase over time 
(p=0.0008). There is also significant difference between macrophages infected with 
resistant strains and uninfected macrophages at each time point (p=0.000 l ). There is 
no significant difference between extracellular PZA in susceptible and resistant strains 
over each time interval (p=0.08). It can be inferred that susceptible strains have a 
better PZA transport system, which allows for more PZA to be taken up by the 
infected macrophages. However, the efflux system into the extracellular environment 
is independent of the influx transport system. The efflux system pumps outs excess 
PZA once the macrophage is saturated irrespective of the Pzase status of the 
intracellular mycobacteria. 
There is significant difference between the extracellular PZA in macrophages infected 
with resistant strains and uninfected macrophages (p<0.000 I) and macrophages 
infected with susceptible strains and uninfected macrophages (p=0.008). The 
extracellular PZA concentration of uninfected macrophages is lowest followed by 
macrophages infected with susceptible and resistant strains. The inability to detect 
PZA or POA in intracellular mycobacteria may be explained by the following 
mathematically calculations. Consider the mycobacteria to be a cylinder and use the 
equation 1t r2 x height to calculate its volume. Mycobacteria have a diameter of 0.2-
0.6 µm and a length of 1.0-10 µm, mid range values were used to calculate the volume 
of mycobacteria. Thus the volume occupied by one mycobacterium is 1t (0.2)2 x 5 = 
0.628 µm3. This volume is Y. Considering the macrophage to be a sphere the formula 
4/3 1t r3 was used to calculate the total volume of macrophages with the diameter of
macrophages being between 25-50 µm. Thus volume occupied by one macrophage 
equals 4/3 1t (17.5)3 == 22449 µm3. This volume is Z. Total volume of intracellular
mycobacteria is equal to the average intracellular colony forming units x volume of 
one mycobacterium = Y x 5 x 106 CFU/ml = 3.14 x 106 µm3. · Therefore the total
volume of 105 macrophages planted equals Z x 105 = 2.24 x 109 µm3. Thus the ratio
• 
6 of volume of macrophage/volume of mycobacteria R= Z x 10'/Y x 5 x 10 = 2.24 x 
109/3.14 x 106 = 713. Thus, the intrabacterial PZAIPOA is 713x dilute in the
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macrophage volume and thus is too dilute to detect within the detection limits set by 
HPLC. If one assumes that the extrabacterial POA detected at 72h for non cell 
associated mycobacteria is the same for macrophage bound mycobacteria at the same 
time then the final concentration of POA in the macrophage lysate would be 
l 0.81/713= 0.0 l �tg/ml which is below the detection limit set by HPLC.
Conclusions 
* The new HPLC methodology developed was successfully used to quantify PZA and
POA in non cell associated tuberculosis cultures as well as in macrophage bound 
cultures. 
* A small fraction of PZA entered Pzase positive and negative mycobacteria grown in
RPM! 1640, with most of the drug remaining in the extrabacterial fraction. 
* Since Raynaud et al. ( 1999) showed that Pzase is located on the inner compartments
of both PZA susceptible and resistant strains, it was concluded in this study that PZA 
must diffuse into the mycobacterial cells to be converted to POA, then diffuses into 
the extrabacterial environment. Thus, PZA and POA concentrations are higher in the 
extrabacterial fraction. 
* Macrophages infected with Pzase positive and negative strains showed limited entry
of PZA, with no POA being detected in any fraction. 
* The reference strain, H37Rv, seems to have a more effective transport mechanism as
20 µg/ml PZA remained undetected at 72h compared to 5 µg/ml PZA undetected at 
the same time in clinical isolates. 
* It was also shown by a mathematically model that the intrabacterial PZA/POA was
diluted and thus could not be detected by HPLC. 
* The significant difference between intracellular PZA in macrophages infected with
resistant and susceptible strains (p=0.00 I) implies that susceptible strains do enhance 
the uptake of PZA intracellularly. 
* There was no significant difference between the extracellular PZA found in the
macrophages infected with susceptible and resistant strains (p=0.07). This suggests 
that the efflux system pumps out excess PZA once the macrophage is saturated 
irrespective of the Pzase status of the intracellular mycobacteria. 
CHAPTERS 
RAISING POLYCLONAL ANTIBODIES TO PZA IN RABBITS 
5.1 INTRODUCTION 
179 
The objective of this chapter is to give a detailed account of the production of 
antibodies to PZA which were used for immunogold labelling studies ( chapter 5) to 
locate the site of action of PZA. Since there are no commercially available PZA 
antibodies that could have been used, we produced polyclonal antibodies to PZA in 
rabbits. 
Antibodies can be generated by inoculation of an animal with any foreign protein. 
Molecules other than proteins are less immunogenic. The sera of immunised animals 
contain a mixture of antibodies produced by different lymphocytes, that react against 
multiple sites on the immunising antigen. Antibodies can be used in a variety of ways 
to detect proteins in cell extracts and can also be used to visualise proteins within 
cells, as well as in lysates (Cooper, 1997). 
In the synthesis of drug-protein conjugate the choice of carrier molecule is important. 
Almost any immunogenic protein may be used as a carrier for an haptenically coupled 
drug. The functional groups in the carrier molecules to which the drugs may be 
conjugated are most frequently the amino, carboxyl or phenolic groups. The method 
of conjugation is also important. In the method selected for the conjugation of a drug 
to a carrier, the chemical conditions must entail minimal structural alterations of the 
hapten and must not cause sufficient denaturation of the carrier rpolecule to render it 
insoluble (Butler, Jr, 1978). 
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Large chemically complex molecules are good immunogens. The general rule for the 
production of antisera to a antigen is that the antigen has to be in pure form or 
antibodies will be produced to the contaminants as well, which may interfere in 
antibody assays. There are many examples of antisera being produced against single 
antigens linked to other molecules. Molecules of a molecular weight less than 1000 
daltons (D) such as many drugs or hormones need to be linked to immunogenic 
carriers and immunisation may lead to production of high affinity antibodies to the 
drug ( English, 1994 ). 
There are many immunogenic carriers, including keyhole limpet haemocyanin (KLH), 
bovine serum albumin (BSA), egg albumin ( ovalbumin) and fowl gamaglobulin 
(English, 1994). KLH is a carrier molecule that has good epitopes to activate T-helper 
cells which produce cytokines to activate antigen specific B-cells. This results m 
clonal proliferation and class switching resulting in good quality antibodies. 
The methodology for polyclonal antibody production is relatively straight-forward. 
The animals are given a priming injection followed usually by a number of booster 
injections. Serum is collected throughout this process (test bleeds) to check the 
quantity of the antibodies produced and a final collection of a large volume of 
antiserum is made when the antibody level is satisfactory (English, 1994). 
The preferred animals for production of polyclonal antibodies are large such as rabbits 
and sheep because of the quantity of serum that can be obtained. Mice and rats are 
good species for the production of antisera, however, the volumes of antisera collected 
from such animals are small. The animal of choice for most polyclonal antibody 
production is the rabbit. Most rabbits will provide a minimum of 100 ml of 
antiserum. However, because they are outbred animals, individual rabbits respond 
differently and it is always wise to include about 3 rabbits m the immunisation 
protocol (English, 1994). 
In general, particulate antigens are good immunogens and can often be injected alone 
into the animals. For soluble materials and small molecules such as drugs, a much 
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improved response can be obtained by the use of adjuvants. These are non-specific 
stimulators of the immune response and have a two-fold effect. Firstly, they form a 
local deposit of the conjugated antigen which is slowly released to the immune system 
and secondly, they stimulate the action of antigen presenting cells and cause an 
inflammatory reaction at the site of injection. The most commonly used adjuvant, 
Freund's adjuvant, is an example of the former being a water-in-oil emulsion 
containing the immunogen. Freud's adjuvant is available in two forms: complete 
Freud's adjuvant (CF A) and incomplete Freud's adjuvant (IF A). CFA does include 
heat killed bacteria such as Bordetella pertussis or M tuberculosis, which stimulate 
the production of different cytokines which promote the inflammatory reaction and 
the stimulation of antigen presenting cells. The antigen is incorporated in the aqueous 
phase of a stabilised water in paraffin oil emulsion for IF A (English, 1994). 
The dose and route that the immunogen is administered to the animal vanes 
considerably depending on the immunogenicity of the antigen. Usually between 50-
1000 ug/ml of immunogen is administered to rabbits. In rabbits and larger animals 
large volumes of immunogen are best given subcutaneously. Animals are bled at 6 
weeks and final bleeds from rabbits are done from the heart under terminal 
anaesthesia, a process known as exsanguination. The collected blood is allowed to 
stand at room temperature to clot. The clot is detached from the sides of the vessel 
and kept in the refrigerator overnight. During this period the clot retracts exuding the 
serum, which is separated from the clot by centrifugation. The serum can then be 
tested for antibodies produced (English, 1994). 
5.2 MATERIAL AND METHODS 
5.2.1 CONJUGATION OF PZA TO N-SUCCINIMIDYL 4-
(N-MALEIMIDOMETHYL) CYCLOHEXANE-1-CARBOXYLA TE 
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2 mg of PZA was dissolved in 300 µl of 0.1 M sodium phosphate buffer, pH 7.0. 5 
mg of N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) 
was dissolved in 90 µl of N-N-dimethyl formamide (DMF). The SMCC solution was 
warmed at 30°C for 1-2 mins before adding to the PZA solution as this prevents 
precipitation of the reagent. The reagent solution was added to the PZA solution and 
the mixture incubated at 30°C for 30 mins with continuous stirring. The reaction 
mixture was centrifuged to remove excess precipitated reagent and the clear 
supernatant applied to a Sephadex G-25 column that was pre-equilibrated with 0.1 M 
sodium phosphate buffer, pH 6.0. 1 ml aliquots were collected and absorbance read at 
280 nm. The aliquot that showed a high absorbance reading was the conjugate which 
was transferred to a collodion bag and concentrated in the cold. 
5.2.2 CONJUGATION OF KEYHOLE LIMPET HAEMOCY ANIN OR BOVINE 
SERUM ALBUMIN TO S-ACETYL MERCAPTOSUCCINIC ANHYDRJDE 
2 mg bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH) was added 
to 900 µl of 0.1 M sodium phosphate buffer, pH 6.5. The BSA and KLH solutions 
were mixed with 25 X excess S-acetyl mercaptosuccinic anhydride (SAMSA) 
dissolved in 10 µI of DMF. The BSA-SAMSA and KLH-SAMSA solutions were 
incubated at 25°C for 30 mins. The following was then added to each of the solutions: 
200 µl of Tris-HCI buffer, pH 7.0, 20 µI of 0.1 M EDTA, pH 7.Q and 200 µI of 1 M 
hydroxylamine, pH 7.0 and incubated at 30°C for 30 mins. Each of the mixtures were 
applied to a Sephadex G25 column that was pre-equilibrated with 0.1 M sodium 
phosphate buffer, pH 6.0. 1 ml aliquots were collected and absorbance measured at 
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280 run. The aliquot that shov,ed a high absorbance reading was the conjugate. This 
fraction was the transferred to a collodion bag and concentrated in the cold. 
5.2.3 CONJUGATION OF PZA-SMCC TO KLH-SAMSA OR BSA-SAMSA 
The PZA-SMCC mixture was added to the KLH-SAMSA or the BSA-SAMSA 
mixture in a 1: I ratio. The PZA-SMCC-SAMSA-KLH conjugate was inoculated into 
3 rabbits for production of PZA antibodies. The PZA-SMCC-SAMSA-BSA 
conjugate was used to coat enzyme linked immunosorbent assay (ELISA) plates to 
determine the specificity of the PZA antibodies formed. A schematic representation 
of the conjugation procedure is illustrated in FIG. 5.1. 
5.2.4 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) TO 
DETERMINE SPECIFICITY OF PZA ANTIBODIES RAISED 
After 6 weeks the rabbits were bled. The ELISA assay was carried out on the pre­
bleed and test bleed serum to determine if antibodies to PZA were produced in the 
rabbits. The ELISA plates were coated with various dilutions of the PZA-SMCC­
SAMSA-BSA conjugate in coating buffer (0.5 M Tris-Cl, 0.1 M NaCl, pH 9.6) and 
incubated at room temperature overnight. ELISA plates were washed with 500 ml 
Tris-saline buffer supplemented with tween 20 (TST). The plates were centrifuged in 
an inverted position to remove all wash buffer. 50 µl of the pre-bleed and test bleed 
serum was added to each well and the plate incubate at 42°C for l h. The serum was 
diluted in 5 % lactogen milk powder in Tris-saline buffer. After I h the plate was 
washed with 500 ml TST and dried as described above. 20 µl sheep anti-rabbit IgG 
diluted in lactogen ( 1/100) were added to the wells and incubated for 0.5 h at 42°C. 
50 µl of alkaline phosphatase was added to each well and the plate incubated in a dark 
drawer for 0.5 h after which the reaction was stopped with I 00 µl of sulphuric acid. 
ELISA reactions were read with an ELISA reader with the measuring filter at 492 run 
and the reference filter at 620 nm. 
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PUR1FICA TION OF ANTISERA 
Solid Na2S04 was added slowly to the antiserum at a final concentration of 14 % and 
mixed on a magnetic stirrer for 15 mins. The solution was centrifuged and 
transferred to dialysis tubing and dialysed at 4°C against distilled water. The dialysate 
was passed through a protein A column. Fractions were collected and absorbance 
measurements were read at 280 nm. The antibodies were in the fractions that gave 
high absorbance readings at 280 nm. These tubes were pooled and dialysed in the 
cold against Tris-saline buffer, pH 8.0. ELISA was repeated to confirm that PZA 
antibodies were present in the pooled fractions. Once this was confirmed the 
antibodies were stored at -20°C for use in immunogold labelling experiments. The 
highest yield of PZA antibodies was obtained from rabbit 2814, this purified serum 
was used in all immunogold labelling experiments. 
5.3 RESULTS 
PZA was conjugated to a carrier molecule KLH and used as inoculum to inoculate 
rabbits. FIG. 5.1. illustrates the conjugation procedure schematically. ELISA was 
performed on pre-bleed and test bleed samples to determine if PZA antibodies were 
being produced (TABLE 5.1.). Sera was purified before use using a protein A column 
(TABLE 5.2.). A second ELISA was performed to confirm that PZA activity was 
maintained (TABLE 5.3.). The purified antibodies were used in all immunogold 
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f"IG. 5.1 Schematic representation of the conjugation of PZA lo KU I or BSA 
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TABLE 5.1. Pre-bleed and test-bleed serum from 3 rabbits tested for PZA antibodies by ELISA. 
Prebleed Test bleed 
coating buffer neat neat neat neat Rabbit 
dilutions serum serum 1/20 1/20 1/100 1/100 serum serum 1/20 1/20 1/100 1/100 number 
1/20 0.241 0.289 0.052 0.053 0.074 0.094 2.737 2.443 2.489 2.498 2.066 2.153 2814 
1/100 0.333 0.295 0.061 0.098 0.089 0.111 2.083 2.350 2.041 1.773 1.104 0.954 2814 
1/20 0.275 0.229 0.072 0.099 0.103 0.104 2.181 2.214 1.313 1.395 0.498 0.531 2815 
1/100 0.273 0.242 0.117 0.078 0.091 0.081 1.669 1.724 0.508 0.526 0.201 0.220 2815 
1/20 0.209 0.288 0.071 0.085 0.066 0.132 2.318 2.423 1.995 2.153 1.195 1.226 2816 
1/100 0.289 0.143 0.076 0.093 0.055 0.077 1.881 1.878 1.086 1.148 0.606 0.467 2816 
TABLE 5.2. Purification of PZA antibodies by passage through a Prosep protein A 
column. 
Kev: Underlined: unbound antibodies 
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Bold: Bound PZA antibodies 
Test tube Number Absorbance 
21 0.018 
22 -







30 1.445 (lgG-PZA) 
31 2.950 (lgG-PZA) 
32 2.661 (lgG-PZA) 










TABLE 5.3. ELISA absorbance readings indicating the fractions that contain the IgG-PZA antibodies. 
COATING 
BUFFER UNBOUND PZA ANTIBODIES IgG-PZA ANTIBODIES 
DILUTIONS 
neat serum 1/20 1/40 1/100 neat serum 1/20 1/40 1/100 
1/100 0.380 0.008 0.015 0.006 2.750 1.037 0.755 0.629 
1/100 0.359 0.009 0.009 0.009 2.835 1.158 0.712 0.585 
1/100 0.329 0.008 0.008 0.011 2.784 1.136 0.942 0.649 
5.4 DISCUSSION 
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After HPLC analysis of intracellular, extracellular and intra-bacterial concentrations 
of PZA and POA was assessed an attempt was made to further quantify PZA activity 
by immunocytochemistry. Since there are no commercially available gold labelled 
PZA antibodies, theses antibodies had to be raised. 
The structure of PZA and POA are very similar, thus we could not raise antibodies 
that would distinguish between them. PZA was conjugated to KLH and used as 
inoculum to inject rabbits that were used to raise PZA antibodies. Because PZA is a 
very small molecule, it would not serve as a good immunogen on its own. Therefore, 
a carrier molecule was used. PZA conjugated to BSA was used to coat the ELISA 
plates. Thus, if antibodies were produced against KLH instead of PZA, the ELISA 
would be negative as the ELISA plates have BSA instead of KLH attached to PZA. A 
positive ELISA would indicate that antibodies produced are indeed against PZA only. 
ELISA was carried out on pre-bleed and test bleed samples of 3 inoculated rabbits 
Coating buffer as well as serum was diluted to obtain good absorbance readings and 
served as a technically necessity. The ELISA readings for the pre-bleed samples were 
low over the entire dilution range, thus indicating that there was no interfering 
substances present in the serum prior to inoculating the PZA-KLH conjugate. ELISA 
readings obtained for the test bleeds indicated that PZA antibodies were produced in 
the rabbits. Sera obtained from rabbit 28 I 4 gave the highest absorbance readings and 
was used for all further experiments (TABLE 5. I). 
The antibodies were a crude extract, thus they had to be purified. Purification 
involved passing the antibody solution through a Prosep protein A column (TABLE 
5.2) and collection of I ml aliquots. The absorbance was read on every alternate 
aliquot until a high absorbance reading was obtained, then every aliquot was read. 
There were 2 sets of aliquots that showed high absorbance readings. These aliquots 
were pooled and ELISA repeated to determine which pooled aliquot had the PZA 
antibodies. 
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The second ELISA was carried out on the 2 sets of pooled aliquots (TABLE 5.3). the 
pooled aliquot that was eluted first contained the non-specific antibodies. The aliquot 
(test tubes 30-33) eluted second contained the purified PZA antibodies. 
The purified PZA antibodies were stored in small aliquots at -20°C. This was used for 
immunogold labelling experiments as discussed in detail in chapter 6. 
CHAPTER6 
AN IMMUNOCYTOCHEMISTRY PERSPECTIVE ON THE MODE OF 
ACTION OF PZA 
6.1 INTRODUCTION 
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The objective of this chapter is to show by means of immunogold labelled PZA 
antibodies and transmission electron microscopy (TEM) the exact location of PZA 
activity in infected macrophages. Since PZA antibodies are commercially 
unavailable, these antibodies were raised in rabbits as described in detail in chapter 5. 
The structure of PZA and POA are very identical, thus the antibodies raised do not 
give distinction between PZA and POA. 
TEM differs markedly and in many respects from the optical microscopic techniques. 
TEM provides very high levels of magnification because of the much higher 
resolution obtainable with the extremely short wavelength of the electron beam used 
to magnify the specimen. With TEM employing 60-80 kV electrons the wavelength is 
only 0.05 angstrom. The resolving power of the TEM is more than I 00 times that of 
the light microscope. For TEM, specimens to be examined must be prepared in 
extremely thin dry film on grids. The grids are introduced into the instrument at a 
point between the magnetic condenser and the magnetic objective. To make 
observations of intracellular structures, the specimen must be extremely thin. An 
intact microbial cell is too thick to allow distinct visualisation of its internal fine 
structure. Techniques are available for bacterial cells to be embedded in resin and 
ultrathin sections to be cut. The sections reveal cells at different levels and at 
different angles (Pelczar et al, 1986). 
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In 1971, Faulk and Taylor introduced their "immunocolloid" method for the study of 
cell surface antigens. Specific antibodies adsorbed to colloidal gold particles were 
used to visualise Salmonella antigens by TEM. Since then a large number of studies 
have documented the potential of colloidal gold as a marker for immunocyto­
chemistry. Colloidal gold particles are particularly interesting as markers for 
immunocytochemistry because they can be used both at high and low resolution 
levels. Due to their electron dense properties, they are easily detected by TEM. The 
specificity and sensitivity of an immunocytochemical technique is limited by the 
specific activity of the antibodies used in the different steps of the procedures (W.aele 
et al, 1983). 
6.2 MA TE RIALS AND METHODS 
6.2.1 LOCATION OF PZA/POA IN NON CELL AS SOCIA TED 
MYCOBACTERIA 
A McFarland No l standard of the reference strain, H37Rv, as well as all PZA 
susceptible and resistant clinical mycobacterial isolates was exposed to l 00 µg/ml 
PZA in RPM! 1640 tissue culture medium. After exposure for 24 h, the 
mycobacterial isolates were fixed with 2.5 % glutaraldehyde (made in RPM! 1640 
medium) at 4°C overnight. The bacteria were then processed for transmission 
electron microscopy. 
6.2.2 LOCATION OF PZA/POA IN MACROPHAGES INFECTED WITH 
MY CO BACTERIA 
Macrophages were exposed to the mycobacteria in the ratio l: l q for l h, after which 
all unbound mycobacteria were washed off. Fresh RPM! 1640 supplemented with 
100 µg/ml PZA was added to the petri dishes. After exposure to PZA for 24 h, the 
infected macrophages were fixed with 2.5 % glutaraldehyde (made in RPM! 1640 
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medium) at 4°C overnight. The infected cells were gently scraped off 3 petri dishes 
using Sterilin quadloops, pooled and processed for TEM. 
6.2.3 PREPARATION OF SAMPLES FOR TEM 
The macrophage infected cells as well as the free mycobacterial isolates were 
centrifuged, resuspended in 1 ml of glutaraldehyde and transferred to an eppendorf 
tube. The cells were washed twice with cacodylate buffer, pH 7.2. The pellets were 
dehydrated for 10 mins each through alcohol in an ascending concentration ( 70 %, 90  
%, 3X100 %). The cells were not subject to osmium tetroxide treatment as this would 
mask the results of immunogold labelling experiments. A final dehydration was 
carried out with propylene oxide for 20 mins. At each of the dehydration step the 
pellets were resuspended in the alcohol. After dehydration cells were infiltrated 
stepwise with Spurr resin in propylene oxide. This was achieved by suspending the 
cells first in 25 % resin for I h, 50% resin overnight, 75 % resin for 6 h and finally 
I 00 % for 1 h. All steps took place at room temperature apart from the last one during 
which the cells were incubated at 60 °c. At each infiltration step the pellet was 
carefully resuspended to ensure maximum penetration of the resin into the cells. The 
pellets were then embedded in I 00 % resin, centrifuged to allow all the cells to fom1 a 
pellet and cured at 60°C for 24 h. 
6.2.4 IMMUNOGOLD LABELLING OF SECTIONS 
Sections of 50-60 nm in thickness were cut using a Sorvall Ultramicrotome MT 5000 
with glass knives. Nickel grids with sections were placed onto 40 µl droplets of 5 % 
H202 for 3 mins. The grids were washed with distilled water, dried and placed on 40 
µl droplets of commercially available blocking agent for 30 .mins in a humidity 
chamber. The blocking agent was drained, the grids placed onto PZA antibody (raised 
in rabbits-chapter 4) solution at a dilution of 1/75 and incubated at room temperature 
in a humidity chamber for 3 h. Thereafter, the grids were washed thoroughly with 3 
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% bovine serum albumin (BSA) in phosphate buffered saline (PBS), dried and placed 
onto 40 µl droplets of 1/75 dilution of 10 run gold labelled anti rabbit IgG, which was 
incubated for 1 h at room temperature in a humidity chamber (Beatty et al., 1994). 
The grids were washed with 3 % BSA in PBS, followed by washes in PBS, then 
distilled water. This was following by uranyl acetate staining (Appendix II). For this, 
the grids were placed onto 40 µl droplets of 2 % uranyl acetate for 4 mins, after 
washing with distilled water, they were dried on filter paper and counterstained using 
Reynolds lead citrate (Appendix II) for 4 mins. The grids were again washed with 
distilled water dried, on filter paper and stored in eppendorf tubes until viewed using a 
Jeol 1010 TEM. 
6.3 RESULTS 
Uninfected macrophages as they appear prior to infection are showed in FIG. 6.1 (A­
D). Micrographs of the infected macrophages are shown in FIG. 6.2, A shows 
infection at low power, B a single internalised mycobacterium at high power and C a 
phagosome at high power. Controls treated with PBS instead of the PZA antibodies 
are indicated in FIG 6.3 (A-C). This shows that no non-specific binding occurred as 
no gold label is observed in any of the 3 regions of randomly selected areas of the 
macrophage. FIG 6.4-6.20 show the TEM micrographs of all the M tuberculosis 
strains used. The arrows indicate gold label. FIG 6.4-6.14 (A-O) are micrographs 
showing PZA gold label distribution in macrophages infected with susceptible M 
tuberculosis strains, while FIG. 6.4-6.14 (E, F) show the distribution of PZA gold 
label in non-cell associated free susceptible mycobacteria. PZA gold label distribution 
in macrophages infected with resistant strains are showed in FIG. 6.15-6.20 (A-O), 
while FIG. 6.15-6.20 (E, F) show gold label distribution in non cell associated free 
resistant mycobacteria. 
Analysis of gold label in the different compartments of the infected macrophages as 
well as in free mycobacteria were carried out using the Zeiss Kontron 300 Image 
Analyser. The calculation methodology is indicated in Appendix 4. The mean values 
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of gold label as calculated for susceptible and resistant strains are represented 
graphically FIG. 6.21-6.25. FIG. 6.21 gives a graphical representation of PZA gold 
label distribution in free susceptible and resistant M tuberculosis strains. The most 
gold label is located in free susceptible bacteria followed by free resistant bacteria. 
FIG. 6.22, 6.23 and 6.24 shows the distribution of PZA gold label in the cytoplasm, 
membrane bound mycobacteria and nuclei, respectively, of macrophages infected with 
susceptible and resistant M. tuberculosis strains. Distribution of gold label is higher 
in the cytoplasm (FIG. 6.22) and membrane bound mycobacteria (FIG. 6.23) for 
macrophages infected with susceptible strains of M tuberculosis compared to 
resistant strains. However, more gold label is located in the nucleus of macrophages 
infected with resistant strains compared to macrophages infected with susceptible 
strains (FIG. 6.24). No gold label was located in lysosomes (bacteria free vesicles) in 
macrophages infected with susceptible or resistant strains. FIG. 6.25 is a composite 
representation of the PZA gold label in the different components of the infected 
macrophages. 
The immunogold labelling results were analysed statistically to assess whether the 
differences found were significant. A non-parametric test was used because the 
number of particles/ area was not evenly distributed. The test used was the Wilcoxon 
rank sum test. Non cell associated free susceptible mycobacteria showed the most 
accumulation of gold, followed by free resistant strains (FIG. 6.21 ). Comparisons 
were made between resistant and susceptible strains for each compartment of the 
macrophage. There is a slight graphical difference between the gold label found in 
macrophage bound susceptible and resistant strains (FIG. 6.23), however, statistical 
analysis showed that there was no significant difference (p=0.23). Infection of the 
macrophage with Pzase positive mycobacteria does not seem to drastically increase 
the accumulation of PZA by internalised mycobacteria. 
The amount of label detected in the cytoplasm of macrophages infected with 
susceptible strains is higher than when infected with resistant strains (FIG. 6.22). This 
difference is statistically significant (p=0.001). The amount of label in the nucleus of 
macrophages infected with susceptible strains is lower than the nucleus of 
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macrophages infected with resistant strains by graphically representation, (FIG. 6.24), 
however, statistically this difference is not significant (p=0.07). 
To compare significant differences among the different compartments of macrophages 
infected with susceptible and resistant strains as well as with free mycobacteria, the 
K.ruskal-Wallis test (a non-parametric test) with adjustment for multiple comparisons 
were used. The overall comparison showed statistically significant differences among 
the compartments for both susceptible and resistant strains. Pairwise comparisons 
were made to identify more specifically where the differences could be found. A 
significant value of p<0.007 was used to adjust for multiple comparisons. The 
composite graph (FIG 6. 25) gives a clear indication of the distribution of PZA in all 
the different components of the macrophages. It is clear that the most label is present 
in the mycobacteria with the free mycobacteria (FIG. 6.21) having more label than the 
macrophage bound mycobacteria (FIG. 6.23), followed by the cytoplasm and nucleus. 
The gold label located over the free susceptible mycobacteria was significantly 
different from the cytoplasm, nucleus and membrane bound mycobacteria of 
macrophages (p<0.0001 ). Within the compartments of the macrophages infected with 
susceptible mycobacteria, the gold label located over the membrane bound 
mycobacteria is significantly different from the gold label located in the cytoplasm 
and nucleus (p<0.0001 ). However, the gold label located in the nucleus and 
cytoplasm of these macrophages is not significantly different. The gold label located 
over free resistant mycobacteria is significantly different from the gold label located in 
the cytoplasm, nucleus and membrane bound mycobacteria in macrophages 
(p<0.000 I). The gold label located over membrane bound mycobacteria in 
macrophages infected with resistant mycobacteria is significantly different from the 
cytoplasm (p<0.0009) but it is not significantly different from the nucleus. 
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FIG. 6.1 Micrographs of uninfected macrophages prior to infection with the different 
M. tuberculosis strains, (A) 2.3K, (B) 7K, (C) 6.5K, (D) 11 K.
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FIG. 6.2 (A) Infection of macrophage with At/ tuberculosis as observed at low power 




FIG. 6.3. Random areas of macrophages to indicate method controls incubated with 
PBS instead of PZA antibodies. No non-specific label is observed (A) 51 K, (B) 46K, 
(C) 55K.
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FIG. 6.4. Distribution of PZA gold label in (A-O) macrophages infected with 
susceptible strain H37Rv: (A) nucleus [44K], (B) cytoplasm with membrane bound 
mycobacteria [48K], (C) internalised mycobacterium [SOK], (D) membrane bound 





FIG. 6.5. Distribution of PZA gold label in (A-D) macrophages infected with 
susceptible strain 200R: (A) nucleus and cytoplasm [52K], (B) membrane bound 
rnycobacteria (83K), (C) internalised mycobacteria and cytoplasm [48K], (D) 
internalised mycobacteria and cytoplasm [43K] and (E, F) non cell associated 200R, 
(E) 51 K and (F) 46K.
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FIG. 6.6. Distribution of PZA gold label in (A-D) macrophages infected with 
susceptible strain JOOR: (A) nucleus (45K], (B) membrane bound mycobacteria 
(47K], (C) cy10plasm [49K), (D) internalised mycobacterium in cytoplasm (68K] and 
(E, F) non cell associated I OOR, (E) 60K and (F) 84K. 
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FIG. 6.7. Distribution of PZA gold label in (A-O) macrophages infected with 
suscep.tible strain 11344: (A) nucleus and cytoplasm (47K], (B) nucleus (90K], (C) 
internalised mycobacteria in cytoplasm (51 K], (D) internalised mycobacterium m 





FIG. 6.8. Distribution of PZA gold label in (A-D) macrophages infected with 
susceptible strain 90s: {A) cytoplasm (45K], (B) membrane bound mycobacteria 
( 45K], (C) internalised mycobacteria in cytoplasm (71 K], (D) nucleus and internalised 





FIG. 6.9. Distribution of PZA gold label in (A-O) macrophages infected with 
susceptible strain 11102: (A) nucleus and cytoplasm [ 44K], (B) cytoplasm [ 48K], (C) 
internalised mycobacterium in cytoplasm [75K], (D) internalised mycobacteria m 
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FIG. 6.10. Distribution of PZA gold label in (A-0) macrophages infected with 
susceptible strain 11191: (A) nucleus, membrane bound mycobacteria and cytoplasm 
(51 K], (B) membrane bound mycobacteria and cytoplasm [ 45K], (C) cytoplasm 
[57K], (D) internalised mycobacteria in cytoplasm (75K] and (E, F) non cell 
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FIG. 6.11. Distribution of PZA gold label in (A-0) macrophages infected with 
susceptible strain 1 I 341: (A) nucleus and cytoplasm [ 46K], (B) cytoplasm [ 46K], (C) 
membrane bound mycobacteria and cytoplasm [47K], (D) internalised mycobacterium 
in cytoplasm [50K] and (E, F) non cell associated 1 I 341, (E) 56K and (F) 77K. 
E 
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FIG. 6.12. Distribution of PZA gold label in (A-0) macrophages infected with 
susceptible strain 11851: (A) nucleus and cytoplasm [SOK], (B) membrane bound 
mycobacteria and cytoplasm (SOK], (C) internalised mycobacteria in cytoplasm [51 K], 
(D) internalised mycobacteria in cytoplasm [ 49K] and (E, F) non cell associated
11851, (E) 48K and (F) 49K. 
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FIG. 6.13. Distribution of PZA gold label in (A-0) macrophages infected with 
susceptible strain 10486: (A) nucleus and cytoplasm (52K), (B) cytoplasm (66K], (C) 
internalised mycobacteria in cytoplasm (66K], (D) internalised mycobacterium m 
cytoplasm [54K] and (E, F) non cell associated 10486, (E) 75K and (F) 48K. 
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FIG. 6.14. Distribution of PZA gold label in (A-D) macrophages infected with 
susceptible strain 1195: (A) cytoplasm [57K], (B) membrane bound mycobacteria and 
cytoplasm [48K), (C) nucleus and internalised mycobacteria in cytoplasm [49K], (D) 
internalised mycobacterium in cytoplasm [52K] and (E, F) non cell associated 1195, 
(E) 56K and (F) 60K.
E 
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FIG. 6.15. Distribution of PZA gold label in (A-O) macrophages infected with 
reference strain (Pzase negative) iv! bovis: (A) cytoplasm [ 48K], (B) nucleus and 
cytoplasm [45K], (C) internalised mycobacterium in cytoplasm [44K], (D) cytoplasm 
[45K] and (E, F) non cell associated M bovis, (E) 46K and (F) 85K. 
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FIG. 6.16. Distribution of PZA gold label in (A-0) macrophages infected with 
resistant strain 3886: (A) cytoplasm [SOK], (B) nucleus and cytoplasm [50K], (C) 
internalised mycobacteria in cytoplasm [38K], (0) internalised mycobacterium m 
cytoplasm [46K] and (E, F) non cell associated 3886, (E) 72K and (F) 90K. 
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FIG. 6.17. Distribution of PZA gold label in (A-O) macrophages infected with 
resistant strain 3732: (A) cytoplasm and nucleus [44K], (B) nucleus and cytoplasm 
[41K], (C) internalised mycobacterium in cytoplasm [49K], (D) membrane bound 




FIG. 6.18. Distribution of PZA gold label in (A-D) macrophages infected with 
resistant strain 60650: (A) cytoplasm and nucleus [51 K], (B) nucleus and cytoplasm 
[42K], (C) membrane bound mycobacteria and cytoplasm [44K], (D) internalised 




FIG. 6.19. Distribution of PZA gold label in (A-D) macrophages infected with 
resistant strain 79386: (A) cytoplasm and nucleus [41K], (B) cytoplasm [SOK], (C) 
membrane bound mycobacteria and cytoplasm [44K], (D) mycobacterium entering 




FIG. 6.20. Distribution of PZA gold label in (A-D) macrophages infected with 
resistant strain 6114: (A) cytoplasm and nucleus [41K), (B) membrane bound 
mycobacteria and cytoplasm [53K], (C) mycobacterium internalised in cytoplasm 
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FIG. 6. 24 Mean values for gold label distribution in nucleus of macrophages infected with susceptible and resistant strains of M. tuberculosis.
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FIG. 6.25 Composite representation of the mean values for gold label analysis in the different compartments of the macrophages infected with susceptible (a-d) and 
resistant (e-h) M. tuberculosis strains. 
6.4 DISCUSSION 
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There have been no reports on the use of gold labelled PZA antibodies to study the 
site of action of PZA. We successfully produced PZA antibodies in rabbits (as 
outlined in chapter 5) and performed immunocytochemistry experiments to try to 
elucidate the site of action of PZA in macrophages. No distinction can be made 
between PZA and POA by these experiments as the structural features of both are too 
similar to be able to differentiate between them by means of antibodies. 
Each of the susceptible and resistant strains were used to infect macrophages and 
subject to exposure to PZA. The susceptible and resistant strains are represented in 
FIGS. 6.4-6.14 and FIGS. 6.15-6.20, respectively. Each strain was studied as 
internalised mycobacteria and as non cell associated free mycobacteria. Each figure 
gives an account of the gold label distribution in the nucleus, cytoplasm and 
membrane bound mycobacteria. However, visual comparison among strains would 
not be an accurate account of the distribution of gold label. Therefore, the gold label 
located in the different compartments of the macrophages were statistically analysed. 
There is no literature which describes similar studies with PZA antibodies, thus to 
make comparisons and contrasts is difficult. The gold label located over the free 
susceptible and resistant mycobacteria was significantly different from the cytoplasm, 
nucleus and membrane bound mycobacteria (p<0.000 I). This suggests that the action 
of PZA is not solely restricted to the macrophage. The significant difference 
(p=0.001) between the accumulation of gold label in the cytoplasm of macrophages 
infected with susceptible and resistant bacteria suggests that the mycobacteria may 
influence the uptake of PZA. Susceptible strains may have a better PZA transport 
system in addition to Pzase positivity, thus they are able to take up more PZA, 
however, the accumulation is not over the intracellular bacteria but rather in the 
cytoplasm. The cytoplasm serves as a harbour for the antibiotic _until it diffuses into 
the intracellular bacteria or back into the extracellular environment depending on the 
saturation capacity of the intracellular mycobacteria and the time period of incubation. 
The significant difference between the gold label located over the membrane bound 
susceptible mycobacteria in macrophages and the nucleus suggests that the PZA could 
interfere with the DNA nucleotides as PZA and POA is similar in structure. The gold 
label accumulation between the internalised mycobacteria and nucleus of 
macrophages infected with resistant strains is not statistically significant, which 
suggests that only when Pzase activity is present, does the interference at the nuclear 
level take place, which infers that Pzase activity is important in PZA activity since it 
seems that the PZA metabolite POA is actually causing the interference at the nuclear 
level. 
Addition of the mean gold label counts/nrn2 within the components of the macrophage 
equals to 5.34 x 10·5 gold label particles/nrn2 for susceptible strains and 4.39 x 10·5
gold label/nrn2 for resistant strains. This is lower than the mean gold label count for 
the free susceptible mycobacteria which is 8. 78 x 10·5 gold label particles/nrn2 but 
comparable to free resistant mycobacteria which has a mean count of 5.38 x 10·5 gold 
label particles/nrn2 . This suggests that accumulation of PZA takes place best in free 
Pzase positive mycobacterial strains and that the macrophage may not be the only site 
of action of PZA. 
Although, the PZA and POA could not be found within mycobacteria located in the 
macrophages by HPLC due to the antibiotic being diluted within the macrophage as 
shown in calculations in chapter 4, the gold label experiments with PZA antibodies 
enabled quantification of the intracellular PZA. Thus, there is an accumulation of 
PZA in intracellular mycobacteria. Also, the high accumulation of PZA antibodies in 
free mycobacteria questions the theory that PZA acts in macrophages only. 
This study does not address the question whether accumulation takes place in 
phagosome or phagolysosome because clear distinction between the phagosome 
bound and cytoplasm bound mycobacteria cannot be made on physical characteristics 
only. Double gold labelling using markers that distinguish phagosome would be 
needed. It would enable one to ascertain whether the accumulation of PZA is higher 
in the phagosomes or in cytoplasm enclosed mycobacteria. However, vesicles with no 
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bacteria (lysosomes) did not have any gold label. This suggests that PZA does not 
have a specific affinity for such organelles. Also, PZA accumulated over the 
intracellular bacteria suggesting that the antibody has more affinity for the bacteria. If 
the membrane bound bacteria fused with the lysosomes, the gold label located here is 
due to the bacteria and not the organelle. 
Conclusions 
* The PZA antibodies raised in rabbits was successfully used to locate the sites of
action of PZA in macrophages infected with M tuberculosis.
* Due to the similar structural features of PZA and POA, no distinction can be made
between them by antibodies. 
* The significant difference between gold label located over the free susceptible and
resistant mycobacteria compared to cytoplasm, nucleus and membrane bound 
mycobacteria (p<0.000 I) suggests that the action of PZA is not solely restricted to 
macrophages 
* The high accumulation of PZA antibodies in the free mycobacteria suggests that the
macrophage is not solely the site of action of PZA 
* The cytoplasm serves as a harbour for the antibiotic since there is a significant
difference between the gold label located in the macrophages infected with susceptible 
and resistant bacteria. 





PZA has a special place in tuberculosis chemotherapy in that it allows shortening the 
duration of treatment from the earlier norm of 12-18 months to the current standard of 
6 months. It is thought that this results from its ability to kill a population of semi­
dormant tubercle bacilli that are not affected by other antituberculous drugs. The drug 
has long been known to be active in humans with pulmonary tuberculosis and is now 
for more than a decade used in routine chemotherapy for tuberculosis, however, its 
mechanism of action is still obscure (Raynaud et al, 1999). Heifets (I 999) 
summarises the results of studies that address the question; how PZA affects 
mycobacteria? PZA is active only against Al tuberculosis and iv! africanum, but does 
not exhibit any antimicrobial activity against J\tf bovis or any of the non tuberculous 
mycobacteria. The mode of action of PZA is associated with POA, an enzyme 
generated product considered the active moiety. Less is known about the mode of 
action of PZA than about that of any other antimycobacterial agent. At peak 
concentrations attainable in vivo (30-40 µg/ml) PZA activity in vitro can only be 
shown in acidic environments, at pH 5.5 to 5.6. It has therefore been suggested that 
the effect of PZA in vivo takes place in the acidic intracellular environment of the 
phagolysosome inside macrophages. This study addressed the question: is the site of 
action of PZA indeed the phagolysosome of macrophages? Experiments were 
conducted in such cells infected with susceptible and resistant strains of M
tuberculosis. An attempt was made to identify in which compartment the drug is 
active, and this was compared with extracellular bacteria i.e., non macrophage 
associated mycobacteria. Survival of mycobacteria over time was assessed by colony 
counts. Intracellular, extracellular and intrabacterial PZA and POA concentrations 
were measured by HPLC and finally gold labelled antibodies gave an insight into the 
site of accumulation of the drug. 
The colony counts have shown that there is no bactericidal effect over the 72 h period 
studied with infected macrophages and the 336 h period studied with non cell 
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associated cultures. There is limited entry of PZA into macrophages although the 
extracellular PZA concentration ( 100 µg/ml) is 2-3 times the concentration found in
vivo. POA was only detected in the experiments with free bacteria. The gold labelling 
experiments showed an accumulation of PZA and/or POA in mycobacteria, even in 
the intracellular environment. 
When macrophages were infected with reference strain H3 7R v, 20 µg/ml of the initial 
concentration of l 00 µg/ml PZA could not be detected. This suggests that the PZA or 
its metabolite POA is bound in cellular components of the macrophage or in the 
bacteria. Also, as discussed in chapter 4 the dilution factor of 700 would make any 
POA undetectable as it would be below the detection limit of 0.5 µg/ml set by HPLC. 
In macrophages infected with Pzase positive clinical isolates 5 µg/ml of PZA could 
not be accounted for. This suggests that PZA is converted to POA intracellularly and 
that the proposed mode of action of PZA could be true. However, this study showed 
that there is far greater conversion of PZA to POA in cell free susceptible 
mycobacteria. The PZA did enter non cell associated free mycobacteria and POA was 
present at a steady amount during the time period studied. However, most of the PZA 
and POA was found extracellularly. During the 336 h period studied the PZA and 
POA had no bactericidal effect on the free mycobacteria in RPMI 1640. It was not 
possible to measure bacteriostasis in this milieu because bacterial replication could 
not be observed in drug free RPMI 1640. 
The HPLC observations in this study suggest that a reverse transport system exists 
that transports PZA out of the macrophages back into the extracellular environment. 
This was evident by the disappearance of extracellular PZA followed by an increase in 
extracellular PZA in macrophage experiments. How this mechanism works is not 
known but it suggests that the transport mechanism over time changes into a reverse 
state. Another observation is that a percentage (5-20%) of the drug cannot be 
accounted for and the exact location of this drug is unknown. However, gold labelling 
has shown accumulation in intracellular bacteria. The mathematical model showed if 
the drug is indeed present in the intracellular bacteria it would not be detected by 
HPLC due to the dilution factor in the cytoplasmic fraction. 
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So far, HPLC has only been used in pharmacokinetic studies. PZA concentrations 
were determined in CSF and plasma in rabbits (Chan, 1986). Woo (1987) used HPLC 
to determine PZA and rifampicin concentration is serum samples from patients with 
tuberculous meningitis while Yamamoto et al. (1987) used HPLC to determine PZA 
and its metabolites concentrations in human plasma. Walubo et al. (1994) used HPLC 
to detect PZA, rifampicin and INH in human plasma by HPLC. These authors showed 
that in vivo PZA concentration is below 100 µg/ml (20-70 µg/ml). The in vitro
experiments carried out in this study also showed that the PZA concentration 
attainable intracellularly in macrophages is low ( <5 µg/ml) although the macrophages 
were exposed to 100 µg/ml PZA. The present study is unique in that a correlation was 
made between PZA concentrations in the various fractions of the infected macrophage 
model by HPLC to the effect it has on growth of intracellular mycobacteria as well as 
with its location in macrophages. All of the studies that have studied PZA activity 
have investigated these two aspects separately. 
There have been studies assessing the effect of PZA on macrophage bound bacteria, 
however, these studies have only made assessment by using colony counts. Also, 
more than one drug was included in the experiments, thus combination effects were 
studied rather than the sole effect of PZA. Carlone et al. ( 1985) investigated the 
killing capacity of rifampicin, PZA and POA on macrophages that had ingested live 
M tuberculosis. No rapid increase in the killing effect was observed with the 
combinations compared to the individual drugs. They found over a 3 to 24h period 
more rapid, although not statistically significant killing of intracellular bacteria. The 
study of Carlone et al. ( I 985) differed from this study in that in the latter no 
combinations of drugs were tested. The infected macrophages were exposed to PZA 
only. Thus, there was no competition among the drugs for entry into the 
macrophages. PZA used as a single drug had no bactericidal effect over the 72 h 
period studied. 
Acocella et al. ( I 985) investigated the degree of penetration of rifampicin, PZA and 
POA in mouse macrophages in different metabolic stages. These authors used 
radiolabelled drugs and scintillation spectrophotometry to assess penetration into the 
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macrophage. It was found that stimulation of macrophages had a marked effect on the 
degree of penetration of rifampicin at higher concentration. It affected PZA 
penetration only at the lower concentration and seemed not to affect penetration of 
POA. This study differed from the studies of Acocella et al. (I 985) in that infected 
macrophages not stimulated by cytokines were used and that only PZA effect was 
studied. Also, HPLC was used instead of scintillation spectrometry because this 
allows differentiation between PZA and POA since the conversion of PZA to POA 
was of importance. 
Crowle et al. ( 1986) studied the effect of PZA on intracellular bacilli by counts of acid 
fast bacilli and CFUs. The authors comment that PZA could be bacteriostatic or 
bactericidal against intramacrophage tubercle bacilli depending on its concentration, 
the donor of macrophages and length of exposure of the infected macrophage to the 
drug. The donor of the macrophages did not influence the results obtained in this PhD 
study because a pool of peripheral blood was used to isolate monocytes and cultured 
to the macrophage stage. These authors found that PZA was active in the macrophage 
model as it was inhibiting virulent bacilli at a concentration of 20 µg/ml or higher 
over a 7 day period. The macrophages were exposed to a higher concentration of I 00 
µg/ml PZA. Inhibition of gro'vvth was observed in infected macrophages but no 
killing of intracellular bacteria was observed in the 72 h period studied. Longer 
incubation periods could result in a killing effect being observed. The macrophage 
experiments were only studied for 72 h, due to the HPLC measurements done 
concurrently to be able to relate this to killing. If RPMI 1640 was renewed and the 
incubation period prolonged, the true intracellular PZA concentration could not be 
measured as addition of medium would have an affect on the initial concentration of 
drug added. 
Also, Sbarbaro et al. ( 1986) demonstrated an inhibitory effect of PZA and a quinolone 
(otloxacin) on intracellular mycobacteria by colony counts, whil� Mor and Esfandiari 
( 1997) investigated the synergistic effect of clarithromycin (CLA) and PZA on M 
tuberculosis. It was shown that CLA tends to enhance the effectiveness of PZA 
against tubercle bacilli within macrophages. These authors showed that the 
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combination of drugs does have an effect on the behaviour of PZA intracellularly in 
macrophages. This study did not assess combination of drugs as it was important to 
establish the site of accumulation of PZA and POA solely. Although, this study 
wanted to establish the site of accumulation of PZA and POA, it is evident from other 
studies like Sbarbaro et al. (1986) and Mor and Esfandiari (1997) that PZA may best 
have its place in combination therapy of tuberculosis. 
The immunogold label experiments were able to locate PZAIPOA in infected 
macrophages. It also allowed quantification of PZA within different compartments of 
the macrophage. However, the drawback of this methodology is that the antibodies 
can not distinguish between PZA and POA due to the structural similarity. 
Nevertheless, the gold label studies complement the HPLC studies in an attempt to 
identify the significant compartments within the macrophages that play a role in the 
mode of action of PZA. Also, we were able to compare macrophage bound 
mycobacteria with free mycobacteria. The extracellular antibiotic has to pass through 
the cytoplasmic membrane to enter the macrophages. The cytoplasmic membrane can 
either enhance the uptake of PZA or restrict its uptake. The uptake is not by mere 
diffusion across the cytoplasmic membrane. If uptake was by diffusion, there would 
be an influx into the macrophages infected with Pzase positive mycobacteria because 
it was found that these bacteria remove PZA from the cells. However, such influx is 
not observed. A constant amount remains intracellularly throughout the 72 h period 
studied. This infers that membrane transport molecules are involved but the actual 
dynamics of the mechanism is not known. In this study it is not possible to comment 
whether activity takes place in the phagolysosome as double gold labelling to identify 
phagolysosome was not used. However, the gold labelling experiments have shown 
that it is unlikely that activity takes place in the extrabacterial component of 
phagolysosomes because gold label accumulated inside bacteria and not in bacteria 
free vesicles. This is further emphasised by the accumulation of gold label over free 
bacteria where the HPLC methodology was able to quantify PO� as it was present in 
detectable amounts. 
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The gold label experiments also showed an accumulation of PZA antibodies in the 
nucleus, when Pzase was present. This suggests that POA acccumulates in the 
nucleus, which could not be assessed by HPLC. HPLC showed PZA in the total 
macrophage and also within internalised bacteria. However, large amounts were 
present extracellularly. This did influence the observation with gold label 
experiments because the extracellular fluid was removed by washing. 
The gold label experiments may provide precise insight into the accumulation of gold 
label within macrophages by using two antibodies, one identifying the structural 
feature and the second identifying the drug. Thus, a definite comment can be made as 
to the accumulation of the drug. Confocal microscopy using double fluorescent 
antibodies may also serve as an alternative to TEM. Also, pH determinations of the 
phagosomes in uninfected and infected macrophages will serve to give a complete 
explanation as to whether pH plays a pivotal role in the site of action of PZA within 
macrophages. It is unlikely that the drop in pH has an effect on intracellular bacteria 
in macrophages as the drug accumulates in the bacteria and it is unlikely that enough 
PZA could be converted to POA to allow for the drop in pH. It is also unlikely to be a 
natural drop in pH because a natural drop in pH takes place after fusion and activation 
of the phagosome and lysosome which leads to bacterial kill and would thus make 
PZA redundant. 
The higher extracellular PZA concentration detected by HPLC in the macrophage 
experiments as well as the higher intrabacterial PZNPOA antibody concentration 
found in extracellular bacteria by gold labelling experiments serves to question the 
belief that PZA acts solely in macrophages. The effect of PZA in vivo is not restricted 
to macrophages. It is unclear whether the predominant interaction between PZA and 
bacteria is taking place intracellularly in macrophages or extracellularly in the acidic 
environments of the inflammation sites (Heifets, 1999). From this PhD study, the 
high extracellular PZA concentration found outside macrophage� as well as the high 
extrabacterial PZA and POA concentrations found with non cell associated free 
bacteria tend to favour the latter part of Heifets ( 1999) statement. 
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PZA is important in the therapy of tuberculosis patients in that the length of therapy is 
reduced when PZA is included in the first 2 months of therapy. This suggests that 
PZA itself is able to decrease the bacterial load drastically within the 2 month time 
frame or allows other drugs to do that more effectively. The latter is most likely 
because early bactericidal assays have shown that in vivo kill by PZA alone is rather 
poor. The mycobacteria maybe in a "so called injured state" and the other drugs like 
INH and rifampicin are thus able to kill the bacteria more effectively reducing the 
bacterial load more rapidly and so allowing for short course treatment. 
The HPLC methodology developed was able to quantify extracellular and intracellular 
PZA within macrophages. However, antibiotic found within intracellular bacteria 
could not be quantified due to a dilution factor (a mathematical model gives the 
explanation in chapter 4). The immunogold labelling studies were more sensitive as 
intrabacterial drug could be quantified. Although the intrabacterial PZA accumulation 
was low, immunogold labelled PZA antibodies have the ability to locate the site of 
action of PZA. The drawback of these immunogold labelling experiments is that no 
distinction can be made between PZA and POA because of the similar structural 
features. 
New findings: 
* Development of a HPLC methodology i.e., use of methanol and phosphate buffer as
a mobile phase to separate PZA and POA. 
* Production of polyclonal antibodies to PZA.
* Development of an immunogold labelling technique to locate PZA activity within
macrophages and on free mycobacteria using the antibodies produced. 
* The HPLC methodology and the immunogold labelling experiments showed that the
activity of PZA is not solely restricted to macrophages but is present more 
significantly in the extracellular environment where free mycobacteria are found. 
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APPENDICES 
Appendix I: Nfycobacterium tuberculosis strains 

















6 I 14 negative 
Appendix II: Media and Reagents 
2.1 Antibiotic stock solutions: PZA, POA and PARA dissolved in warm 
distilled water 
HPLC standard solutions: 
2.2 Middlebrook 7H IO agar: 
2.3 Middlebrook 7H9 broth: 
2.4 Mobile phase: 
Solution A: 
Solution B: 
PZA: I 00, 50, 25, I 0, 5 µg/ml 
POA: 50, 25, l 0, 5 µg/ml 
PARA: l 00 µg/ml (internal standard) 
suspend 19g in 900 ml distilled water 
add 5 ml glycerol 
sterilize 121 °C for 15 ruins 
cool and add l 00 ml OADC ( oleic acid, albumin 
fraction V bovine, dextrose, catalase, sodium 
chloride-Bio lab) 
final pH 6.6 
suspend 4.7 g in 900 ml distilled water 
add 5 g glycerol 
sterilize 121 °C for 15 ruins 
cool and add 100 ml OADC 
final pH 6.6 
20% methanol: 80% KH2PO4
10 mM KH2PO4, pH 3 .5 
dissolve 136.09g KH2PO4 in I 00 ml distilled 
water and filter sterilise 
methanol (analytical grade) 
acetonitrile (analytical grade) 
2.5 Reynolds lead citrate 
( electron microscopy stain): dissolve 1.33g lead citrate 
1. 76g sodium citrate in 30 ml distilled water
To complete conversion of lead nitrate to lead citrate, shake the mixture 
vigorously until a uniform milky suspension is observed. Add 8 ml of IN 
NaOH until suspension clears 
2.6 Uranyl acetate 
( electron microscopy stain): Dissolve sufficient uranyl acetate to form a 
saturated solution in 50 % ethanol 
2.7 Washing solution for Immunogold labelling: 3 % BSA diluted in PBS 
2.8 Wayne's test agar: 
Indicator: 
suspend 1.84 g Middlebrook 7H 11 agar 
in 400 ml distilled water 
Add: 0.08 g PZA 
0.8 g pyruvic acid 
Autoclave 121 °C for 15 mins 
2 % Fe(NH4)i(SO4)2 
reddish brown colour is positive for Pzase 
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Appendix III: Standard curves for HPLC 
The standard curves for PZA (FIG. 3A) and POA (FIG. 3B) were generated 
automatically using the HP software used to the run the HPLC instrument. The curve 
for the internal standard is also shown. It is evident from this curve that a constant 


















PZA at exp. RT: 4.167 
DAul A, Sig=26:i,4 Ref=.c;SCJ,16 
Correlacion: 0.99993 
Residual Std. Dev.: 0.01155 




x: Amount S.atio 
y: A.::-ea Rat:io 
PA�.A at exp. RT: 5.547 
DADl A, Sig=265,4 Ref=450,16 
Correlation: :.00000 
Residual Std. Dev.: 0. OOOOC
Formula: y = mx + b 
m: 1.00000 
b: 0.00000 
x: P..mount Ratio 
y: Area Ratio 























PO.Z\ at ex�. RT: 2 . 8 l 7 
D.'illl A, Sig=2 65, 4 ::<.e f=4 50, 16
Correlation: 0.99992 




mx + b 
2.07060e-2 
-9.40077e-3 
x: Arr,ount Ra i:io 
y: Area Ratio 
PARA at exp. RT: 5.542 
DADl A, Sig=265,4 Ref=450,16 
Correlation: 1.00000 
Residual Std. Dev.: 0. 00000
Formula: y = mx + b 
m: 1.00000 
b: 0.00000 
x: Amount Ratio 
y: .l\rea Ratio 
-=-=-============-----=--==---=====----------------------------------
FIG. 3B Standard curve for POA: 50, 25, I 0, 5 µg/ml. 
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Appendix IV: Calculation of PZA gold label distribution 
4.1 Distribution of PZA gold label in non cell associated and macrophage bound 
mycobacteria 
All measurements were carried out from negatives with a constant magnification of 
30K. Using the Zeiss Kontron 300 Image Analyser, surface areas of the bacteria were 
measured by drawing along the perimeter of the mycobacteria (FIG. 4A). The area of 
3-5 mycobacteria per strain were measured. The gold label (10nm black dots) were
counted within this area as indicated in FIG. 4A. The average area among the 
susceptible and resistant strains at 30K were 255001 and 282955 run 2, respectively. 
Gold label distribution was then calculated per 1 nm2 of mycobacterium. 
4.2 Distribution of PZA izold label in nucleus and cvtoplasm of the infected 
macrophages 
All calculations were carried out from negatives with a 30K magnification. A square 
with a defined area of 572867nm
2 was drawn as indicated in FIG. 4B. This square 
was randomly moved in each of the 2 areas of interest viz., nucleus and cytoplasm. 
Gold label (10 nm black dots) were counted within this square in each area. 3-5 
blocks were used for each area and strain. The average gold label per 1 nm2 was 
calculated for each area within the macrophages infected with susceptible and 
resistant strains of M tuberculosis.
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FIG. 4A Use of the Zeiss Kontron 300 Image Analyser for measurements of the area 
of the mycobacteria and counting of the PZA gold label. 
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FIG. 4B Use of the Zeiss Kontron 300 Image Analyser for measurements of areas 
within the cytoplasm and counting of the PZA gold label. 
